Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents

Info

Publication number: 20040048844
Type: Application
Filed: May 1, 2003
Publication Date: Mar 11, 2004
Applicant: Bristol-Myers Squibb Pharma Company
Inventors: David Nugiel (Cherry Hill, NJ), David Carini (Wilmington, DE), Susan DiMeo (Wilmington, DE), Anup Vidwans (Avondale, PA), Eddy Yue (Landenberg, PA)
Application Number: 10427540

Abstract

The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): 1

Description

Description

FIELD OF THE INVENTION

[0001] This invention relates generally to novel 5-substituted-indeno[1,2-c]pyrazol-4-ones which are useful as cyclin dependent kinase (cdk) inhibitors, pharmaceutical compositions comprising the same, methods for using the same for treating proliferative diseases, and intermediates and processes for making the same.

BACKGROUND OF THE INVENTION

[0002] One of the most important and fundamental processes in biology is the division of cells mediated by the cell cycle. This process ensures the controlled production of subsequent generations of cells with defined biological function. It is a highly regulated phenomenon and responds to a diverse set of cellular signals both within the cell and from external sources. A complex network of tumor promoting and suppressing gene products are key components of this cellular signaling process. Over expression of the tumor promoting components or the subsequent loss of the tumor suppressing products will lead to unregulated cellular proliferation and the generation of tumors (Pardee, Science 246:603-608, 1989).

[0003] Cyclin dependent kinases (cdks) play a key role in regulating the cell cycle machinery. These complexes consist of two components: a catalytic subunit (the kinase) and a regulatory subunit (the cyclin). To date, six kinase subunits (cdk 1-7) have been identified along with several regulatory subunits (cyclins A-H). Each kinase associates with a specific regulatory partner and together make up the active catalytic moiety. Each transition of the cell cycle is regulated by a particular cdk complex: G1/S by cdk2/cyclin E, cdk4/cyclin D1 and cdk6/cyclinD2; S/G2 by cdk2/cyclin A and cdk1/cyclin A; G2/M by cdk1/B. The coordinated activity of these kinases guides the individual cells through the replication process and ensures the vitality of each subsequent generation (Sherr, Cell 73:1059-1065, 1993; Draetta, Trends Biochem. Sci. 15:378-382, 1990)

[0004] An increasing body of evidence has shown a link between tumor development and cdk related malfunctions. Over expression of the cyclin regulatory proteins and subsequent kinase hyperactivity have been linked to several types of cancers (Jiang, Proc. Natl. Acad. Sci. USA 90:9026-9030, 1993; Wang, Nature 343:555-557, 1990). More recently, endogenous, highly specific protein inhibitors of cdks were found to have a major affect on cellular proliferation (Kamb et al, Science 264:436-440, 1994; Beach, Nature 336:701-704, 1993). These inhibitors include p16INK4 (an inhibitor of cdk4/D1), p21CIP1 (a general cdk inhibitor), and p27KIP1 (a specific cdk2/E inhibitor). A recent crystal structure of p27 bound to cdk2/A revealed how these proteins effectively inhibit the kinase activity through multiple interactions with the cdk complex (Pavletich, Nature 382:325-331, 1996). These proteins help to regulate the cell cycle through specific interactions with their corresponding cdk complexes. Cells deficient in these inhibitors are prone to unregulated growth and tumor formation.

[0005] This body of evidence has led to an intense search for small molecule inhibitors of the cdk family as an approach to cancer chemotherapy. There are no known examples of molecules related to the current invention which describe 5-substituted-indeno[1,2-c]pyrazoles as cdk inhibitors. There is one case describing indeno[1,2-c]pyrazoles having anticancer activity. There are two other examples which describe indeno[1,2-c]pyrazoles having unrelated utilities and structures.

[0006] A series of indeno[1,2-c]pyrazoles having anticancer activity are described in JP 60130521 and JP 62099361 with the following generic structure: 2

[0007] No substitution is claimed on the indenophenyl portion of the molecule and the molecules are not indicated to be cdk inhibitors. In addition, we discovered that substitution at the 5-position was critical for cdk inhibitory activity.

[0008] A series of indeno[1,2-c]pyrazoles having herbicidal activity are described in GB 2223946 with the following generic structure: 3

[0009] The above compounds differ from the presently claimed invention in Xn is defined as halo, alkyl, haloalkyl, and haloalkoxy; n=0-2. In addition, R1 is defined as acyl and R2 is defined as alkyl or cycloalkyl.

[0010] A series of 1-(6′-substituted-4′-methylquinol-2′-yl)-3-methylindeno[1,2-c]pyrazoles having CNS activity are described by Quraishi, Farmaco 44:753-8, 1989 with the following generic structure: 4

[0011] Compounds of this series are not considered to be part of the presently claimed invention.

SUMMARY OF THE INVENTION

[0012] The present invention describes a novel class of indeno[1,2-c]pyrazol-4-ones or pharmaceutically acceptable salt forms thereof that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk 1-7 and their regulatory subunits know as cyclins A-H.

[0013] It is another object of this invention to provide a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof.

[0014] It is another object of this invention to provide a novel method of treating cancer or other proliferative diseases, which comprises administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

[0015] These and other objectives have been achieved by the inventors' discovery that compounds of formula (I): 5

[0016] wherein R1, R2 and X are defined below or pharmaceutically acceptable salts thereof are cyclin dependent kinase inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0017] The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. The inhibitors of this invention are indeno[1,2-c]pyrazol-4-one analogs. Certain analogs were selective for their activity against cdks and their cyclin bound complexes and were less active against other known serine/threonine kinases such as Protein Kinase A (PKA) and Protein Kinase C (PKC). In addition, these inhibitors were less active against tyrosine kinases such as c-Abl.

[0018] As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently would be useful in modulating cell-cycle progression, which would ultimately control cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation, such as the treatment of cancer, psoriasis, immunological disorders involving unwanted leukocyte proliferation, in the treatment of restinosis and other smooth muscle cell disorders, and the like.

[0019] The present invention, in a first embodiment, describes a novel compound of formula (I): 6

[0020] or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

[0021] X is selected from the group: O, S, and NR;

[0022] R is selected from the group: H, C1-4 alkyl, and NR5R5a;

[0023] R1 is selected from the group: H, C1-10 alkyl substituted with 0-3 Rc, C2-10 alkenyl substituted with 0-3 Rc, C2-10 alkynyl substituted with 0-3 Rc, —NHR4, C3-10 carbocycle substituted with 0-5 Ra, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

[0024] R2 is selected from the group: H, C1-10 alkyl substituted with 0-3 Rc, C2-10 alkenyl substituted with 0-3 Rc, C2-10 alkynyl substituted with 0-3 Rc, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 Ra, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

[0025] R is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR5R5a, NR5NR5R5a, NR5C(O)OR5 NR5C(O)R5═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

[0026] provided that if R3 is phenyl, it is substituted with 1-5 Ra;

[0027] R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0028] provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

[0029] Ra is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3, R3a, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3a, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0030] alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

[0031] Rb is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, and SO2R3b;

[0032] Rc is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R NR5NR5R5a, NR3C(O)OR3, NR3C(O)R3, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0033] R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0034] alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 4-8 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

[0035] R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0036] R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3b, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3b, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0037] R5 is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

[0038] R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

[0039] R5b is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

[0040] R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

[0041] m is selected from 0, 1, 2, and 3.

[0042] In a preferred embodiment, the present invention provides a novel compound of formula (I), wherein:

[0043] X is selected from the group: O, S, and NR;

[0044] R is selected from the group: H, C1-4 alkyl, and NR5R5a;

[0045] R1 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-5 alkenyl substituted with 0-3 Rc, C2-5 alkynyl substituted with 0-3 Rc, —NHR4, C3-6 carbocycle substituted with 0-5 Ra, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

[0046] R2 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-5 alkenyl substituted with 0-3 R3, C2-5 alkynyl substituted with 0-3 Rc, —(CF2)mCF3, C3-6 carbocycle substituted with 0-5 Ra, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

[0047] R3 is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR5R5a, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

[0048] provided that if R3 is phenyl, it is substituted with 1-5 Ra;

[0049] R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0050] provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

[0051] Ra is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0052] alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

[0053] Rb is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, and SO2R3b;

[0054] Rc is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, NR5NR5R5a, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0055] R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0056] alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 4-8 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

[0057] R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0058] R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3b, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0059] R5 is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0060] R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

[0061] R5b is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0062] R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

[0063] m is selected from 0, 1, 2, and 3.

[0064] In a more preferred embodiment, the present invention provides a novel compound of formula (I), wherein:

[0065] X is selected from the group: O and S;

[0066] R1 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-5 alkenyl substituted with 0-3 Rc, —NHR4, C3-6 carbocycle substituted with 0-5 Ra, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

[0067] R2 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-s alkenyl substituted with 0-3 Rc, —(CF2)mCF3, C3-6 carbocycle substituted with 0-5 Ra, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

[0068] R3 is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR5R5a, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

[0069] provided that if R3 is phenyl, it is substituted with 1-5 Ra;

[0070] R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0071] provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, (CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

[0072] Ra is independently at each occurrence selected from the group: halo, —CN, N3, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)R3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0073] alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

[0074] Rb is independently at each occurrence selected from the group: halo, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, and SO2R3b;

[0075] Rc is independently at each occurrence selected from the group: halo, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR5NR5R5a, NR3C(O)OR3, NR3C(O)R3, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0076] R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0077] alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 5-6 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

[0078] R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0079] R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3b, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3b, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0080] R5 is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0081] R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

[0082] R5b is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0083] R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

[0084] m is selected from 0, 1, 2, and 3.

[0085] In a even more preferred embodiment, the present invention provides a novel compound of formula (I), wherein:

[0086] X is selected from the group: O and S;

[0087] R1 is selected from the group: H, C1-5 alkyl substituted with 0-2 Rc, —NHR4, C3-6 carbocycle substituted with 0-5 Ra, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

[0088] R2 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, —(CF2)mCF3, C3-6 carbocycle substituted with 0-5 Ra, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-3 Rb;

[0089] R3 is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR5R5a, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

[0090] provided that if R3 is phenyl, it is substituted with 1-5 Ra;

[0091] R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0092] provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

[0093] Ra is independently at each occurrence selected from the group: halo, —CN, N3, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0094] alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

[0095] Rb is independently at each occurrence selected from the group: halo, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, and SO2R3b;

[0096] Rc is independently at each occurrence selected from the group: halo, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR5NR5R5a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

[0097] R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0098] alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 5-6 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

[0099] R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

[0100] R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3b, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3b, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

[0101] R5 is independently selected from the group: H and C1-4 alkyl;

[0102] R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

[0103] R5b is independently selected from the group: H and C1-4 alkyl;

[0104] R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

[0105] m is selected from 0, 1, 2, and 3.

[0106] In a most preferred embodiment, the compounds of formula (I) are selected from:

[0107] 3-(4-methoxyphenyl)-5-(2-benzoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

[0108] 3-(4-methoxyphenyl)-5-(2-isonicotinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

[0109] 3-(4-methoxyphenyl)-5-(2-nictinoylhydrazinecarbox amido)indeno[1,2-c]pyrazol-4-one;

[0110] 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

[0111] 3-(4-methoxyphenyl)-5-(2-(4-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

[0112] 3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

[0113] 3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

[0114] 3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

[0115] 3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylaminobenzoyl) hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

[0116] 3-(4-methoxyphenyl)-5-(2-phenethylacetylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

[0117] 3-(4-methoxyphenyl)-5-(2-(2-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one; and

[0118] 3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

[0119] or pharmaceutically acceptable salt form thereof.

[0120] Another embodiment of the present invention is a pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I).

[0121] Another embodiment of the present invention is a method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically effective salt form thereof.

DEFINITIONS

[0122] As used herein, the following terms and expressions have the indicated meanings. The compounds of the present invention may contain an asymmetrically substituted carbon atom, and may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

[0123] The term “alkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. In addition, the term is intended to include both unsubstituted and substituted alkyl groups, the latter referring to alkyl moieties having one or more hydrogen substituents replaced by, but not limited to halogen, hydroxyl, carbonyl, alkoxy, ester, ether, cyano, phosphoryl, amino, imino, amido, sulfhydryl, alkythio, thioester, sulfonyl, nitro, heterocyclo, aryl or heteroaryl. It will also be understood by those skilled in the art that the substituted moieties themselves can be substituted as well when appropriate.

[0124] The terms “halo” or “halogen” as used herein refer to fluoro, chloro, bromo and iodo. The term “aryl” is intended to mean an aromatic moiety containing the specified number of carbon atoms, such as, but not limited to phenyl, indanyl or naphthyl. The terms “cycloalkyl” and “bicycloalkyl” are intended to mean any stable ring system, which may be saturated or partially unsaturated. Examples of such include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, bicyclo[2.2.2]nonane, adamantly, or tetrahydronaphthyl (tetralin).

[0125] As used herein, “carbocycle” or “carbocyclic residue” is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl; [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).

[0126] As used herein, the term “heterocycle” or “heterocyclic system” is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term “aromatic heterocyclic system” is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1.

[0127] Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

[0128] As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

[0129] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, Pa., 1990, p. 1445, the disclosure of which is hereby incorporated by reference.

[0130] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.

[0131] “Prodrugs”, as the term is used herein, are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (i.e., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same, and compositions containing the same. Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.

[0132] “Substituted” is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., ═O) group, then 2 hydrogens on the atom are replaced.

[0133] As used herein, the term “anti cancer” or “anti-proliferative” agent includes, but is not limited to, altretamine, busulfan, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, thiotepa, cladribine, fluorouracil, floxuridine, gemcitabine, thioguanine, pentostatin, methotrexate, 6-mercaptopurine, cytarabine, carmustine, lomustine, streptozotocin, carboplatin, cisplatin, oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335, fludarabine, aminoglutethimide, flutamide, goserelin, leuprolide, megestrol acetate, cyproterone acetate, tamoxifen, anastrozole, bicalutamide, dexamethasone, diethylstilbestrol, prednisone, bleomycin, dactinomycin, daunorubicin, doxirubicin, idarubicin, mitoxantrone, losoxantrone, mitomycin-c, plicamycin, paclitaxel, docetaxel, topotecan, irinotecan, 9-amino camptothecan, 9-nitro camptothecan, GS-211, etoposide, teniposide, vinblastine, vincristine, vinorelbine, procarbazine, asparaginase, pegaspargase, octreotide, estramustine, hydroxyurea.

SYNTHESIS

[0134] The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those methods described below. Each of the references cited below are hereby incorporated herein by reference. 7

[0135] An approach to preparing indeno[1,2-c]pyrazol-4-ones is presented in Scheme 1 and can be used to prepare compounds of the present invention. The nitro group of dimethyl 3-nitrophthalate was reduced to the amine using catalytic hydrogenation. The aniline was acylated using acetic anhydride and pyridine as a base. A mixture of the resulting acetamide 2 and an acetophenone were treated with a strong base in an appropriate solvent at elevated temperature to give the desired triketone 3. Additional means of preparing triketones are known to one skilled in the art as described in Kilgore et al, Industrial and Engineering Chemistry 34:494-497, 1946, the contents of which are hereby incorporated herein by reference. The triketone was treated with hydrazine at elevated temperature in an appropriate solvent to give the indeno[1,2-c]pyrazol-4-one ring system. Additional means of preparing indeno[1,2-c]pyrazol-4-ones are known to one skilled in the art as described in Lemke et al., J. Heterocyclic Chem. 19:1335-1340, 1982; Mosher and Soeder, J. Heterocyclic Chem. 8:855-59, 1971; Hrnciar and Svanygova Collect. Czech. Chem. Commun. 59:2734-40, 1994 the contents of which are hereby incorporated herein by reference. The amide was deacylated by heating with a strong acid in an appropriate solvent to give aniline 4. This aniline was acylated under standard conditions using an acid chloride in an appropriate solvent to give the desired product 5. 8

[0136] An alternative method for making compounds of the present invention is shown in Scheme 2. The intermediate triketone 3 can be deacylated with strong acid and reacylated with an appropriate acid chloride using methods known to those skilled in the art. Subsequently, triketone 6 can the be converted to the indeno[1,2-c]pyrazol-4-one ring system using the same conditions described previously in Scheme 1. 9

[0137] Another method for preparing the triketones 6 of Scheme 2 employs the condensation of a 1,3-diketone 6a with 3-nitrophthalic anhydride as described in Rotberg and Oshkaya, Zh. Organ. Khim. 8:84-87, 1972; Zh. Organ. Khim. 9:2548-2550, 1973, the contents of which are hereby incorporated herein by reference. The 1,3-diketones, when not commercially available can be readily prepared by one skilled in the art by the acetylation or trifluoroacetylation of the requisite methyl ketone, R1COCH3. Reduction of the nitro derivative 6b to the aniline 6c can be accomplished in a variety of ways including catalyic hydrogenation, treatment with zinc or iron under acidic conditions, or treatment with other reducing agents such as sodium dithionite or stannous chloride. Subsequently the aniline 6c can be converted to the indeno[1,2-c]pyrazol-4-ones of this invention by acylation followed by treatment with hydrazine as described previously in Scheme 2. 10

[0138] Another method for making the indeno[1,2-c]pyrazol-4-one ring system is shown in Scheme 4. Dimethyl hydrazine was reacted with 3-acetylpyridine with no solvent to give the hydrazone 7. This was treated in a similar fashion as described in Scheme 1 to give the desired intermediate 8. Additional means of preparing similar intermediates are known to one skilled in the art as described in Rappoport, J. Org. Chem. 49:2948-2953, 1984, the contents of which are hereby incorporated herein by reference. This intermediate was carried through the sequence in a similar fashion as described in Scheme 1. 11

[0139] Another approach to preparing indeno[1,2-c]pyrazol-4-ones is presented in Scheme 5 and can be used to prepare compounds of the present invention. Treating the intermediate 5-aminoindeno[1,2-c]pyrazol-4-one with 2-(trimethylsilyl) ethoxymethylmethyl chloride (SEMCL) and a suitable base in an inert solvent under reflux gives the SEM protected intermediate. The aniline is converted to the carbamate with phenylchloroformate using methods known to those skilled in the art. This intermediate is reacted with carbaztes in DMSO at elevated temperatures and then the SEM group is removed by treating with acid in a polar protic solvent to give the desired acylsemicarbazide-containing indenopyrazole analogs.

[0140] Other features of the invention will become apparent during the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

[0141] Abbreviations used in the Examples are defined as follows: “° C.” for degrees Celsius, “CIMS” for chemical ionization mass spectroscopy, “eq” for equivalent or equivalents, “g” for gram or grams, “h” for hour or hours, “mg” for milligram or milligrams, “mL” for milliliter or milliliters, “mmol” for millimolar, “M” for molar, “min” for minute or minutes, “p-TsOH” for para-toluenesulphonic acid, “DMF” for dimethylformamide, and “TFA” for trifluoroacetic acid.

Example I Preparation of 3-(4-methoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0142] 12

[0143] Step 1. Synthesis of 2 from dimethyl 3-nitrophthalate.

[0144] A solution of dimethyl 3-nitrophthalate (25 g, 105 mmol) in methanol (100 mL) was treated with 5% Pd/C (2.5 g) and hydrogenated on a Parr Shaker at 50 psi for 2 h. The solution was filtered (Celite), the filtrate collected and the solvent removed at reduced pressure. The residue was dissolved in acetic anhydride (20 mL) treated with pyridine (0.05 mL) and heated to 80° C. for 1 min. The reaction was cooled and stirred at 25° C. for 2 h. The solvent was removed at reduced pressure and the residue recrystallized from ethanol to give the product as a white solid (21 g, 79%). mp 104-105° C.; CIMS m/e calc'd for C12H14NO5: 252.0872, found 252.0888; Analysis calc'd for C12H13NO5: C, 57.37; H, 5.22; N, 5.58; found: C, 57.67; H, 5.29; N, 5.77.

[0145] Step 2. Synthesis of Triketone 11 from 2.

[0146] A solution of 2 (1 g, 4.0 mmol) in dry DMF (2 mL) was treated with sodium hydride (0.15 g, 60% suspension in oil, 0.4 mmol) in one portion. After 1 h, 4-methoxyacetophenone (0.6 g, 4.0 mmol) was added in one portion and the reaction heated to 90° C. A second portion of sodium hydride (0.15 g, 60% suspension in oil, 0.4 mmol) was added and the exothermic reaction turns deep red. After 20 min, the reaction was cooled to 25° C., diluted with water (20 mL), extracted with EtOAc (10 mL) and the aqueous phase separated. The aqueous phase was acidified with 2 N HCl to pH 2 and the crude product collected. Recrystalization with ethanol gave the desired product as a yellow solid (0.4 g, 30%). mp 174-175° C.; CIMS m/e calc'd for C19H16NO5: 338.1028, found 338.1022; Analysis calc'd for C19H15NO5: C, 67.65; H, 4.48; N, 4.15; found: C, 67.87; H, 4.29; N, 3.99.

[0147] Step 3. Synthesis of 12 from 11.

[0148] A solution of 11 (0.2 g, 0.6 mmol) in EtOH (5 mL) was treated with hydrazine hydrate (0.1 mL, 1.8 mmol) and p-TsOH (3 mg). The reaction was heated to reflux and stirred for 2 h. The reaction was cooled to 25° C. and the product collected as a yellow solid (0.1 g, 50%). mp 268° C.; CIMS m/e calc'd for C19H16N3O3: 334.1192, found: 334.1168; Analysis calc'd for C19H15N3O3: C, 68.46; H, 4.54; N, 12.61; found: C, 68.81; H, 4.39; N, 12.45.

Example II Preparation of 3-(4-methoxyphenyl)-5-(chloroacetamido)indeno[1,2-c]pyrazol-4-one

[0149] 13

[0150] Step 1. Synthesis of 13 from 12.

[0151] A suspension of 12 (1.0 g, 3.0 mmol) in MeOH (10 mL) was treated with conc. HCl (1 mL) and heated to reflux. After 2 h, the reaction was cooled and the product was collected as a greenish solid (0.7 g, 81%). mp 273° C.; CIMS m/e calc'd for C17H14N3O2: 292.1086, found: 292.1080; Analysis calc'd for C17H13N3O2: C, 69.85; H, 4.83; N, 14.37; found: C, 69.99; H, 4.59; N, 14.44.

[0152] Step 2. Synthesis of 14 from 13.

[0153] A suspension of 13 (20 mg, 0.07 mmol) in dioxane (2 mL) was treated with aqueous sat. NaHCO3 (1 mL) and chloroacetyl chloride (30 mL, 0.21 mmol). The reaction was heated to 50° C. and stirred for 2 h. The reaction was cooled, poured into water (2 mL), extracted with EtOAc (10 mL), the organic layer separated, dried (MgSO4) and the solvent removed at reduced pressure. The solid residue was recrystallized from EtOH to give the product as a yellow solid (9 mg, 35%). mp 274° C.; CIMS m/e calc'd for C19H15N3O3Cl: 368.0802, found: 368.0818.

Example III Preparation of 3-(4-methoxyphenyl)-5-(cyclopropylamido)indeno[1,2-c]pyrazol-4-one

[0154] Prepared in a similar fashion as described for example II using cyclopropylacetyl chloride as the starting material. mp 289° C.; CIMS m/e calc'd for C21H18N3O3: 360.1348, found: 360.1330.

Example IV Preparation of 3-(4-methoxyphenyl)-5-(isopropylamido)indeno[1,2-c]pyrazol-4-one

[0155] Prepared in a similar fashion as described for example II using isopropylacetyl chloride as the starting material. mp 288° C.; CIMS m/e calc'd for C21H20N3O3: 362.1505, found: 362.1535.

Example V Preparation of 3-(4-methoxyphenyl)-5-(ethylamido)indeno[1,2-c]pyrazol-4-one

[0156] Prepared in a similar fashion as described for example II using propionyl chloride as the starting material. mp 287° C.; CIMS m/e calc'd for C20H18N3O3: 348.1348, found: 348.1313.

Example VI Preparation of 3-(4-methoxyphenyl)-5-(cyclopentylamido)indeno[1,2-c]pyrazol-4-one

[0157] Prepared in a similar fashion as described for example II using cyclopentylacetyl chloride as the starting material. mp 267° C.; CIMS m/e calc'd for C23H22N3O3: 388.1661, found: 388.1626.

Example VII Preparation of 3-(4-methoxyphenyl)-5-(cyclobutylamido)indeno[1,2-c]pyrazol-4-one

[0158] Prepared in a similar fashion as described for example II using cyclobutylacetyl chloride as the starting material. mp 297° C.; CIMS m/e calc'd for C22H20N3O3: 374.1505, found: 374.1530.

Example VIII Preparation of 3-(4-methoxyphenyl)-5-(phenylacetamido)indeno[1,2-c]pyrazol-4-one

[0159] Prepared in a similar fashion as described for example II using phenylacetyl chloride as the starting material. mp 280° C.; CIMS m/e calc'd for C25H20N3O3: 410.1505, found: 410.1533.

Example IX Preparation of 3-(4-methoxyphenyl)-5-(butylamido)indeno[1,2-c]pyrazol-4-one

[0160] Prepared in a similar fashion as described for example II using butyryl chloride as the starting material. mp 282° C.; CIMS m/e calc'd for C21H20N3O3: 362.1505, found: 362.1500.

Example X Preparation of 3-(4-methoxyphenyl)-5-((4-chlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0161] Prepared in a similar fashion as described for example II using 4-chlorophenylacetyl chloride as the starting material. mp 238° C.; CIMS m/e calc'd for C25H19N3O3Cl: 444.1115, found: 444.1110.

Example XI Preparation of 3-(4-methoxyphenyl)-5-((3-methoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0162] Prepared in a similar fashion as described for example II using 3-methoxyphenylacetyl chloride as the starting material. mp>300° C.; CIMS m/e calc'd for C26H22N3O4: 440.1610, found: 440.1620.

Example XII Preparation of 3-(4-methoxyphenyl)-5-((4-methoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0163] Prepared in a similar fashion as described for example II using 4-methoxyphenylacetyl chloride as the starting material. mp 280° C.; CIMS m/e calc'd for C26H22N3O4: 440.1610, found: 440.1630.

Example XIII Preparation of 3-(4-methoxyphenyl)-5-((3,4-dimethoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0164] Prepared in a similar fashion as described for example II using 3,4-dimethoxyphenylacetyl chloride as the starting material. mp>300° C.; CIMS m/e calc'd for C27H24N3O5: 470.1716, found: 470.1731.

Example XIV Preparation of 3-(4-methoxyphenyl)-5-((2,5-dimethoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0165] Prepared in a similar fashion as described for example II using 2,5-dimethoxyphenylacetyl chloride as the starting material. mp 226° C.; CIMS m/e calc'd for C27H24N3O5: 470.1716, found: 470.1739.

Example XV Preparation of 3-(2-methoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0166] Prepared in a similar fashion as described for example I using 2-methoxyacetophenone as the starting material. mp 276° C.; CIMS m/e calc'd for C19H16N3O3: 334.1192, found: 334.1169.

Example XVI Preparation of 3-(3,4-dimethoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0167] Prepared in a similar fashion as described for example I using 3,4-dimethoxyacetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C20H18N3O4: 364.1297, found: 364.1288.

Example XVII Preparation of 3-(4-methoxyphenyl)-5-((3,4-ethylenedioxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0168] 14

[0169] Step 1. Synthesis of 15 from 11.

[0170] A suspension of 11 (5 g, 14.8 mmol) in MeOH (50 mL) was treated with conc. HCl (3 mL) and heated to reflux. After stirring for 2 h, the reaction was cooled to 0° C. and the product collected as a yellow solid (4.2 g, 96%). mp 173° C.; CIMS m/e calc'd for C17H14NO4: 296.0923, Found: 296.0901.

[0171] Step 2. Synthesis of 16 from 15.

[0172] A suspension of 15 (20 mg, 0.07 mmol) in acetone (2 mL) was treated with NaHCO3 (10 mg) and the acid chloride of (3,4-methylenedioxyphenyl)acetic acid (prepared by heating the acid in a benzene:thionyl chloride 4:1 mixture at 50° C. for 2 h, removing the volatile components at reduced pressure, and using the crude acid chloride without further purification). The reaction was heated to 50° C. and stirred for 2 h. The reaction was cooled, poured into water (4 mL), extracted with EtOAc (10 mL), dried (MgSO4), filtered and concentrated. The crude triketone was suspended in EtOH (2 mL), treated with hydrazine hydrate (0.05 mL) and p-TsOH (1 mg) and heated to reflux for 2 h. The reaction was cooled to 0° C. and the product filtered to give a yellow solid (6.5 mg, 20%). mp 297° C.; CIMS m/e calc'd for C26H20N3O5: 454.1403, Found: 454.1398.

Example XVIII Preparation of 3-(4-dimethoxyphenyl)-5-((3-thiophene)acetamido)indeno[1,2-c]pyrazol-4-one

[0173] Prepared in a similar fashion as described for example XVII using the acid chloride of 3-thiopheneacetic acid as the starting material. mp 293° C.; CIMS m/e calc'd for C23H18N3O3S: 416.1069, found: 416.1088.

Example XIX Preparation of 3-(4-methoxyphenyl)-5-((2-methoxyphenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0174] Prepared in a similar fashion as described for example XVII using the acid chloride of 2-methoxyphenylacetic acid as the starting material. mp 255° C.; CIMS m/e calc'd for C26H22N3O4: 440.1610, found: 440.1622.

Example XX Preparation of 3-(4-methoxyphenyl)-5-((3,4-dichlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0175] Prepared in a similar fashion as described for example XVII using the acid chloride of 3,4-dichlorophenylacetic acid as the starting material. mp 299° C.; CIMS m/e calc'd for C25H18N3O3Cl2: 478.0725, found: 478.0744.

Example XXI Preparation of 3-(4-methoxyphenyl)-5-((2,4-dichlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0176] Prepared in a similar fashion as described for example XVII using the acid chloride of 2,4-dichlorophenylacetic acid as the starting material. mp 286° C.; CIMS m/e calc'd for C25H18N3O3Cl2: 478.0725, found: 478.0734.

Example XXII Preparation of 3-(4-methoxyphenyl)-5-((2-chlorophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0177] Prepared in a similar fashion as described for example XVII using the acid chloride of 2-chlorophenylacetic acid as the starting material. mp 300° C.; CIMS m/e calc'd for C25H19N3O3Cl: 444.1115, found: 444.1111.

Example XXIII Preparation of 3-(4-methoxyphenyl)-5-(aminoacetamido)indeno[1,2-c]pyrazol-4-one

[0178] 15

[0179] A suspension of 14 (15 mg, 0.04 mmol) in EtOH (1 mL) was treated with conc. NH4OH (1 mL), placed in a sealed tube and heated to 80° C. for 3 h. The reaction was cooled and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (9 mg, 62%). mp>300° C.; CIMS m/e calc'd for C20H19N4O3: 363.1457, Found: 363.1431.

Example XXIV Preparation of 3-(4-methoxyphenyl)-5-((2-hydroxyethyl)aminoacetamido)indeno[1,2-c]pyrazol-4-one

[0180] Prepared in a similar fashion as described for example XXIII using hydroxylamine as the starting material. mp 243° C.; CIMS m/e calc'd for C21H21N4O4: 393.1563, found: 393.1539.

Example XXV Preparation of 3-(4-methoxyphenyl)-5-(N,N-dimethylaminoacetamido)indeno[1,2-c]pyrazol-4-one

[0181] Prepared in a similar fashion as described for example XXIII using dimethylamine as the starting material. mp 279° C.; CIMS m/e calc'd for C21H21N4O3: 377.1614, found: 377.1640.

Example XXVI Preparation of 3-(4-methoxyphenyl)-5-(piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

[0182] Prepared in a similar fashion as described for example XXIII using piperazine as the starting material. mp 277° C.; CIMS m/e calc'd for C23H24N5O3: 418.1879, found: 418.1899.

Example XXVII Preparation of 3-(4-methoxyphenyl)-5-(4-methylpiperazinylacetamido)indeno[1,2-c]pyrazol-4-one

[0183] Prepared in a similar fashion as described for example XXIII using 4-methylpiperizine as the starting material. mp>300° C.; CIMS m/e calc'd for C24H26N5O3: 432.2036, found: 432.2030.

Example XXVIII Preparation of 3-(4-methoxyphenyl)-5-(4-(2-hydroxyethyl)piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

[0184] Prepared in a similar fashion as described for example XXIII using 4-hydroxyethylpiperizine as the starting material. mp>300° C.; CIMS m/e calc'd for C25H28N5O4: 462.2141, found: 462.2128.

Example XXIX Preparation of 3-(4-methoxyphenyl)-5-(piperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0185] Prepared in a similar fashion as described for example XXIII using piperidine as the starting material. mp 291° C.; CIMS m/e calc'd for C24H25N4O3: 417.1927, found: 417.1955.

Example XXX Preparation of 3-(4-methoxyphenyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0186] Prepared in a similar fashion as described for example XXIII using 4-aminomethylpiperidine as the starting material. mp>300° C.; CIMS m/e calc'd for C25H28N5O3: 446.2192, found: 446.2166.

Example XXXI Preparation of 3-(4-methoxyphenyl)-5-(ethylaminoacetamido)indeno[1,2-c]pyrazol-4-one

[0187] Prepared in a similar fashion as described for example XXIII using ethylamine as the starting material. mp 250° C.; CIMS m/e calc'd for C21H21N4O3: 377.1614, found: 377.1644.

Example XXXII Preparation of 3-(4-methoxyphenyl)-5-(thiomorpholinylacetamido)indeno[1,2-c]pyrazol-4-one

[0188] Prepared in a similar fashion as described for example XXIII using thiomorpholine as the starting material. mp 298° C.; CIMS m/e calc'd for C23H23N4O3S: 435.1491, found: 435.1477.

Example XXXIII Preparation of 3-(4-methoxyphenyl)-5-(morpholinylacetamido)indeno[1,2-c]pyrazol-4-one

[0189] Prepared in a similar fashion as described for example XXIII using morpholine as the starting material. mp 295° C.; CIMS m/e calc'd for C23H23N4O4: 419.1719, found: 419.1744.

Example XXXIV Preparation of 3-(4-methoxyphenyl)-5-(pyrrolidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0190] Prepared in a similar fashion as described for example XXIII using pyyrolidine as the starting material. mp 279° C.; CIMS m/e calc'd for C23H23N4O3: 403.1770, found: 403.1761.

Example XXXV Preparation of 3-(4-methoxyphenyl)-5-(4-pyridinylaminomethylacetamido)indeno[1,2-c]pyrazol-4-one

[0191] Prepared in a similar fashion as described for example XXIII using 4-aminomethylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C25H22N5O3: 440.1723, found: 440.1762.

Example XXXVI Preparation of 3-(4-methoxyphenyl)-5-((4-acetamidophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0192] 16

[0193] A suspension of 18 (10 mg, 0.02 mmol) in dioxane (1 mL) was treated with aqueous sat. NaHCO3 (0.5 mL) and acetyl chloride (0.01 mL) and heated at 50° C. for 1 h. The reaction was cooled, poured into water (5 mL), extracted with EtOAc (10 mL), the organic layer separated, dried (MgSO4) and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (5.6 mg, 61%). mp 268° C.; CIMS m/e calc'd for C27H23N4O4: 467.1719, Found: 467.1730.

Example XXXVII Preparation of 3-(4-methoxyphenyl)-5-((4-methoxycarbonylaminophenyl)acetamido) indeno[1,2-c]pyrazol-4-one

[0194] Prepared in a similar fashion as described for example XXXII using methylchloroformate as the starting material. mp 257° C.; CIMS m/e calc'd for C27H23N4O5: 483.1668, found: 483.1633.

Example XXXVIII Preparation of 3-(4-methoxyphenyl)-5-((4-aminomethylcarbonylaminophenyl)acetamido) indeno[1,2-c]pyrazol-4-one

[0195] Prepared in a similar fashion as described for example XXIII and XXXII using chloroacetyl chloride and conc. NH4OH as the starting materias. mp 228° C.; CIMS m/e calc'd for C27H24N5O4: 482.1828, found: 482.1844.

Example XXXIX Preparation of 3-(4-methoxyphenyl)-5-((4-N,N-dimethylaminomethylcarbonylaminophenyl)acetamido) indeno[1,2-c]pyrazol-4-one

[0196] Prepared in a similar fashion as described for example XXIII and XXXII using chloroacetyl chloride and dimethyl amine as the starting materias. mp>300° C.; CIMS m/e calc'd for C29H28N5O4: 510.2141, found: 510.2121.

Example XL Preparation of 3-(4-methoxyphenyl)-5-((4-azidophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0197] A solution of example XXXVI (20 mg, 0.04 mmol) in DMF (2 mL) was treated with 5% palladium on carbon (5 mg) and hydrogentaed at atmospheric pressure using a hydrogen baloon. After 2 h, the solution was filtered (Celite), and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (15 mg, 78%). mp>300° C.; CIMS m/e calc'd for C25H19N6O3: 451.1519, found: 451.1544.

Example XLI Preparation of 3-(4-methoxyphenyl)-5-((4-aminophenyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0198] Prepared in a similar fashion as described for example XXVII using the acid chloride of 4-azidophenylacetic acid as the starting material. mp 283° C.; CIMS m/e calc'd for C25H21N4O3: 425.1614, found: 425.1643.

Example XLII Preparation of 3-(4-methoxyphenyl)-5-(phenylcarbamoyl)aminoindeno [1,2-c]pyrazol-4-one

[0199] 17

[0200] Step 1. Synthesis of 20 from 15.

[0201] A suspension of 15 (0.5 g, 1.7 mmol) in acetone (10 mL) was treated with NaHCO3 (0.5 g) and phenyl chloroformate. The mixture was heated to 50° C. for 2 h. The reaction was cooled, poured into water (20 mL), extracted with EtOAc (40 mL), the organic layer separated, dried (MgSO4) and the solvent removed at reduced pressure. The residue was suspended in EtOH (10 mL) and treated with hydrazine hydrate (0.16 mL, 5.1 mmol) and p-TsOH (10 mg). The mixture was heated to reflux and stirred for 3 h. The reaction was cooled to 0° C. and the product collected as a yellow solid (0.25 g, 36%). mp 195° C.; CIMS m/e calc'd for C24H18N3O4: 412.1297, Found: 412.1308.

[0202] Step 2. Synthesis of 21 from 20.

[0203] A solution of 20 (20 mg, 0.05 mmol) in DMSO (2 mL) was treated with aniline (20 mL, mmol) and dimethylaminopyridine (1 mg). The mixture was heated to 80° C. for 2 h. The reaction was cooled, poured into water (4 mL), extracted with EtOAc (15 mL), the organic layer separated, dried (MgSO4) and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the product as a yellow solid (9 mg, 44%). mp>300° C.; CIMS m/e calc'd for C24H19N4O3: 411.1457, Found: 411.1432.

Example XLIII Preparation of 3-(4-methoxyphenyl)-5-(butylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0204] Prepared in a similar fashion as described for example XLII using butyl amine as the starting material. mp 252° C.; CIMS m/e calc'd for C21H21N4O3: 377.1614, found: 377.1633.

Example XLIV Preparation of 3-(4-methoxyphenyl)-5-(4-aminobenzylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0205] Prepared in a similar fashion as described for example XLII using 4-aminobenzyl amine as the starting material. mp>300° C.; CIMS m/e calc'd for C25H22N5O3: 440.1723, found: 440.1700.

Example XLV Preparation of 3-(4-methoxyphenyl)-5-(4-pyridylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0206] Prepared in a similar fashion as described for example XLII using 4-aminomethylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C24H20N5O3: 426.1566, found: 426.1533.

Example XLVI Preparation of 3-(4-hydroxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0207] 18

[0208] A suspension of 12 (20 mg, 0.07 mmol) in CH2Cl2 (2 mL) was treated with excess BBr3 (1.0 mL, 1.0 M in CH2Cl2) and stirred for 20 h. The reaction was slowly poured into aqueous sat. NaHCO3 (5 mL), extracted with EtOAc (10 mL), dried (MgSO4) and concentrated. The residue was recrystallized from EtOH to give the desired product as a yellow solid (7.5 mg, 33%). mp>300° C.; CIMS m/e calc'd for C18H14N3O3: 320.1035, Found: 320.1050.

Example XLVII Preparation of 3-(4-methoxyphenyl)-5-(formamido)indeno[1,2-c]pyrazol-4-one

[0209] 19

[0210] A suspension of 13 (20 mg, 0.06 mmol) in formic acid (2 mL) was heated to 100° C. for 2 h. The reaction mixture was cooled and the solvent removed at reduced pressure. The residue was recrystallized from EtOH to give the desired product as a yellow solid (12 mg, 63%). mp 280° C.; CIMS m/e calc'd for C18H14N3O3: 320.1035, Found: 320.1040.

Example XLVIII Preparation of 3-(3-pyridyl)-5-(acetamido)indeno [1,2-c]pyrazol-4-one

[0211] 20

[0212] Step 1. Synthesis of 24 from 3-acetylpyridine.

[0213] A solution of 3-acetylpyridine (1.0 g, 8.3 mmol) in benzene (3 mL) was treated with 1,1-dimethylhydrazine (0.62 mL, 8.3 mmol) and p-TsOH (5 mg). The mixture was heated to 85° C. and stirred for 3 h. The reaction was cooled and the solvent removed at reduced pressure. This crude hydrazone was treated with 1.0 M NaN(TMS)2 in THF (16.6 mL, 16.6 mmol) at 25° C. over 5 min. After 30 min dimethyl 3-acetamidophthalate (2.1 g, 8.3 mmol) was added in one portion and the reaction heated to reflux. Stirring was continued for 6 h. The reaction was cooled and quenched by the slow addition of TFA. The solvent was removed at reduced pressure and the residue chromatographed (silica, 2.5-5% MeOH/CH2Cl2) to give the product as a yellow solid (0.35 g, 14%). mp 265° C.; CIMS m/e calc'd for C17H13N2O4: 309.0875, Found: 309.0888.

[0214] Step 2. Synthesis of 25 from 24.

[0215] A suspension of 24 (30 mg, 0.09 mmol) in EtOH (2 mL) was treated with hydrazine hydrate (0.05 mL) and p-TsOH (1 mg) and heated to reflux. After stirring for 2 h. the reaction was cooled and the product filtered to give a yellow solid (12 mg, 44%). mp>300° C.; CIMS m/e calc'd for C17H13N4O2: 305.1039, Found: 305.1048.

Example XLIX Preparation of 3-(4-pyridyl)-5-(acetamido)indeno [1,2-c]pyrazol-4-one

[0216] Prepared in a similar fashion as described for example XLVIII using 4-acetylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C17H13N4O2: 305.1039, found: 305.1046.

Example L Preparation of 3-(4-pyridyl)-5-(formamido)indeno [1,2-c]pyrazol-4-one

[0217] Prepared in a similar fashion as described for example XLVII using 4-acetylpyridine as the starting material. mp>300° C.; CIMS m/e calc'd for C16H11N4O2: 291.0882, found: 291.0882.

Example LI Preparation of 3-phenyl-5-(acetamido)indeno [1,2-c]pyrazol-4-one

[0218] Prepared in a similar fashion as described for example I using acetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C18H13N3O2: 304.1065, found: 304.1086.

Example LII Preparation of 3-(4-methylthiophenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0219] Prepared in a similar fashion as described for example I using 4′-methylthioacetophenone as the starting material. mp 283° C.; CIMS m/e calc'd for C19H15N3O2S: 350.0956, found: 350.0963.

Example LIII Preparation of 3-(4-methylsulphonylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0220] Prepared by oxidation of the product of example LII. mp>300° C.; CIMS m/e calc'd for C19H15N3O4S: 382.0860, found: 382.0862.

Example LIV Preparation of 3-(4-N,N-dimethylaminophenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0221] Prepared in a similar fashion as described for example I using 4′-N,N,-dimethylaminoacetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C20H18N4O2: 347.1496, found: 347.1508.

Example LV Preparation of 3-(4-N,N-dimethylaminophenyl)-5-(morpholinylacetamido)indeno[1,2-c]pyrazol-4-one

[0222] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and morpholine as the starting materials. mp>300° C.; CIMS m/e calc'd for C24H26N5O3: 432.2036, found: 432.2020.

Example LVI Preparation of 3-(4-N,N-dimethylaminophenyl)-5-(dimethylaminoacetamido)indeno[1,2-c]pyrazol-4-one

[0223] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and dimethylamine as the starting materials. mp>300° C.; CIMS m/e calc'd for C22H24N5O2: 390.1930, found: 390.1948.

Example LVII Preparation of 3-(4-(1-piperidinyl)phenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0224] Prepared in a similar fashion as described for example I using 4′-(1-piperidinyl)acetophenone as the starting material. mp 291° C.; CIMS m/e calc'd for C23H22N4O2: 387.1801, found: 387.1821.

Example LVIII Preparation of 3-(4-morpholinyl)phenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0225] Prepared in a similar fashion as described for example I using 4′-morpholinylacetophenone as the starting material. mp>300° C.; CIMS m/e calc'd for C22H20N4O3: 388.1528, found: 388.1535.

Example LIX Preparation of 3-(4-ethoxyphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0226] Prepared in a similar fashion as described for example I using 4′-ethoxyacetophenone as the starting material. mp 288° C.; CIMS m/e calc'd for C20H17N3O3: 348.1325, found: 348.1348.

Example LX Preparation of 3-(4-butylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0227] Prepared in a similar fashion as described for example I using 4′-butylacetophenone as the starting material. mp 259° C.; CIMS m/e calc'd for C22H21N3O2: 360.1701, found: 360.1712.

Example LXI Preparation of 3-(4-ethylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0228] Prepared in a similar fashion as described for example I using 4′-ethylacetophenone as the starting material. mp 294° C.; CIMS m/e calc'd for C21H17N3O2: 331.1310, found: 331.1321.

Example LXII Preparation of 3-(4-n-propylphenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0229] Prepared in a similar fashion as described for example I using 4′-n-propylacetophenone as the starting material. mp 269° C.; CIMS m/e calc'd for C21H19N3O2: 346.1555, found: 346.1554.

Example LXIII Preparation of 3-(4-methoxyphenyl)-5-carbamoylaminoindeno[1,2-c]pyrazol-4-one

[0230] Prepared in a similar fashion as described for example XLII using concentrated ammonium hydroxide as the starting material. mp>300° C.; CIMS m/e calc'd for C18H15N4O3: 335.1144, found: 335.1113.

Example LXIV Preparation of 3-(4-methoxyphenyl)-5-(dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0231] Prepared in a similar fashion as described for example XLII using dimethylamino hydrazine as the starting material. mp>300° C.; CIMS m/e calc'd for C20H20N5O3: 378.1566, found: 378.1555.

Example LXV Preparation of 3-(4-methoxyphenyl)-5-(methylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0232] Prepared in a similar fashion as described for example XLII using methylamine as the starting material. mp>300° C.; CIMS m/e calc'd for C19H17N4O3: 349.1300, found: 349.1311.

Example LXVI Preparation of 3-(4-methoxyphenyl)-5-(morpholinocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0233] Prepared in a similar fashion as described for example XLII using N-aminomorpholine as the starting material. mp>300° C.; CIMS m/e calc'd for C22H22N5O4: 420.1671, found: 420.1655.

Example LXVII Preparation of 3-(4-methoxyphenyl)-5-(cis-2-aminocyclohexanylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0234] Prepared in a similar fashion as described for example XLII using cis-1,2-diaminocyclohexane as the starting material. mp>300° C.; CIMS m/e calc'd for C24H26N5O3: 432.2035, found: 432.2020.

Example LXVIII Preparation of 3-(4-methoxyphenyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0235] Prepared in a similar fashion as described for example XLII using (4-amino)methylpiperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C23H25N6O3: 433.1987, found: 433.1999.

Example LXIX Preparation of 3-(4-methoxyphenyl)-5-(4-uridomethylpiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

[0236] Prepared in a similar fashion as described for example XXIII using example XXX as the starting material. mp>300° C.; CIMS m/e calc'd for C26H29N6O4: 489.2250, found: 489.2209.

Example LXX Preparation of 3-(4-methoxyphenyl)-5-(4-(2-pyridyl)piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

[0237] Prepared in a similar fashion as described for example XXIII using 4-(2-pyridyl)piperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C28H27N6O3: 495.2144, found: 495.2111.

Example LXXI Preparation of 3-(4-methoxyphenyl)-5-(4-(aminoethyl)piperazinylacetamido)indeno[1,2-c]pyrazol-4-one

[0238] Prepared in a similar fashion as described for example XXIII using 4-(aminoethyl)piperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C25H29N6O3: 461.2300, found: 461.2333.

Example LXXII Preparation of 3-(4-methoxyphenyl)-5-(4-amidopiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

[0239] Prepared in a similar fashion as described for example XXIII using isonipecotamide as the starting material. mp>300° C.; CIMS m/e calc'd for C25H26N5O4: 460.1984, found: 460.1998.

Example LXXIII Preparation of 3-(4-methoxyphenyl)-5-(4-hydroxypiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

[0240] Prepared in a similar fashion as described for example XXIII using 4-hydroxypiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C24H25N4O4: 433.1875, found: 433.1844.

Example LXXIV Preparation of 3-(4-methoxyphenyl)-5-(4-hydroxmethylypiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

[0241] Prepared in a similar fashion as described for example XXIII using 4-hydroxmethylypiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C25H27N4O4: 447.2032, found: 447.2002.

Example LXXV Preparation of 3-(4-methoxyphenyl)-5-(4-amidopiperazinylacetamido)indeno[1,2-c]pyrazol-4-one

[0242] Prepared in a similar fashion as described for example XXIII using 4-amidopiperazine as the starting material. mp>300° C.; CIMS m/e calc'd for C24H25N6O6: 493.1835, found: 493.1802.

Example LXXVI Preparation of 3-(4-methoxyphenyl)-5-(4-dimethylaminopiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

[0243] Prepared in a similar fashion as described for example XXIII using 4-dimethylaminopiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C26H30N5O5: 492.2246, found: 492.2220.

Example LXXVII Preparation of 3-(4-methoxyphenyl)-5-(4-aminopiperadinylacetamido)indeno[1,2-c]pyrazol-4-one

[0244] Prepared in a similar fashion as described for example XXIII using 4-aminopiperadine as the starting material. mp>300° C.; CIMS m/e calc'd for C24H26N5O5: 464.1933, found: 464.1975.

Example LXXVIII Preparation of 3-(4-(dimethylamino)phenyl)-5-((4-methyl-1-piperazinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0245] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and 1-methylpiperazine as the starting materials. mp>300° C.; ESI-MS m/e calc'd for C25H29N6O2: 445.2352, found: 445.2359.

Example LXXIX Preparation of 3-(4-(dimethylamino)phenyl)-5-((4-amino methyl-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0246] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and 4-(aminomethyl)piperidine as the starting materials. ESI-MS m/e calc'd for C26H31N6O2: 459.2508, found: 459.2508.

Example LXXX Preparation of 3-(4-(dimethylamino)phenyl)-5-((4-hydroxy-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0247] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LIV and 4-hydroxypiperidine as the starting materials. mp 267° C.; ESI-MS m/e calc'd for C25H28N5O3: 446.2192, found: 446.2206.

Example LXXXI Preparation of 3-(4-(4-morpholinyl)phenyl)-5-(4-morpholinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0248] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and morpholine as the starting materials. mp 258° C.; ESI-MS m/e calc'd for C26H28N5O4: 474.2141, found: 474.2151.

Example LXXXII Preparation of 3-(4-(4-morpholinyl)phenyl)-5-((4-methyl-1-piperazinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0249] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and 1-methylpiperazine as the starting materials. mp 258° C.; ESI-MS m/e calc'd for C27H31N6O3: 487.2457, found: 487.2447.

Example LXXXIII Preparation of 3-(4-(4-morpholinyl)phenyl)-5-((4-hydroxy-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0250] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and 4-hydroxypiperidine as the starting materials. mp 245° C.; ESI-MS m/e calc'd for C27H30NSO4: 488.2298, found: 488.2290.

Example LXXXIV Preparation of 3-(4-(4-morpholinyl)phenyl)-5-((4-amino methyl-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0251] Prepared in a similar fashion as described for examples II and XXIII employing the product of example LVIII and 4-(aminomethyl)piperidine as the starting materials. mp 240° C.; ESI-MS m/e calc'd for C28H33N6O3: 501.2614, found: 501.2619.

Example LXXXV Preparation of 3-(4-(dimethylamino)phenyl)-5-((((4-methyl-1-piperazinyl)amino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0252] Prepared in a similar fashion as described for examples I, XXVII, and XLII employing the 4-(dimethylamino) acetophenone and l-amino-4-methylpiperazine as the starting materials. mp>300° C.; ESI-MS m/e calc'd for C24H28N7O2: 446.2304, found: 446.2310.

Example LXXXVI Preparation of 3-(i-propyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0253] 21

[0254] Step 1. Synthesis of 26 from 3-nitrophthalic Anhydride.

[0255] A solution of 3-nitrophthalic anhydride (9.7 g, 50 mmol) and 1,1,1-trifluoro-5-methyl-2,4-hexanedione (9.1 g, 50 mmol) in acetic anhydride (28.3 mL, 300 mmol) was treated with triethylamine (13.95 mL, 100 mmol) and stirred at 25° C. for 4 h. The solution was diluted with 1 N HCl (200 mL) and the precipate collected and washed with water (200 mL) and hexane (400 mL) to give the product as a yellow solid (11.1 g, 85%). mp 127-129° C.; CIMS (M+H) calc'd for C13H12NO5: 262.0715, found: 262.0694.

[0256] Step 2. Synthesis of Triketone 27 from 26.

[0257] A solution of 26 (11 g, 42 mmol) in EtOH (224 mL) and water (56 mL) was treated with zinc (90 g, 1.4 mol) and calcium chloride (3 g, 27 mmol) and heated to reflux for 16 h. The reaction was filtered (Celite) and the filtrate was concentrated at reduced pressure to give an aqueous residue which was extracted with EtOAc (100 mL). The organic layer was separated and washed with sat. EDTA (100 ml) and brine (100 mL), dried (MgSO4), filtered, and concentrated at reduced pressure to give a yellow solid. Trituration with hexane gave the product as a yellow solid (7.1 g, 73%). mp 241-243° C.; CIMS (M+H) calc'd for C13H14NO3: 232.0974, found: 232.0962.

[0258] Step 3. Synthesis of 28 from 27.

[0259] A solution of 27 (500 mg, 2.16 mmol) in CH2Cl2 (5 mL) was treated with Et3N (0.36 mL, 2.59 mmol) and stirred at 25° C. for 15 min. The reaction mixture was treated with acetyl chloride (0.18 mL, 2.38 mmol) and stirred at 25° C. for 1 h. The reaction mixture was quenched with 1 N HCl (20 mL) and extracted with EtOAc (20 mL). The organic layer was separated, dried (MgSO4), filtered, and concentrated at reduced pressure to give a brown residue. Trituration with hexane gave the product as a tan solid (484 mg, 82%). mp 241-243° C.; CIMS (M+H) calc'd for C15H16NO4: 274.1079, found: 274.1093.

[0260] Step 4. Synthesis of 29 from 28.

[0261] A solution of 28 (240 mg, 0.88 mmol) in BuOH (5 mL) was treated with hydrazine hydrate (0.055 mL, 1.76 mmol) and p-TsOH (8.4 mg, 0.044 mmol). The reaction was heated to reflux and stirred for 4 h. The reaction was cooled to 25° C. and the solvent removed at reduced pressure. Recrystalization with i-propyl alcohol gave the product collected as an off-white solid (173 mg, 73%). mp>250° C.; ESIMS (M+H) calc'd for C15H16N3O2: 270.1242, found: 270.1258.

Example LXXXVII Preparation of 3-(c-propyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0262] Prepared in a similar fashion as described for example LXXXVI using the c-propyl analog of 26 as the starting material. mp 220-221° C.; CIMS (M+H) calc'd for C15H14N3O2: 268.1086, found: 268.1078.

Example LXXXVIII Preparation of 3-(t-butyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0263] Prepared in a similar fashion as described for example LXXXVI using the t-butyl analog of 26 as the starting material. mp>250° C.; CIMS (M+H) calc'd for C16H18N3O2: 284.1399, found: 284.1395.

Example LXXXIX Preparation of 3-(2-thienyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0264] Prepared in a similar fashion as described for example LXXXVI using the 2-thienyl analog of 26 as the starting material. mp 269° C.; CIMS (M+H) calc'd for C16H12N3O2S: 310.0650, found: 310.0635.

Example XC Preparation of 3-(3-methyl-2-thienyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0265] Prepared in a similar fashion as described for example LXXXVI using the 3-methyl-2-thienyl analog of 26 as the starting material. mp 275° C.; ESIMS (M+H) calc'd for C17H14N3O2S: 324.0811, found: 324.0807.

Example XCI Preparation of 3-(ethyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0266] Prepared in a similar fashion as described for example LXXXVI using ammonia and the ethyl analog of 15 as the starting materials. mp>250° C.; CIMS (M+H) calc'd for C13H13N4O2: 257.1039, found: 257.1033.

Example XCII Preparation of 3-(n-propyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0267] Prepared in a similar fashion as described for example LXXXVI using ammonia and the n-propyl analog of 15 as the starting materials. mp 187-189° C.; CIMS (M+H) calc'd for C14H15N4O2: 271.1195, found: 271.1187.

Example XCIII Preparation of 3-(i-propyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0268] Prepared in a similar fashion as described for example LXXXVI using ammonia and the i-propyl analog of 15 as the starting materials. mp>250° C.; CIMS (M+H) calc'd for C14H15N4O2: 271.1195, found: 271.1196.

Example XCIV Preparation of 3-(c-propyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0269] Prepared in a similar fashion as described for example LXXXVI using ammonia and the c-propyl analog of 15 as the starting materials. mp 252-253° C.; ESIMS (M−H) calc'd for C14H11N4O2: 267.0881, found: 267.0884.

Example XCV Preparation of 3-(c-hexyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0270] Prepared in a similar fashion as described for example LXXXVI using ammonia and the c-hexyl analog of 15 as the starting materials. mp 178-179° C.; ESIMS (M+H) calc'd for C17H19N4O2: 311.1507, found: 311.1500.

Example XCVI Preparation of 3-(2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0271] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 2-thienyl analog of 15 as the starting materials. mp 214° C.; CIMS m+calc'd for C15H10N4O2S: 310.0517, found: 310.0524.

Example XCVII Preparation of 3-(3-methyl-2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0272] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 3-methyl-2-thienyl analog of 15 as the starting materials. mp 270° C.; ESIMS (M+H) calc'd for C16H13N4O2S: 325.0759, found: 325.0744.

Example XCVIII Preparation of 3-(5-methyl-2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0273] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 5-methyl-2-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C16H13N4O2S: 325.0759, found: 325.0761.

Example XCIX Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0274] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C18H15N4O4S: 383.0813, found: 383.0788.

Example C Preparation of 3-(3-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0275] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 3-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C15H11N4O2S: 311.0603, found: 311.0594.

Example CI Preparation of 3-(5-chloro-3-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0276] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 5-chloro-3-thienyl analog of 15 as the starting materials. mp>300° C.; ESIMS (M+H) calc'd for C15H10N4O2SCl: 345.0209, found: 345.0213.

Example CII Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0277] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C17H15N4O2S: 339.0916, found: 339.0905.

Example CIII Preparation of 3-(2-furanyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0278] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 2-furanyl analog of 15 as the starting materials. mp 278° C.; ESIMS (M+H) calc'd for C15H11N4O3: 295.0831, found: 295.0838.

Example CIV Preparation of 3-(i-propyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0279] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the i-propyl analog of 15 as the starting materials. mp 231-233° C.; ESIMS (M+H) calc'd for C16H20N5O2: 314.1616, found: 314.1599.

Example CV Preparation of 3-(c-propyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0280] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the c-propyl analog of 15 as the starting materials. mp XXX ° C.; ESIMS (M+H) calc'd for C16H18N5O2: 312.1460, found: 312.1487.

Example CVI Preparation of 3-(c-hexyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0281] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the c-hexyl analog of 15 as the starting materials. mp 229-231° C.; ESIMS (M+H) calc'd for C19H24N5O2: 354.1929, found: 354.1932.

Example CVII Preparation of 3-(2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0282] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 2-thienyl analog of 15 as the starting materials. mp 279° C.; ESIMS (M+H) calc'd for C17H16N5O2S: 354.1024, found: 354.1025.

Example CVIII Preparation of 3-(5-methoxy-2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0283] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 5-methoxy-2-thienyl analog of 15 as the starting materials. mp 280° C.; ESIMS (M+H) calc'd for C18H18N5O3S: 384.1130, found: 384.1119.

Example CIX Preparation of 3-(5-methyl-2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0284] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 5-methyl-2-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C18H18N5O2S: 368.1181, found: 368.1171.

Example CX Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0285] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp 252° C.; ESIMS (M+H) calc'd for C20H20N5O4S: 426.1236, found: 426.1251.

Example CXI Preparation of 3-(3-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0286] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 3-thienyl analog of 15 as the starting materials. mp 202° C.; ESIMS (M+H) calc'd for C17H16N5O2S: 354.1025, found: 354.1031.

Example CXII Preparation of 3-(1-methyl-3-pyrrolyl)-5-(carbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0287] Prepared in a similar fashion as described for example LXXXVI using ammonia and the 1-methyl-3-pyrrolyl analog of 15 as the starting materials. mp>300° C.; ESIMS (M+H) calc'd for C16H14N5O2: 308.1147, found: 308.1166.

Example CXIII Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0288] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp 252° C.; ESIMS (M+H) calc'd for C19H20NSO2S: 382.1338, found: 382.1357.

Example CXIV Preparation of 3-(2-furanyl)-5-(N,N-dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0289] Prepared in a similar fashion as described for example LXXXVI using 1,1-dimethylhydrazine and the 2-furanyl analog of 15 as the starting materials. mp 202° C.; ESIMS (M+H) calc'd for C17H16N5O3: 338.1253, found: 338.1248.

Example CXV Preparation of 3-(i-propyl)-5-(4-carbamoylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0290] Prepared in a similar fashion as described for example XXIII using isonipecotamide and the i-propyl analog of 14 as the starting materials. mp 224-225° C.; ESIMS (M+H) calc'd for C21H26N5O3: 396.2035, found: 396.2036.

Example CXVI Preparation of 3-(c-hexyl)-5-(4-carbamoylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0291] Prepared in a similar fashion as described for example XXIII using isonipecotamide and the c-hexyl analog of 14 as the starting materials. mp 228-229° C.; ESIMS (M+H) calc'd for C24H30N5O3: 436.2348, found: 436.2345.

Example CXVII Preparation of 3-(ethyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0292] Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the ethyl analog of 14 as the starting materials. mp 174-176° C.; ESIMS (M+H) calc'd for C20H26N5O2: 368.2086, found: 368.2078.

Example CXVIII Preparation of 3-(i-propyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0293] Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the i-propyl analog of 14 as the starting materials. mp 218-220° C.; ESIMS (M+H) calc'd for C21H28N5O2: 382.2242, found: 382.2227.

Example CXIX Preparation of 3-(c-propyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0294] Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the c-propyl analog of 14 as the starting materials. mp 138-140° C.; ESIMS (M+H) calc'd for C21H26N5O2: 380.2086, found: 380.2079.

Example CXX Preparation of 3-(c-hexyl)-5-(4-aminomethylpiperidinylacetamido)indeno[1,2-c]pyrazol-4-one

[0295] Prepared in a similar fashion as described for example XXIII using 4-(aminomethyl)piperidine and the c-hexyl analog of 14 as the starting materials. mp 196-198° C.; ESIMS (M+H) calc'd for C24H32N5O2: 422.2555, found: 422.2540.

Example CXXI Preparation of 3-(i-propyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0296] Prepared in a similar fashion as described for example LXXXVI using 1-amino-4-methylpiperazine and the i-propyl analog of 15 as the starting materials. mp 231-233° C.; ESIMS (M+H) calc'd for C19H25N6O2: 369.2038, found: 369.2039.

Example CXXII Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0297] Prepared in a similar fashion as described for example LXXXVI using 1-amino-4-methylpiperazine and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp 249° C.; ESIMS (M+H) calc'd for C23H25N6O4S: 481.1657, found: 481.1642.

Example CXXIII Preparation of 3-(5-carboxyl-2-thienyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0298] A solution of CXXII (30 mg, 0.05 mmol) in 3:1 THF/water (2 mL) was treated with LiOH (23 mg, 0.5 mmol) and the reaction was stirred at 25° C. for 12 h and then heated to reflux for 1 h. The organic solvent was removed at reduced pressure and the residue was partioned between EtOAc (5 mL) and water (5 mL). The organic layer was separated and the aqueous phase was adjusted to pH=2 with 1 M HCl and re-extracted with EtOAc (5 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated at reduced pressure to give a crude residue. Purification by reverse phase HPLC gave the product as a yellow solid (10.4 mg, 46%). mp 270° C.; ESIMS (M+H) calc'd for C21H21N6O4S: 453.1344, found: 453.1353.

Example CXXIV Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(4-methylpiperazinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0299] Prepared in a similar fashion as described for example LXXXVI using 1-amino-4-methylpiperazine and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp 250° C.; ESIMS (M+H) calc'd for C22H25N6O2S: 437.1760, found: 437.1771.

Example CXXV Preparation of 3-(i-propyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0300] Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the i-propyl analog of 15 as the starting materials. mp 256-258° C.; ESIMS (M−H) calc'd for C18H20N5O3: 354.1566, found: 354.1543.

Example CXXVI Preparation of 3-(N-methylcarbamoyl-4-piperidinyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0301] Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the N-methylcarbamoyl-4-piperidinyl analog of 15 as the starting materials. mp 216-218° C.; ESIMS (M+H) calc'd for C22H27N6O5: 455.2042, found: 455.2036.

Example CXXVII Preparation of 3-(5-methyl-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0302] Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 5-methyl-2-thienyl analog of 15 as the starting materials. mp 261° C.; ESIMS (M+H) calc'd for C20H20N5O3S: 410.1287, found: 410.1308.

Example CXXVIII Preparation of 3-(5-chloro-3-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0303] Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 5-chloro-3-thienyl analog of 15 as the starting materials. mp 259° C.; ESIMS (M+H) calc'd for C19H17N5O3SCl: 430.0741, found: 430.0757.

Example CXXIX Preparation of 3-(2,5-dimethyl-3-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0304] Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 2,5-dimethyl-3-thienyl analog of 15 as the starting materials. mp>280° C.; ESIMS (M+H) calc'd for C21H22N5O3S: 424.1443, found: 424.1431.

Example CXXX Preparation of 3-(5-ethylcarboxyl-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0305] Prepared in a similar fashion as described for example LXXXVI using 4-aminomorpholine and the 5-ethylcarboxyl-2-thienyl analog of 15 as the starting materials. mp 258° C.; ESIMS (M+H) calc'd for C22H22N5O5S: 468.1341, found: 468.1331.

Example CXXXI Preparation of 3-(5-carboxyl-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0306] Prepared in a similar fashion as described for example LXXXVI (HYDROLYSIS OF PREVIOUS ESTER). mp 273° C.; ESIMS (M+H) calc'd for C20H18N5O5S: 440.1028, found: 440.1026.

Example CXXXII Preparation of 3-(5-benzylcarboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0307] A solution of benzylamine (0.01 mL, 0.09 mmol) in DMF (1 mL) was treated with acid CXXXI (40 mg, 0.09 mmol) and stirred at 25° C. The reaction was treated with TBTU (29 mg, 0.09 mmol) and stirred at 25° C. for 30 min. Triethylamine (0.01 mL, 0.09 mmol) was added and the reaction stirred at 25° C. for 12 h. After adding more TBTU (15 mg, 0.045 mmol) and triethylamine (0.01 mL, 0.09 mmol) the reaction was stirred at 25° C. for an additional 4 h. The reaction was diluted with EtOAc (10 mL) and water (10 mL) and the aqueous layer was extracted with EtOAc (5×10 mL). The combined organic layers were dried (Na2SO4), filtered, and the solvent removed at reduced pressure. Purification of the residue using reverse phase HPLC gave the product as a yellow solid (21 mg, 42%). mp 275° C.; ESIMS (M+H) calc'd for C27H25N5O4S: 529.1659, found: 529.1682.

Example CXXXIII Preparation of 3-(5-(4-methylpiperazinyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0308] Prepared in a similar fashion as described for example CXXXII using 1-amino-4-methylpiperazine as the starting material. mp 190° C.; ESIMS (M+H) calc'd for C25H29N8O4S: 537.2032, found: 537.2055.

Example CXXXIV Preparation of 3-(5-(2-(1-methylpyrrolidinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0309] Prepared in a similar fashion as described for example CXXXII using 2-(2-aminoethyl)-1-methylpyrrolidine as the starting material. mp 235° C.; ESIMS (M+H) calc'd for C27H32N7O4S: 550.2236, found: 550.2229.

Example CXXXV Preparation of 3-(5-(N,N-dimethylamino)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0310] Prepared in a similar fashion as described for example CXXXII using 1,1-dimethylhydrazine as the starting material. mp 201° C.; ESIMS (M+H) calc'd for C22H24N7O4S: 482.1610, found: 482.1588.

Example CXXXVI Preparation of 3-(5-(2-(N,N-dimethylamino)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0311] Prepared in a similar fashion as described for example CXXXII using N,N-dimethylethylenediamine as the starting material. mp 190° C.; ESIMS (M+H) calc'd for C24H28N7O4S: 510.1923, found: 510.1922.

Example CXXXVII Preparation of 3-(5-(2-(pyrrolidinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0312] Prepared in a similar fashion as described for example CXXXII using 1-(2-aminoethyl)pyrrolidine as the starting material. mp 224° C.; ESIMS (M+H) calc'd for C26H30N7O4S: 536.2080, found: 536.2091.

Example CXXXVIII Preparation of 3-(5-(2-(morpholinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0313] Prepared in a similar fashion as described for example CXXXII using 4-(2-aminoethyl)morpholine as the starting material. mp 241° C.; ESIMS (M+H) calc'd for C26H30N7O5S: 552.2029, found: 552.2043.

Example CXXXIX Preparation of 3-(5-morpholinylcarboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0314] Prepared in a similar fashion as described for example CXXXII using 4-aminomorpholine as the starting material. mp 271° C.; ESIMS (M+H) calc'd for C24H26N7O5S: 524.1716, found: 524.1719.

Example CXL Preparation of 3-(5-(3-(pyrrolidonyl)propyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0315] Prepared in a similar fashion as described for example CXXXII using 1-(3-aminopropyl)-2-pyrrolidinone as the starting material. mp 260° C.; ESIMS (M+H) calc'd for C27H30N7O5S: 564.2029, found: 564.2031.

Example CXLI Preparation of 3-(5-(2-(3-pyridyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0316] Prepared in a similar fashion as described for example CXXXII using 3-(2-aminoethyl)pyridine as the starting material. mp 203° C.; ESIMS (M+H) calc'd for C27H26N7O4S: 544.1766, found: 544.1760.

Example CXLII Preparation of 3-(5-(3-(imidazolyl)propyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0317] Prepared in a similar fashion as described for example CXXXII using 1-(3-aminopropyl)imidazole as the starting material. mp 263° C.; ESIMS (M+H) calc'd for C26H27N8O4S: 547.1875, found: 547.1872.

Example CXLIII Preparation of 3-(5-(2-(2-pyridyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0318] Prepared in a similar fashion as described for example CXXXII using 2-(2-aminoethyl)pyridine as the starting material. mp>280° C.; ESIMS (M+H) calc'd for C27H26N7O4S: 544.1767, found: 544.1778.

Example CXLIV Preparation of 3-(5-((2-pyridyl)methyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0319] Prepared in a similar fashion as described for example CXXXII using 2-(aminomethyl)pyridine as the starting material. mp 239° C.; ESIMS (M+H) calc'd for C26H24N7O4S: 530.1610, found: 530.1603.

Example CXLV Preparation of 3-(5-(2-(piperidinyl)ethyl)carboxamido-2-thienyl)-5-(morpholinylcarbamoyl)aminoindeno[1,2-c]pyrazol-4-one

[0320] Prepared in a similar fashion as described for example CXXXII using 1-(2-aminoethyl)piperidine as the starting material. mp 228° C.; ESIMS (M+H) calc'd for C27H32N7O4S: 550.2236, found: 550.2236.

Example CXLVI Preparation of 3-(4-(trifluoromethyl)phenyl)-5-(acetamido)indeno[1,2-c]pyrazol-4-one

[0321] Prepared in a similar fashion as described for example LXXXVI employing 1-(4-(trifluoromethyl)phenyl)-4,4,4-trifluoro-1,3-butanedione as the starting material. mp>300° C.; ESI−-MS m/e calc'd for C19H11N3O2: 370.0804, found: 370.0809.

Example CXLVII Preparation of 3-(4-(4-t-butoxycarbonyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0322] 22

[0323] Step 1. Synthesis of 30.

[0324] A solution of 4-piperazinoacetophenone (24.8 g, 121 mmol) and di-tert-butyl dicarbonate (27.8 g, 128 mmol) in 480 mL of tetrahydrofuran was refluxed for 16 h. After cooling to room temperature the solution was concentrated under vacuum. The resulting solids were washed with hexane and dried under vacuum to afford 29.4 g (80%) of the product as an off-white solid. NMR (CDCl3) &dgr; 7.89 (d, 2H, J=9 Hz), 6.87 (d, 2H, J=9 Hz), 3.59 (m, 4H), 3.33 (m, 4H), 2.53 (s, 3H), 1.49 (s, 9H)

[0325] Step 2. Synthesis of 31 from 30.

[0326] To a solution of 30 (11.35 g, 37 mmol) and ethyl trifluoroacetate (5.40 mL, 45 mmol) in 50 mL of tetrahydrofuran at 25° C. was added dropwise over 15 min. 21% sodium ethoxide in ethanol (16.8 mL, 45 mmol), and the resulting solution then was stirred at 25° C. for 14 h. The reaction mixyure was diluted with water, adjusted to pH 5 with conc. hydrochloric acid, and extracted with ethyl acetate. The combined extracts was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting solid was washed with diethyl ether and dried to furnish 12.1 g (81%) of the product as an orange solid. NMR (CDCl3) &dgr; 7.87 (d, 2H, J=9 Hz), 6.87 (d, 2H, J=9 Hz), 6.45 (s, 1H), 3.60 (m, 4H), 3.41 (m, 4H), 1.48 (s, 9H).

[0327] Step 3. Synthesis of CXLVII from 31.

[0328] Prepared in a similar fashion as described for examples LXXVI and XLII employing 31 and 4-aminomorpholine as starting materials. mp 242° C.; ESI-MS m/e calc'd for C30H36N7O5574.2778, found: 574.2762.

Example CXLVIII Preparation of 3-(4-(1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0329] A solution of CXLVII (0.58 g, 1.0 mmol) in 20 mL of trifluoroacetic acid was stirred at 25° C. for 2 h. The reaction mixture was concentrated under vacuum, and the residue was recrystallized from ethanol to provide 0.53 g (89%) of the yellow product as its TFA-salt. mp 263° C.; ESI-MS m/e calc'd for C25H28N7O3: 474.2254, found: 474.2280.

Example CXLIX Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((aminocarbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0330] Prepared in a similar fashion as described for examples XLII and CXLVIII employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII and ammonia as the starting materials. mp 257° C.; ESI-MS m/e calc'd for C21H21N6O2: 389.1726, found: 389.1724.

Example CL Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((hydrazinocarbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0331] Prepared in a similar fashion as described for examples XLII and CXLVIII employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII and hydrazine as the starting materials. mp 257° C.; ESI-MS m/e calc'd for C21H22N7O2: 404.1835, found: 404.1834.

Example CLI Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((dimethylamino)acetamido)indeno[1,2-c]pyrazol-4-one

[0332] Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with dimethylamine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. mp 243° C.; ESI-MS m/e calc'd for C24H27N6O2: 431.2196, found: 431.2198.

Example CLII Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((4-morpholinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0333] Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with morpholine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. mp 259° C.; ESI-MS m/e calc'd for C26H29N6O3: 473.2301, found: 473.2302.

Example CLIII Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((4-methyl-1-piperazinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0334] Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with 1-methylpiperazine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. ESI-MS m/e calc'd for C27H32N7O2: 486.2618, found: 486.2608.

Example CLIV Preparation of 3-(4-(1-piperazinyl)phenyl)-5-((4-amino methyl-1-piperidinyl)acetamido)indeno[1,2-c]pyrazol-4-one

[0335] Prepared employing 2-(4-(4-t-butoxycarbonyl-1-piperazinyl)benzoyl)-4-amino-1,3-indanedione obtained in example CXLVII as the starting material. Chloroacetylation and treatment with 4-(aminomethyl)piperidine in a similar fashion as described for examples II and XXIII, followed by treatment with hydrazine and removal of the t-butoxycarbonyl group in a similar fashion as described for examples I and CXLVIII, afforded the example compound. mp 239° C.; ESI-MS m/e calc'd for C28H34N7O2: 500.2774, found: 500.2772.

Example CLV Preparation of 3-(4-(4-methyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0336] 23

[0337] To a solution of CXLVITI (0.17 g, 0.29 mmol) in 10 mL of methanol and 2 mL of water at 25° C. was added sequentially 37% aqueous formaldehyde (0.45 g, 5.8 mmol), sodium cyanoborohydride (0.18 g, 2.9 mmol), and 4 drops of acetic acid. The resulting solution was stirred at 25° C. for 16 h. The mixture was diluted with water. It then was made acidic (˜pH 1) with conc. hydrochloric acid and stirred for 10 min. The solution next was made basic (˜pH 13) with 50% aqueous sodium hydroxide and finally adjusted to pH 10 with 1 N hydrochloric acid. The mixture was extracted with 4:1 chloroform/isopropanol. The combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, and filtered. To the filtrate was added excess trifluoroacetic acid, and the solution was concentrated under vacuum. The residue was recrystallized from isopropanol to furnish 0.16 g (92%) of the yellow product as its TFA-salt. mp 245° C.; ESI-MS m/e calc'd for C26H30N7O3: 488.2410, found: 488.2420.

Example CLVI Preparation of 3-(4-(4-ethyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0338] Prepared in a similar fashion as described for example CLV employing CXLVIII and acetaldehyde as the starting materials. mp 245° C.; ESI-MS m/e calc'd for C27H32N7O3: 502.2567, found: 502.2555.

Example CLVII Preparation of 3-(4-(4-isopropyl-1-piperazinyl)phenyl)-5-(((4-morpholinylamino)carbonyl)amino)indeno[1,2-c]pyrazol-4-one

[0339] Prepared in a similar fashion as described for example CLV employing CXLVIII and acetone as the starting materials. mp 253° C.; ESI-MS m/e calc'd for C28H34N7O3: 516.2723, found: 516.2726.

Example CLVIII Preparation of 3-(4-methoxyphenyl)-5-(2-benzoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0340] Step 1. Synthesis of 31 from 13. 24

[0341] A suspension of aniline 31 (0.5 g, 1.7 mmol) in dioxane (10 mL) was treated with triethylamine (0.48 mL, 3.4 mmol) in one portion at room temperature. Then 2-(trimethylsilyl) ethyloxy chloride (SEMCl) (0.48 mL, 2.6 mmol) was added in one portion and the mixture heated to reflux for 2 h. The reaction was cooled, diluted with EtOAc (20 mL) washed with water (10 mL), dried (MgSO4) and the solvent removed at reduced pressure. The residue was taken up in benzene (3 mL), applied to a plug of silica gel (10 g) and eluted with EtOAc/Hexane (1:3) until all the yellow color was washed from the silica gel plug. The solvent was evaporated and the residue taken on to the next step. This material was dissolved in dioxane (10 mL) and treated with K2CO3 (0.36 g, 2.6 mmol) in one portion. Then phenylchloroformate (0.27 mL, 2.23 mmol) was added in one portion and the reaction heated to 50 C for 2 h. The reaction was cooled and the solvent removed at reduced pressure. The residue was recrystalized from EtOH to give a yellow solid (0.4 g, 43%). mp OC; CIMS m/e calculated for C30H32N3O5Si: 542.2111, found: 542.2101;

[0342] Step 2. Synthesis of Ex. CLVIII from 31.

[0343] Compound 31 (0.015 g, 0.03 mmol) in DMSO (0.2 mL) was treated with phenylcarbazte (0.008 g, 0.06 mmol) in one portion and heated to 80 C for 30 minutes. The solvent was removed at reduced pressure heating to 65 C. The residue was disolved in EtOH (0.5 mL) and treated with 4N HCl/dioxane (0.4 mL). The mixture was heated to 80 C for 20 minutes and then cooled. The desired product was filtered and air dried (0.008 g, 62%). mp>300° C.; CIMS m/e calculated for C26H27N4O4: 459.2032, found: 459.1999;

Example CLIX Preparation of 3-(4-methoxyphenyl)-5-(2-isonicotinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0344] Prepared in a similar fashion as described for example CLVIII using 4-pyridylcarbazate as the starting material. mp 248° C.; CIMS m/e calculated for C24H19N6O4: 455.1468, found: 455.1400;

Example CLX Preparation of 3-(4-methoxyphenyl)-5-(2-nictinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0345] Prepared in a similar fashion as described for example CLVIII using 3-pyridylcarbazate as the starting material. mp 227° C.; CIMS m/e calc'd for C24H19N6O4: 455.1468, found: 455.1487;

Example CLXI Preparation of 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxy benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0346] Prepared in a similar fashion as described for example CLVIII using 3,4-dihydroxyphenyl carbazate as the starting material. mp>300° C.; CIMS m/e calc'd for C25H20N5O6: 486.1414, found: 486.1497;

Example CLXII Preparation of 3-(4-methoxyphenyl)-5-(2-(4-hydroxy benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0347] Prepared in a similar fashion as described for example CLVIII using 4-hydroxyphenyl carbazate as the starting material. mp 283° C.; CIMS m/e calc'd for C25H20N5O5: 470.1464, found: 470.1544;

Example CLXIII Preparation of 3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0348] Prepared in a similar fashion as described for example CLVIII using 3-aminophenyl carbazate as the starting material. mp 250° C.; CIMS m/e calc'd for C25H21N6O4: 469.1624, found: 469.1513;

Example CLXIV Preparation of 3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0349] Prepared in a similar fashion as described for example CLVIII using 4-aminophenyl carbazate as the starting material. mp 247° C.; CIMS m/e calc'd for C25H21N6O4: 469.1624, found: 469.1528;

Example CLXV Preparation of 3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0350] Prepared in a similar fashion as described for example CLVIII using 2-aminophenyl carbazate as the starting material. mp 257° C.; CIMS m/e calc'd for C25H21N6O4: 469.1624, found: 469.1548;

Example CLXVI Preparation of 3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylamino benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0351] Prepared in a similar fashion as described for example CLVIII using 4-N,N-dimethylaminophenyl carbazate as the starting material. mp 259° C.; CIMS m/e calc'd for C27H25N6O4: 497.1937, found: 497.1876;

Example CLXVII Preparation of 3-(4-methoxyphenyl)-5-(2-phenethylacetyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0352] Prepared in a similar fashion as described for example CLVIII using benzyl carbazate as the starting material. mp 269° C.; CIMS m/e calc'd for C26H22N5O4: 468.1672, found: 468.1313;

Example CLXVIII Preparation of 3-(4-methoxyphenyl)-5-(2-(2-hydroxy benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0353] Prepared in a similar fashion as described for example CLVIII using 2-hydroxyphenyl carbazate as the starting material. mp 280° C.; CIMS m/e calc'd for C25H20N5O5: 470.1464, found: 470.1419;

Example CLXIX Preparation of 3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

[0354] Prepared in a similar fashion as described for example CLVIII using carbazic acid methyl ester as the starting material. mp>300° C.; CIMS m/e calc'd for C20H28N5O5: 408.1308, found: 408.1397;

Utility Inhibition of Kinase/Cyclin Complex Enzymatic Activity

[0355] Several of the compounds disclosed in this invention were assayed for their inhibitory activity against cdk4/D1 and cdk2/E kinase complexes. Briefly, the in vitro assays employ cell lysates from insect cells expressing either of the kinases and subsequently their corresponding regulatory units. The cdk2/cyclinE is purified from insect cells expressing His-tagged cdk2 and cyclin E. The cdk/cyclin lysate is combined in a microtitre-type plate along with a kinase compatible buffer, 32P-labeled ATP at a concentration of 50 mM, a GST-Rb fusion protein and the test compound at varying concentrations. The kinase reaction is allowed to proceeded with the radiolabled ATP, then effectively stopped by the addition of a large excess of EDTA and unlabeled ATP. The GST-Rb labeled protein is sequestered-on a GSH-Sepharose bead suspension, washed, resuspended in scintillant, and the 32P activity detected in a scintillation counter. The compound concentration which inhibits 50% of the kinase activity was calculated for each compound. A compound was considered active if its IC50 was found to be less than 1 &mgr;M.

Inhibition of HCT116 Cancer Cell Proliferation

[0356] To test the cellular activity of several compounds disclosed in this invention, we examined the effect of these compounds on cultured HCT116 cells and determined their effect on cell-cycle progression by the calorimetric cytotoxcity test using sulforhodamine B (Skehan et al. J. Natl. Cancer Inst. 82:1107-12, 1990). Briefly, HCT116 cells are cultured in the presence of test compounds at increasing concentrations. At selected time points, groups of cells are fixed with trichloroacetic acid and stained with sulforhodamine B (SRB). Unbound dye was removed by washing and protein-bound dye was extracted for determination of optical density. A compound was considered active if its IC50 was found to be less than 10 &mgr;M. 1 TABLE 1 25 Example R1 R2 mass mp # R1 R2 (M + H) (° C.) I Methyl 4-MeOC6H4 334 268 II ClCH2 4-MeOC6H4 382 274 III cyclopropyl 4-MeOC6H4 360 289 IV isopropyl 4-MeOC6H4 352 288 V ethyl 4-MeOC6H4 348 287 VI cyclopentyl 4-MeOC6H4 388 267 VII cyclobutyl 4-MeOC6H4 374 297 VIII benzyl 4-MeOC6H4 410 280 IX n-propyl 4-MeOC6H4 362 282 X 4-ClC6H4CH2 4-MeOC6H4 444 238 XI 3-MeOC6H4CH2 4-MeOC6H4 440 >300 XII 4-MeOC6H4CH2 4-MeOC6H4 440 280 XIII 3,4-diMeOC6H4CH2 4-MeOC6H4 470 >300 XIV 2,5-diMeOC6H4CH2 4-MeOC6H4 470 226 XV Methyl 2-MeOC6H4 334 276 XVI Methyl 3,4-diMeOC6H4 364 >300 XVII 3,4-(OCH2O)C6H4CH2 4-MeOC6H4 454 297 XVIII 3-thiophenylCH2 4-MeOC6H4 416 293 XIX 2-MeOC6H4CH2 4-MeOC6H4 440 255 XX 3,4-diClOC6H4CH2 4-MeOC6H4 479 299 XXI 2,4-diClOC6H4CH2 4-MeOC6H4 479 286 XXII 2-ClC6H4CH2 4-MeOC6H4 444 300 XXIII H2NCH2 4-MeOC6H4 349 >300 XXIV HOCH2CH2NHCH2 4-MeOC6H4 393 243 XXV Me2NCH2 4-MeOC6H4 377 279 XXVI piperaziflylCH2 4-MeOC6H4 418 277 XXVII 4-Me-piperaziflylCH2 4-MeOC6H4 432 >300 XXVIII 4-HOCH2CH2- 4-MeOC6H4 462 >300 piperazinylCH2 XXIX piperidinylCH2 4-MeOC6H4 417 291 XXX 4-NH2CH2- 4-MeOC6H4 446 >300 piperidinylCH2 XXXI CH3CH2NHCH2 4-MeOC6H4 377 250 XXXII thiornorpholiraylCH2 4-MeOC6H4 435 298 XXXIII morpholinylCH2 4-MeOC6H4 419 295 XXXIV pyrrolidinylCH2 4-MeOC6H4 403 279 XXXV 4-pyridylCH2NHCH2 4-MeOC6H4 440 >300 XXXVI 4-CH3CONHC6H4CH2 4-MeOC6H4 467 268 XXXVII 4-CH3OCONHC6H4CH2 4-MeOC6H4 483 257 XXXVIII 4-NH2CH2CONHC6H4CH2 4-MeOC6H4 482 228 XXXIX 4-Me2NCH2CONHC6H4CH2 4-MeOC6H4 510 >300 XL 4-N3C6H4CH2 4-MeOC6H4 451 >300 XLI 4-NH2C6H4CH2 4-MeOC6H4 425 283 XLII C6C6H5NH 4-MeOC6H4 411 >300 XLIII CH3CH2CH2NH 4-MeOC6H4 377 252 XLIV 4-NH2C6H4CH2NH 4-MeOC6H4 440 >300 XLV 4-pyridylCH2NH 4-MeOC6H4 426 >300 XLVI Methyl 4-HOC6H4 320 >300 XLVII H 4-MeOC6H4 320 280 XLVIII Methyl 3-pyridyl 305 >300 XLIX Methyl 4-pyridyl 305 >300 L H 4-pyridyl 291 >300 LI Methyl C6C6H5 305 >300 LII Methyl 4-MeSC6H4 351 283 LIII Methyl 4-MeSO2C6H4 383 >300 LVI Methyl 4-Me2NC6H4 348 >300 LV morpholinylCH2 4-Me2NC6H4 432 >300 LVI Me2NCH2 4-Me2NC6H4 390 >300 LVII Methyl 4-(piperdinyl)C6H4 388 291 LVIII Methyl 4- 389 >300 (morpholinyl) C6H4 LIX Methyl 4-CH3CH2OC6H4 349 288 LX Methyl 4-CH3CH2CH2CH2C6H4 361 259 LXI Methyl 4-CH3CH2C6H4 332 294 LXII Methyl 4-CH3CH2CH2C6H4 347 269 LXIII NH2 4-MeOC6H4 335 >300 LXIV Me2NNH 4-MeOC6H4 378 >300 LXV MeNH 4-MeOC6H4 349 >300 LXVI morpholiriylNH 4-MeOC6H4 420 >300 LXVII cis-1,2- 4-MeOC6H4 432 >300 diaminocyclohexanyl LXVIII 4- 4-MeOC6H4 433 >300 methylpiperazinylNH LXVIX 4- 4-MeOC6H4 489 >300 uridomethylpiperadin ylCH2 LXX 4-(2- 4-MeOC6H4 495 >300 pyridyl)piperazinyl CH2 LXXI 4- 4-MeOC6H4 461 >300 (aminoethyl)piperazl iylCH2 LXXII 4-amidopiperidinylCH2 4-MeOC6H4 460 >300 LXXIII 4- 4-MeOC6H4 433 >300 hydroxypiperidiflYl CH2 LXXIV 4- 4-MeOC6H4 447 >300 hydroxymethylpiperid inylCH2 LXXV 4-amidopiperaziflylCH2 4-MeOC6H4 493 >300 LXXVI 4- 4-MeOC6H4 492 >300 dimethylamiflOpiperad inylCH2 LXXVII 4-aminopiperadinylCH2 4-MeOC6H4 464 >300 LXXVIII 4-Me-piperazinylCH2 4-Me2NC6H4 445 >300 LXXIX 4-NH2CH2- 4-Me2NC6H4 459 NA piperidinylCH2 LXXX 4-OH-piperidiflYlCH2 4-Me2NC6H4 446 267 LXXXI morpholinylCH2 4- 474 258 (morpholinyl) C6H4 LXXXII 4-Me-piperazinylCH2 4- 258 (morpholinyl) C6H4 LXXXIII 4-OH-piperidinylCH2 4- 488 245 (morpholinyl) C6H4 LXXXIV 4NH2CH2 4- 501 240 (morpholinyl) C6H4 piperidinyl CH2 LXXXV 4-Me-piperazinylNH 4-Me2NC6H4 446 >300 LXXXVI Methyl i-propyl 270 >250 LXXXVII Methyl c-propyl 268 220 LXXXVIII Methyl t-butyl 284 >250 LXXXIX Methyl 2-thienyl 310 269 XC Methyl 3-Me-2-thienyl 324 275 XCI NH2 Ethyl 257 >250 XCII NH2 n-propyl 271 187 XCIII NH2 i-propyl 271 >250 XCIV NH2 c-propyl 267 252 (M-H) XCV NH2 c-hexyl 311 178 XCVI NH2 2-thienyl 310 214 (M+) XCVII NH2 3-Me-2-thienyl 325 270 XCVIII NH2 5-Me-2-thienyl 325 >280 XCIX NH2 5-CO2Et-2-thienyl 383 >280 C NH2 3-thienyl 311 >280 CI NH2 5-Cl-3-thienyl 345 >300 CII NH2 2,5-diMe-3-thienyl 339 >280 CIII NH2 2-furanyl 295 278 CIV Me2NNH i-propyl 314 231 CV Me2NNH c-propyl 312 CVI Me2NNH c-hexyl 354 229 CVII Me2NNH 2-thienyl 354 279 CVIII Me2NNH 5-MeO-2-thienyl 384 280 CIX Me2NNH 5-Me-2-thienyl 368 >280 CX Me2NNH 5-CO2Et-2-thienyl 426 252 CXI Me2NNH 3-thienyl 354 202 CXII NH2 i-methyl-3- 308 >300 pyrrolyl CXIII Me2NNH 2,5-diMe-3-thienyl 382 252 CXIV Me2NNH 2-furanyl 338 202 CXV 4-NH2CO- 1-propyl 396 224 piperidinylCH2 CXVI 4-NH2CO- c-hexyl 436 228 piperidinylCH2 CXVII 4-NH2CH2- ethyl 368 174 piperidinylCH2 CXVIII 4-NH2CH2- i-propyl 382 218 piperidinylCH2 CXVIX 4-NH2CH2- c-propyl 380 138 piperidinylCH2 CXX 4-NH2CH2- c-hexyl 422 196 piperidinylCH2 CXXI 4-CH3-piperazinylNH 1-propyl 369 231 CXXII 4-CH3-piperazinylNH 5-CO2Et-2-thienyl 481 249 CXXIII 4-CH3-piperazinylNH 5-CO2H-2-thienyl 453 270 CXXIV 4-CH3-piperazinylNH 2,5-diMe-3-thienyl 437 250 CXXV morpholinylNH 1-propyl 354 256 (M-H) CXXVI morpholinylNH 4-CO2Me- 455 216 piperidinyl CXXVII morpholinylNH 5-Me-2-thienyl 410 261 CXXVIII morpholinylNH 5-Cl-3-thienyl 430 259 CXXIX morpholinylNH 2,5-diMe-3-thienyl 424 >280 CXXX morpholinylNH 5-CO2Et-2-thienyl 468 258 CXXXI morpholinylNH 5-CO2H-2-thienyl 440 273 CXXXII morpholinylNH 5-CONHBn-2-thienyl 529 275 CXXXIII morpholinylNH 5-CONH(4-Me- 537 190 piperazinyl) -2- thienyl CXXXIV morpholinylNH 5-CONHCH2CH2(1-Me- 550 235 2-pyrrolidinyl) -2- thienyl CXXXV morpholinylNH 5-CONHNMe2-2- 482 201 thienyl CXXXVI morpholinylNH 5-CONHCH2CH2NMe2- 510 190 2-thienyl CXXXVII morpholinylNH 5-CONHCH2CH2(1- 536 224 pyrrolidinyl) -2- thienyl CXXXVIII morpholinylNH 5-CONHCH2CH2(1- 552 241 morpholinyl) -2- thienyl CXXXIX morpholinylNH 5-CONHmorpholinyl- 524 271 2 -thienyl CXL morpholinylNH 5-CONHCH2CH2CH2(1- 564 260 pyrrolidonyl) -2- thienyl CXLI morpholinylNH 5-CONHCH2CH2(3- 544 203 pyridyl) -2-thienyl CXLII morpholinylNH 5-CONHCH2CH2CH2(1- 547 263 imidazolyl) -2- thienyl CXLIII morpholLinylNH 5-CONHCH2CH2(2- 544 >280 pyridyl) -2-thienyl CXLIV morpholinylNH 5-CONHCH2(3- 530 239 pyridyl) -2-thienyl CXLV morpholinylNH 5-CONHCH2CH2(1- 550 228 piperidinyl) -2- thienyl CXLVI Methyl 4-CF3C6H4 370 >300 (M- H) CXLVII morpholinylNH 4-(4-BoC- 574 242 piperazinyl) C6H4 CXLVIII morpholinylNH 4- 474 263 (piperazinyl) C6H4 CXLIX NH2 4- 389 257 (piperazinyl) C6H4 CL NHhd 2NH 4- 404 257 (piperazinyl) C6H4 CLI Me2NCH2 4- 431 243 (piperazinyl) C6H4 CLII morpholiny-CH2 4- 473 259 (piperazinyl) C6H4 CLIII 4-Me-piperazinylCH2 4- 486 NA (piperazinyl) C6H4 CLIV 4NH2CH2 4- 500 239 (piperazinyl) C6H4 piperidinylCH2 CLV morpholinylNH 4-(4-Me- 488 245 piperazinyl) C6H4 CLVI morpholinylNH 4-(4-Et- 502 245 piperazinyl) C6H4 CLVII morpholinylNH 4-(4-i-Pr- 516 253 piperazinyl) C6H4 CLVIII C6H5C(O)NHNH 4-MeOC6H4 459 >300 CLIX 4-pyridylC(O)NHNH 4-MeOC6H4 455 248 CLX 3-pyridylC(O)NHNH 4-MeOC6H4 455 227 CLXI 3,4-dihydroxy- 4-MeOC6H4 486 >300 C6H3C(0) NHNH CLXII 4-hydroxy- 4-MeOC6H4 470 283 C6H4C(0)NHNH CLXIII 3-amino-C6H4C(0)NHNH 4-MeOC6H4 469 250 CLXIV 4-amino-C6H4C(O)NHNH 4-MeCC6H4 469 247 CLXV 2-amino-C6H4C(O)NHNH 4-MeOC6H4 469 257 CLXVI 4-N,N-dimethylamino- 4-MCOC6H4 497 259 C6H4C (0) NHNH CLXVII C6HSCH2C(0)NHNH 4-Me0C6H4 468 269 CLXVIII 2-hydroxy- 4-MeOC6H4 470 280 C6H4C(0)NHNH CLXIX MeOC(0)NHNH 4-MeOC6H4 408 >300

[0357] 2 TABLE 2 26 Example Number R1 R2 100 2-pyridylmethyl 4-MeOC6H4 101 2-pyridylmethyl 3-MeOC6H4 102 2-pyridylmethyl 4-NH2C6H4 103 2-pyridylmethyl 3-NH2C6H4 104 2-pyridylmethyl 2 -NH2C6H4 105 2-pyridylmethyl 4-Me2NC6H4 106 2-pyridylmethyl 3-Me2NC6H4 107 2-pyridylmethyl 2-Me2NC6H4 108 2-pyridylmethyl 4-pyridyl 109 2-pyridylmethyl 3-pyridyl 110 2-pyridylmethyl 2-pyridyl 111 2-pyridylmethyl 2-thiazolyl 112 2-pyridylmethyl 2-pyrazolyl 113 2-pyridylmethyl 5-isoquinolyl 114 2-pyridylmethyl 3,4- methylenedioxyC6H3 115 2-pyridylmethyl 3,4- ethylenedioxyC6H3 116 2-pyridylmethyl 2-imidazolyl 117 2-pyridylmethyl 2-oxazolyl 118 2-pyridylmethyl 4-isoxazolyl 119 2-pyridylmethyl 4-HOC6H4 120 2-pyridylmethyl 3-HOC6H4 121 2-pyridylmethyl 3,4-diHOC6H4 122 2-pyridylmethyl 4-NH2CH2C6H4 123 2-pyridylmethyl 3-NH2CH2C6H4 124 3-pyridylmethyl 4-MeOC6H4 125 3-pyridylmethyl 3 -MeOC6H4 126 3-pyridylmethyl 4-NH2C6H4 127 3-pyridylmethyl 3-NH2C6H4 128 3-pyridylmethyl 2-NH2C6H4 129 3-pyridylmethyl 4-Me2NC6H4 130 3-pyridylmethyl 3-Me2NC6H4 131 3-pyridylmethyl 2-Me2NC6H4 132 3-pyridylmethyl 4-pyridyl 133 3-pyridylmethyl 3-pyridyl 134 3-pyridylmethyl 2-pyridyl 135 3-pyridylmethyl 2-thiazolyl 136 3-pyridylmethyl 2-pyrazolyl 137 3-pyridylmethyl 5-isoqunolyl 138 3-pyridylmethyl 3,4- methylenedioxyC6H3 139 3-pyridylmethyl 3,4- methylenedioxyC6H3 140 3-pyridylmethyl 2-imidazolyl 141 3-pyridylmethyl 2-oxazolyl 142 3-pyridylmethyl 4-isoxazolyl 143 3-pyridylmethyl 4-HOC6H4 144 3-pyridylmethyl 3-HOC6H4 145 3-pyridylmethyl 3,4-diHOC6H4 146 3-pyridylmethyl 4-NH2CH2C6H4 147 3-pyridylmethyl 3-NH2CH2C6H4 148 4-pyridylmethyl 4-MeOC6H4 149 4-pyridylmethyl 3-MeOC6H4 150 4-pyridylmethyl 4-NH2C6H4 151 4-pyridylmethyl 3-NH2C6H4 152 4-pyridylmethyl 2-NH2C6H4 153 4-pyridylmethyl 4-Me2NC6H4 154 4-pyridylmethyl 3-Me2NC6H4 155 4-pyridylmethyl 2-Me2NC6H4 156 4-pyridylmethyl 4-pyridyl 157 4-pyridylmethyl 3-pyridyl 158 4-pyridylmethyl 2-pyridyl 159 4-pyridylmethyl 2-thiazolyl 160 4-pyridylmethyl 2-pyrazolyl 161 4-pyridylmethyl 5-isoquinolyl 162 4-pyridylmethyl 3,4- methylenedioxyC6H3 163 4-pyridylmethyl 3,4- ethylenedioxyC6H3 164 4-pyridylmethyl 2-imidazolyl 165 4-pyridylmethyl 2 -oxazolyl 166 4-pyridylmethyl 4-isoxazolyl 167 4-pyridylmethyl 4-HOC6H4 168 4-pyridylmethyl 3-HOC6H4 169 4-pyridylmethyl 3, 4-diHOC6H4 170 4-pyridylmethyl 4-NH2CH2C6H4 171 4-pyridylmethyl 3-NH2CH2C6H4 172 2-NH2C6H4CH2 4-MeOC6H4 173 2 -NH2C6H4CH2 3 -MeOC~H4 174 2-NH2C6H4CH2 4-NH2C6H4 175 2-NH2C6H4CH2 3-NH2C6H4 176 2-NH2C6H4CH2 2-NH2C6H4 177 2-NH2C6H4CH2 4-Me2NC6H4 178 2-NH2CSH4CH2 3-Me2NC6H4 179 2-NH2C6H4CH2 2-Me2NC6H4 180 2-NH2C6H4CH2 4-pyridyl 181 2-NH2C6H4CH2 3-pyridyl 182 2-NH2C6H4CH2 2-pyridyl 183 2-NH2C6H4CH2 2-thiazolyl 184 2-NH2C6H4CH2 2-pyrazolyl 185 2-NH2C6H4CH2 5- isoquinolyl 186 2-NH2C6H4CH2 3,4- methylenedioxyC6H3 187 2-NH2C6H4CH2 3,4- ethylenedioxyC6H3 188 2-NH2C6H4CH2 2-imidazolyl 189 2-NH2C6H4CH2 2-oxazolyl 190 2-NH2C6H4CH2 4-isoxazolyl 191 2-NH2C6H4CH2 4-HOC6H4 192 2-NH2C6H4CH2 3-HOC6H4 193 2-NH2C6H4CH2 3,4-diHOC6H4 194 2-NH2C6H4CH2 4-NH2CH2C6H4 195 2-NH2C6H4CH2 3-NH2CH2C6H4 196 3-NH2C6H4CH2 3-MeOC6H4 197 3-NH2C6H4CH2 4-NH2C6H4 198 3-NH2C6H4CH2 3-NH2C6H4 199 3-NH2C6H4CH2 2-NH2C6H4 200 3-NH2C6H4CH2 4-Me2NC6H4 201 3-NH2C6H4CH2 3-Me2NC6H4 202 3-NH2C6H4CH2 2-Me2NC6H4 203 3-NH2C6H4CH2 4-pyridyl 204 3-NH2C6H4CH2 3-pyridyl 205 3-NH2C6H4CH2 2-pyridyl 206 3-NH2C6H4CH2 2-thiazolyl 207 3-NH2C6H4CH2 2-pyrazolyl 208 3-NH2C6H4CH2 5-isoquinolyl 209 3-NH2C6H4CH2 3,4- methylenedioxyC6H3 210 3-NH2C6H4CH2 3,4- ethylenedioxyC5H3 211 3-NH2C6H4CH2 2-imidazolyl 212 3-NH2C6H4CH2 2-oxazolyl 213 3-NH2C6H4CH2 4-isoxazolyl 214 3-NH2C6H4CH2 4-HOC6H4 215 3-NH2C6H4CH2 3-HOC6H4 216 3-NH2C6H4CH2 3,4-diHOC6H4 217 3-NH2C6H4CH2 4-NH2CH2C6H4 218 3-NH2C6H4CH2 3-NH2CH2C6H4 219 4-NH2C6H4CH2 3-MeOC6H4 220 4-NH2C6H4CH2 4-NH2C6H4 221 4-NH2C6H4CH2 3-NH2C6H4 222 4-NH2C6H4CH2 2-NH2C6H4 223 4-NH2C6H4CH2 4-Me2NC6H4 224 4-NH2C6H4CH2 3-Me2NC6H4 225 4-NH2C6H4CH2 2-Me2NC6H4 226 4-Nh2C6H4Ch2 4-pyridyl 227 4-NH2C6H4CH2 3-pyridyl 228 4-NH2C6H4CH2 2-pyridyl 229 4-NH2C6H4CH2 2-thiazolyl 230 4-NH2C6H4CH2 2-pyrazolyl 231 4-NH2C6H4CH2 5-isoquinolyl 232 4-NH2C6H4CH2 3,4- methylenedioxyC6H3 233 4-NH2C6H4CH2 3,4- ethylenedioxyC6H3 234 4-NH2C6H4CH2 2-imidazolyl 235 4-NH2C6H4CH2 2-oxazolyl 236 4-NH2C6H4CH2 4-isoxazolyl 237 4-NH2C6H4CH2 4-HOC6H4 238 4-NH2C6H4CH2 3-HOC6H4 239 4-NH2C6H4CH2 3,4-diHOC6H4 240 4-NH2C6H4CH2 4-NH2CH2C6H4 241 4-NH2C6H4CH2 3-NH2CH2C6H4 242 2-MeOC6H4CH2 3-MeOC6H4 243 2-MeOC6H4CH2 4-NH2C6H4 244 2-MeOC6H4CH2 3-NH2C6H4 245 2-MeOC6H4CH2 2-NH2C6H4 246 2-MeOC6H4CH2 4-Me2NC6H4 247 2-MeOC6H4CH2 3-Me2NC6H4 248 2-MeOC6H4CH2 2-Me2NC6H4 249 2-MeOC6H4CH2 4-pyridyl 250 2-MeOC6H4CH2 3-pyridyl 251 2-MeOC6H4CH2 2-pyridyl 252 2-MeOC6H4CH2 2-thiazolyl 253 2-MeOC6H4CH2 2-pyrazolyl 254 2-MeOC6H4CH2 5-isoquinolyl 255 2-MeOC6H4CH2 3,4- methylenediOXyC6H3 256 2-MeOC6H4CH2 3,4- ethylenediOXyC6H3 257 2-MeOC6H4CH2 2-imidazolyl 258 2-MeOC6H4CH2 2-oxazolyl 259 2-MeOC6H4CH2 4-isoxazolyl 260 2-MeOC6H4CH2 4-HOC6H4 261 2-MeOC6H4CH2 3-HOC6H4 262 2-MeOC6H4CH2 3,4-diHOC6H4 263 2-MeOC6H4CH2 4-NH2CH2C6H4 264 2-MeOC6H4CH2 3-NH2CH2C6H4 265 3-MeOC6H4CH2 3-MeOC6H4 266 3-MeQC6H4CH2 4-NH2C6H4 267 3-MeOC6H4CH2 3-NH2C6H4 268 3-MeOC6H4CH2 2-NH2C6H4 269 3-MeOC6H4CH2 4-Me2NC6H4 270 3-MeOC6H4CH2 3-Me2NC6H4 271 3-MeOC6H4CH2 2-Me2NC6H4 272 3-MeOC6H4CH2 4-pyridyl 273 3-MeOC6H4CH2 3-pyridyl 274 3-MeOC6H4CH2 2-pyridyl 275 3-MeOC6H4CH2 2-thiazolyl 276 3-MeOC6H4CH2 2-pyrazolyl 277 3-MeOC6H4CH2 5-isoquinolyl 278 3-MeOC6H4CH2 3,4- methylenedioxyC6H3 279 3-MeOC6H4CH2 3,4- ethylenedioxyC6H3 280 3-MeQC6H4CH2 2-imidazolyl 281 3-MeOCEH4CH2 2-oxazolyl 282 3-MeOC6H4CH2 4-isoxazolyl 283 3-MeOC6H4CH2 4-HOC6H4 284 3-MeOC6H4CH2 3-HOC6H4 285 3-MeOC6H4CH2 3,4-diHOC6H4 286 3-MeOC6H4CH2 4-NH2CH2C6H4 287 3-MeOC6H4CH2 3-NH2CH2C6H4 288 4-MeOC6H4CH2 3-MeOC6H4 289 4-MeOC6H4CH2 4-NH2C6H4 290 4-MeOC6H4CH2 3-NH2C6H4 291 4-MeOC6H4CH2 2-NH2C6H4 292 4-MCOC6H4CH2 4-Me2NC6H4 293 4-MeOC6H4CH2 3-Me2NC6H4 294 4-MeOC6H4CH2 2-Me2NC6H4 295 4-MeOC6H4CH2 4-pyridyl 296 4-MeOC6H4CH2 3-pyridyl 297 4-MeQC6H4CH2 2-pyridyl 298 4-MeOC6H4CH2 2-thiazolyl 299 4-MeOC6H4CH2 2-pyrazolyl- 300 4-MeOC6H4CH2 5-isoquinolyl 301 4-MeOC6H4CH2 3,4- methylenedioxyC6H3 302 4-MeOC6H4CH2 3,4- ethylenedioxyC6H3 303 4-MeOC6H4CH2 2-imidazolyl 304 4-MeQC6H4CH2 2-oxazolyl 305 4-MeOC6H4CH2 4-isoxazolyl 306 4-MeOC6H4CH2 4-HOC6H4 307 4-MeOC6H4CH2 3-HOC6H4 308 4-MeOC6H4CH2 3,4-diHOC6H4 309 4-MeOC6H4CH2 4-NH2CH2C6H4 310 4-MeOC6H4CH2 3-NH2CH2C6H4 311 2-HOC6H4CH2 4-MeOC6H4 312 2-HOC6H4CH2 3-MeOC6H4 313 2-HOC6H4CH2 4-NH2C6H4 314 2-HOC6H4CH2 3-NH2C6H4 315 2-HOC6H4CH2 2-NH2C6H4 316 2-HOC6H4CH2 4-Me2NC6H4 317 2-HOC6H4CH2 3-Me2NC6H4 313 2-HOC6H4CH2 2-Me2NC6H4 319 2-HOC6H4CH2 4-pyridyl 320 2-HOC6H4CH2 3-pyridyl 321 2-HOC6H4CH2 2-pyridyl 322 2-HOC6H4CH2 2-thiazolyl 323 2-HOC6H4CH2 2-pyrazolyl 324 2-HOC6H4CH2 5-isoquinolyl 325 2-HOC6H4CH2 3,4- methylenedioxyC6H3 326 2-HOC6H4CH2 3,4- ethylenedioxyC6H3 327 2-HOC6H4CH2 2-imidazolyl 328 2-HOC6H4CH2 2-oxazolyl 329 2-HOC6H4CH2 4-isoxazolyl 330 2-HOC6H4CH2 4-HOC6H4 331 2-HOC6H4CH2 3-HOC6H4 332 2-HOC6H4CH2 3,4-diHOC6H4 333 2-HOC6H4CH2 4-NH2CH2C6H4 334 2-HOC6H4CH2 3-NH2CH2C6H4 335 3-HOC6H4CH2 4-MeOC6H4 336 3-HOC6H4CH2 3-MeOC6H4 337 3-HOC6H4CH2 4-NH2C6H4 338 3-HOC6H4CH2 3-NH2C6H4 339 3-HOC6H4CH2 2-NH2C6H4 340 3-HOC6H4CH2 4-Me2NC6H4 341 3-HOC6H4CH2 3-Me2NC6H4 342 3-HOC6H4CH2 2-Me2NC6H4 343 3-HOC6H4CH2 4-pyridyl 344 3-HOC6H4CH2 3-pyridyl 345 3-HOC6H4CH2 2-pyridyl 346 3-HOC6H4CH2 2-thiazolyl 347 3-HOC6H4CH2 2-pyrazolyl 348 3-HOC6H4CH2 5-isoquinolyl 349 3-HOC6H4CH2 3,4- methylenedioxyC6H3 350 3-HOC6H4CH2 3,4- ethylenedioxyC6H3 351 3-HOC6H4CH2 2-imidazolyl 352 3-HOC6H4CH2 2-oxazolyl 353 3-HOC6H4CH2 4-isoxazolyl 354 3-HOC6H4CH2 4-HOC6H4 355 3-HOC6H4CH2 3-HOC6H4 356 3-HOC6H4CH2 3,4-diHOC6H4 357 3-HOC6H4CH2 4-NH2CH2C6H4 358 3-HOC6H4CH2 3-NH2CH2C6H4 359 4-HOC6H4CH2 4-MeOC6H4 360 4-HOC6H4CH2 3-MeOC6H4 361 4-HOC6H4CH2 4-NH2C6H4 362 4-HOC6H4CH2 3-NH2C6H4 363 4-HOC6H4CH2 2-NH2C6H4 364 4-HOC6H4CH2 4-Me2NC6H4 365 4-HOC6H4CH2 3-Me2NC6H4 366 4-HOC6H4CH2 2-Me2NC6H4 367 4-HOC6H4CH2 4-pyridyl 368 4-HOC6H4CH2 3-pyridyl 369 4-HOC6H4CH2 2-pyridyl 370 4-HOC6H4CH2 2-thiazolyl 371 4-HOC6H4CH2 2-pyrazolyl 372 4-HOC6H4CH2 5-isoquinolyl 373 4-HOC6H4CH2 3,4- methylenedioxyC6H3 374 4-HOC6H4CH2 3,4- ethylenedioxyC6H3 375 4-HOC6H4CH2 2-imidazolyl 376 4-HOC6H4CH2 2-oxazolyl 377 4-HOC6H4CH2 4-isoxazolyl 378 4-HOC6H4CH2 4-HOC6H4 379 4-HOC6H4CH2 3-HOC6H4 380 4-HOC6H4CH2 314-diHOC6H4 381 4-HOC6H4CH2 4-NH2CH2C6H4 382 4-HOC6H4CH2 3-NH2CH2C6H4 383 4-ClC6H4CH2 3-MeOC6H4 384 4-ClC6H4CH2 4-NH2C6H4 385 4-ClC6H4CH2 3-NH2C6H4 386 4-ClC6H4CH2 2-NH2C6H4 387 4-ClC6H4CH2 4-Me2NC6H4 388 4-ClC6H4CH2 3-Me2NC6H4 389 4-ClC6H4CH2 2-Me2NC6H4 390 4-ClC6H4CH2 4-pyridyl 391 4-ClC6H4CH2 3-pyridyl 392 4-ClC6H4CH2 2-pyridyl 393 4-ClC6H4CH2 2-thiazolyl 394 4-ClC6H4CH2 2-pyrazolyl 395 4-ClC6H4CH2 5-isoquinolyl 396 4-ClC6H4CH2 3,4- methylenedioxyC6H3 397 4-ClC6H4CH2 3,4- ethylenedioxyC6H3 398 4-ClC6H4CH2 2-imidazolyl 399 4-ClC6H4CH2 2-oxazolyl 400 4-ClC6H4CH2 4-isoxazolyl 401 4-ClC6H4CH2 4-HOC6H4 402 4-ClC6H4CH2 3-HOC6H4 403 4-ClC6H4CH2 3,4-diHOC6H4 404 4-ClC6H4CH2 4-NH2CH2C6H4 405 4-ClC6H4CH2 3-NH2CH2C6H4 406 2-NH2CH2C6H4CH2 4-MeOC6H4 407 2-NH2CH2C6H4CH2 3-MeOC6H4 408 2-NH2CH2C6H4CH2 4-NHC6H4 409 2-NH2CH2C6H4CH2 3-NH2C6H4 410 2-NH2CH2C6H4CH2 2-NH2C6H4 411 2-NH2CH2C6H4CH2 4-Me2NC6H4 412 2-NH2CH2C6H4CH2 3-Me2NC6H4 413 2-NH2CH2C6H4CH2 2-Me2NC6H4 414 2-NH2CH2C6H4CH2 4-pyridyl 415 2-NH2CH2C6H4CH2 3-pyridyl 416 2-NH2CH2C6H4CH2 2-pyridyl 417 2-NH2CH2C6H4CH2 2-thiazolyl 418 2-NH2CH2C6H4CH2 2-pyrazolyl 419 2-NH2CH2C6H4CH2 5-isoquinolyl 420 2-NH2CH2C6H4CH2 3,4- methylenedioxyC6H3 421 2-NH2CH2C6H4CH2 3,4- ethylenedioxyC6H3 422 2-NH2CH2C6H4CH2 2-imidazolyl 423 2-NH2CH2C6H4CH2 2-oxazolyl 424 2-NH2CH2C6H4CH2 4-isoxazolyl 425 2-NH2CH2C6H4CH2 4-HOC6H4 426 2-NH2CH2C6H4CH2 3-HOC6H4 427 2-NH2CH2C6H4CH2 3,4-diHOC6H4 428 2-NH2CH2C6H4CH2 4-NH2CH2C6H4 429 2-NH2CH2C6H4CH2 3-NH2CH2C6H4 430 3-NH2CH2C6H4CH2 4-MOOC6H4 431 3-NH2CH2C6H4CH2 3-MeOC6H4 432 3-NH2CH2C6H4CH2 4-NH2C6H4 433 3-NH2CH2C6H4CH2 3-NH2C6H4 434 3-NH2CH2C6H4CH2 2-NH2C6H4 435 3-NH2CH2C6H4CH2 4-Me2NC6H4 436 3-NH2CH2C6H4CH2 3-Me2NC6H4 437 3-NH2CH2C6H4CH2 2-Me2NC6H4 438 3-NH2CH2C6H4CH2 4-pyriclyl 439 3-NH2CH2C6H4CH2 3-pyridyl 440 3-NH2CH2C6H4CH2 2-pyridyl 441 3-NH2CH2C6H4CH2 2-thiazolyl 442 3-NH2CH2C6H4CH2 2-pyrazolyl 443 3-NH2CH2C6H4CH2 5-isoquinolyl 444 3-NH2CH2C6H4CH2 3,4- methylenedioxyC6H3 445 3-NH2CH2C6H4CH2 3,4- ethylenediOxyC6H3 446 3-NH2CH2C6H4CH2 2-imidazolyl 447 3-NH2CH2C6H4CH2 2-oxazolyl 448 3-NH2CH2C6H4CH2 4-isoxazolyl 449 3-NH2CH2C6H4CH2 4-HOC6H4 450 3-NH2CH2C6H4CH2 3-HOC6H4 451 3-NH2CH2C6H4CH2 3,4-diHOC6H4 452 3-NH2CH2C6H4CH2 4-NH2CH2C6H4 453 3-NH2CH2C6H4CH2 3-NH2CH2C6H4 454 4-NH2CH2C6H4CH2 4-MeOC6H4 455 4-NH2CH2C6H4CH2 3-MeOC6H4 456 4-NH2CH2C6H4CH2 4-NH2C6H4 457 4-NH2CH2C6H4CH2 3-NH2C6H4 458 4-NH2CH2C6H4CH2 2-NH2C6H4 459 4-NH2CH2C6H4CH2 4-Me2NC6H4 460 4-NH2CH2C6H4CH2 3-Me2NC6H4 461 4-NH2CH2C6H4CH2 2-Me2NC6H4 462 4-NH2CH2C6H4CH2 4-pyridyl 463 4-NH2CH2C6H4CH2 3-pyridyl 464 4-NH2CH2C6H4CH2 2-pyridyl 465 4-NH2CH2C6H4CH2 2-thiazolyl 466 4-NH2CH2C6H4CH2 2-pyrazolyl 467 4-NH2CH2C6H4CH2 5-isoquinolyl 468 4-NH2CH2C6H4CH2 3,4- methylenedioxyC6H3 469 4-NH2CH2C6H4CH2 3,4- ethylenedioxyC6H3 470 4-NH2CH2C6H4CH2 2-imidazolyl 471 4-NH2CH2C6H4CH2 2-oxazolyl 472 4-NH2CH2C6H4CH2 4-isoxazolyl 473 4-NH2CH2C6H4CH2 4-HOC6H4 474 4-NH2CH2C6H4CH2 3-HOC6H4 475 4-NH2CH2C6H4CH2 3,4-diHOC6H4 476 4-NH2CH2C6H4CH2 4-NH2CH2C6H4 477 4-NH2CH2C6H4CH2 3-NH2CH2C6H4 478 2-Me2NCH2C6H4CH2 4-MeOC6H4 479 2-Me2NCH2C6H4CH2 3-MCOC6H4 480 2-Me2NCH2C6H4CH2 4-NH2C6H4 481 2-Me2NCH2C6H4CH2 3-NH2C6H4 482 2-Me2NCH2C6H4CH2 2-NH2C6H4 483 2-Me2NCH2C6H4CH2 4-Me2NC6H4 484 2-Me2NCH2C6H4CH2 3-Me2NC6H4 485 2-Me2NCH2C6H4CH2 2-Me2NC6H4 486 2-Me2NCH2C6H4CH2 4-pyridyl 487 2-Me2NCH2C6H4CH2 3-pyridyl 488 2-Me2NCH2C6H4CH2 2-pyridyl 489 2-Me2NCH2C6H4CH2 2-thiazolyl 490 2-Me2NCH2C6H4CH2 2-pyrazolyl 491 2-Me2NCH2C6H4CH2 5-isoquinolyl 492 2-Me2NCH2C6H4CH2 3,4- methylenedioxyC6H3 493 2-Me2NCH2C6H4CH2 3,4- ethylenedioxyC6H3 494 2-Me2NCH2C6H4CH2 2-imidazolyl 495 2-Me2NCH2C6H4CH2 2-oxazolyl 496 2-Me2NCH2C6H4CH2 4-isoxazolyl 497 2-Me2NCH2C6H4CH2 4-HOC6H4 498 2-Me2NCH2C6H4CH2 3-HOC6H4 499 2-Me2NCH2C6H4CH2 3,4-diHOC6H4 500 2-Me2NCH2C6H4CH2 4-NH2CH2C6H4 501 2-Me2NCH2C6H4CH2 3-NH2CH2C6H4 502 3-Me2NCH2C6H4CH2 4-MeOC6H4 503 3-Me2NCH2C6H4CH2 3-MeOC6H4 504 3-Me2NCH2C6H4CH2 4-NH2C6H4 505 3-Me2NCH2C6H4CH2 3-NH2C6H4 506 3-Me2NCH2C6H4CH2 2-NH2C6H4 507 3-Me2NCH2C6H4CH2 4-Me2NC6H4 508 3-Me2NCH2C6H4CH2 3-Me2NC6H4 509 3-Me2NCH2C6H4CH2 2-Me2NC6H4 510 3-Me2NCH2C6H4CH2 4-pyridyl 511 3-Me2NCH2C6H4CH2 3-pyridyl 512 3-Me2NCH2C6H4CH2 2-pyridyl 513 3-Me2NCH2C6H4CH2 2-thiazolyl 514 3-Me2NCH2C6H4CH2 2-pyrazolyl 515 3-Me2NCH2C6H4CH2 5-isoquinolyl 516 3-Me2NCH2C6H4CH2 3,4- methylenedioxyC6H3 517 3-Me2NCH2C6H4CH2 3,4- ethylenedioxyC6H3 518 3-Me2NCH2C6H4CH2 2-imidazolyl 519 3-Me2NCH2C6H4CH2 2-oxazolyl 520 3-Me2NCH2C6H4CH2 4-isoxazolyl 521 3-Me2NCH2C6H4CH2 4-HOC6H4 522 3-Me2NCH2C6H4CH2 3-HOC6H4 523 3-Me2NCH2C6H4CH2 3,4-diHOC6H4 524 3-Me2NCH2C6H4CH2 4-NH2CH2C6H4 525 3-Me2NCH2C6H4CH2 3-NH2CH2C6H4 526 4-Me2NCH2C6H4CH2 4-MeOC6H4 527 4-Me2NCH2C6H4CH2 3-MeOC6H4 528 4-Me2NCH2C6H4CH2 4-NH2C6H4 529 4-Me2NCH2C6H4CH2 3-NH2C6H4 530 4-Me2NCH2C6H4CH2 2-NH2C6H4 531 4-Me2NCH2C6H4CH2 4-Me2NC6H4 532 4-Me2NCH2C6H4CH2 3-Me2NC6H4 533 4-Me2NCH2C6H4CH2 2-Me2NC6H4 534 4-Me2NCH2C6H4CH2 4-pyridyl 535 4-Me2NCH2C6H4CH2 3-pyridyl 536 4-Me2NCH2C6H4CH2 2-pyridyl 537 4-Me2NCH2C6H4CH2 2-thiazolyl 538 4-Me2NCH2C6H4CH2 2-pyrazolyl 539 4-Me2NCH2C6H4CH2 5-isoquinolyl 540 4-Me2NCH2C6H4CH2 3,4- methylenedioxyC6H3 541 4-Me2NCH2C6H4CH2 3,4- ethylenedioxyC6H3 542 4-Me2NCH2C6H4CH2 2-imdazolyl 543 4-Me2NCH2C6H4CH2 2-oxazolyl 545 4-Me2NCH2C6H4CH2 4-isoxazolyl 546 4-Me2NCH2C6H4CH2 4-HOC6H4 547 4-Me2NCH2C6H4CH2 3-HOC6H4 548 4-Me2NCH2C6H4CH2 3,4-diHOC6H4 549 4-Me2NCH2C6H4CH2 4-NH2CH2C6H4 550 4-Me2NCH2C6H4CH2 3-NH2CH2C6H4 551 H 3-MeOC6H4 552 H 4-NH-C6H4 553 H 3-NH2C6H4 554 H 2-NH2C6H4 555 H 4-Me2NC6H4 556 H 3-Me2NC6H4 557 H 2-Me2NC6H4 558 H 3-pyridyl 559 H 2-pyridyl 560 H 2-thiazolyl 561 H 2-pyrazolyl 562 H 5-isoquinolyl 563 H 3,4- methylenedioxyC6H3 564 H 3,4- ethylenedioxyC6H3 565 H 2-imidazolyl 566 H 2-oxazolyl 567 H 4-isoxazolyl 568 H 4-HOC6H4 569 H 3-HOC6H4 570 H 3,4-diHOC6H4 571 H 4-NH2CH2C6H4 572 H 3-NH2CH2C6H4 573 Me 3-MeOC6H4 574 Me 4-NH2C6H4 575 Me 3-NH2C6H4 576 Me 2-NH2C6H4 577 Me 4-Me-NC6H4 578 Me 3-Me2NC6H4 579 Me 2-Me2NC6H4 580 Me 3-pyridyl 581 Me 2-pyridyl 582 Me 2-thiazolyl 583 Me 2-pyrazolyl 584 Me 5-isoquinolyl 585 Me 3,4- ethylenedioxyC6H3 586 Me 2-imidazolyl 587 Me 2-oxazolyl 588 Me 4-isoxazolyl 589 Me 3-HOC6H4 590 Me 3,4-diHOC-H- 591 Me 4-NH2CH2C6H4 592 Me 3-NH2CH2C6H4 593 Et 3-MeOC6H4 594 Et 4-NH2C6H4 595 Et 3-NH2C6H4 596 Et 2-NH2C6H4 597 Et 4-Me2NC6H4 598 Et 3-Me2NC6H4 599 Et 2-Me2NC6H4 600 Et 4-pyridyl 601 Et 3-pyridyl 601 Et 2-pyridyl 603 Et 2-thiazolyl 604 Et 2-pyrazolyl 605 Et 5-isoquinolyl 606 Et 3,4- methylenedioxyC6H3 607 Et 3,4- ethylenedioxyC6H3 608 Et 2-imidazolyl 609 Et 2-oxazolyl 610 Et 4-isoxazolyl 611 Et 4-HOC6H4 612 Et 3-HOC-H- 613 Et 3,4-diHOC6H4 614 Et 4-NH2CH2C6H4 615 Et 3-NH2CH2C6H4 616 Me2NCH2 3-MeOC6H4 617 Me2NCH2 4-NH2C6H4 618 Me2NCH2 3-NH2C6H4 619 Me2NCH2 2-NH2C6H4 620 Me2NCH2 4-Me2NC6H4 621 Me2NCH2 3-Me2NC6H4 622 Me2NCH2 2-Me2NC6H4 623 Me2NCH2 4-pyridyl 624 Me2NCH2 3-pyridyl 625 Me2NCH2 2-pyridyl 626 Me2NCH2 2-thiazolyl 627 Me2NCH2 2-pyrazolyl 628 Me2NCH2 5-isoquinolyl 629 Me2NCH2 3,4- methylenedioxyC6H3 630 Me2NCH2 3,4- ethylenedioxyC6H3 631 Me2NCH2 2-imidazolyl 632 Me2NCH2 2-oxazolyl 633 Me2NCH2 4-isoxazolyl 634 Me2NCH2 4-HOC6H4 635 Me2NCH2 3-HOC6H4 636 Me2NCH2 3,4-diHOC6H4 637 Me2NCH2 4-NH2CH2C6H4 638 Me2NCH2 3-NH2CH2C6H4 639 ELNHCH2 3-MeOC6H4 640 EtNHCH2 4-NH2C6H4 641 EtNHCH2 3-NH2C6H4 642 EtNHCH2 2-NH2C6H4 643 EtNHCH2 4-Me2NC6H4 644 EtNHCH2 3-Me2NC6H4 645 EtNHCH2 2-Me2NC6H4 646 EtNHCH2 4-pyridyl 647 EtNHCH2 3-pyridyl 648 EtNHCH2 2-pyridyl 649 EtNHCH2 2-thiazolyl 650 EtNHCH2 2-pyrazolyl 651 EtNHCH2 5-isoquinolyl 652 EtNHCH2 3,4- methylenedioxyC6H3 653 EtNHCH2 3,4- ethylenedioxyC6H3 654 EtNHCH2 2-imidazolyl 655 EtNHCH2 2-oxazolyl 656 EtNHCH2 4-isoxazolyl 657 EtNHCH2 4-HOC6H4 658 EtNHCH2 3-HOC6H4 659 EtNHCH2 3,4-diHOC6H4 660 EtNHCH2 4-NH2CH2C6H4 661 EtNHCH2 3-NH2CH2C6H4 662 HOCH2CH2NHCH2 3-Me2C-H- 663 HOCH2CH2NHCH2 4-NH2C6H4 664 HOCH2CH2NHCH2 3-NH2C6H4 665 HOCH2CH2NHCH2 2-NH2C6H4 666 HOCH2CH2NHCH2 4-Me2NC6H4 667 HOCH2CH2NHCH2 3-Me2NC6H4 668 HOCH2CH2NI-ICH2 2-Me2NC6H4 669 HOCH2CH2NHCH2 4-pyridyl 670 HOCH2CH2NHCH2 3-pyridyl 671 HOCH2CH2NHCH2 2-pyridyl 672 HOCH2CH2NHCH2 2-thiazolyl 673 HOCH2CR2NHCH2 2-pyrazolyl 674 HOCH2CH2NHCH2 5-isoquinolyl 675 HOCH2CH2NHCH2 3,4- methylenedioxyC6H3 676 HOCH2CH2NHCH2 3,4- ethylenedioxyC6H3 677 HOCH2CH2NHCH2 2-imidazolyl 678 HOCH2CH2NHCH2 2-oxazolyl 679 HOCH2CH2NHCH2 4-isoxazolyl 680 HOCH2CH2NHCH2 4-HOC6H4 681 HOCH2CH2NHCH2 3-HOC6H4 682 HOCH2CH2NHCH2 3,4-diHOC6H4 683 HOCH2CH2NHCH2 4-NH2CH2C6H4 684 HOCH2CH2NHCH2 3-NH2CH2C6H4 685 H2NCH2CH2NHCH2 4-Me2C6H4 686 H2NCH2CH2NHCH2 3-MeOC6H4 687 H2NCH2CH2NHCH2 4-NH2C6H4 688 H2NCH2CH2NHCH2 3-NH2C6H4 689 H2NCH2CH2NHCH2 2-NH2C6H4 690 H2NCH2CH2NHCH2 4-Me2NC6H4 691 H2NCH2CH2NIICH2 3-Me2NC6H4 692 H2NCH2CH2NHCH2 2-Me2NC6H4 693 H2NCH2CH2NHCH2 4-pyridyl 694 H2NCH2CH2NHCH2 3-pyridyl 695 H2NCH2CH2NHCH2 2-pyridyl 696 H2NCH2CH2NHCH2 2-thiazolyl 697 H2NCH2CH2NHCH2 2-pyrazolyl 698 H2NCH2CH2NHCH2 5-isoquinolyl 699 H2NCH2CH2NHCH2 3,4- methylenedioxyC6H3 700 H2NCH2CH2NHCH2 3,4- ethylenedioxyC6H3 701 H2NCH2CH2NHCH2 2-imidazolyl 702 H2NCH2CH2NHCH2 2-oxazolyl 703 H2NCH2CH2NHCH2 4-isoxazolyl 704 H2NCH2CH2NHCH2 4-HOC6H4 705 H2NCH2CH2NHCH2 3-HOC6H4 706 H2NCH2CH2NHCH2 3,4-diHOC6H4 707 H2NCH2CH2NHCH2 4-N112CH2C6H4 708 H2NCH2CH2NHCH2 3-NH2CH2C6H4 709 Me2NCH2CH2NHCH2 4-MeOC6H4 710 Me2NCH2CH2NHCH2 3-MeOC6H4 111 Me2NCH2CH2NHCH2 4-NH2C6H4 712 Me2NCH2CH2NHCH2 3-NH2C6H4 713 Me2NCH2CH2NHCH2 2-NH2C6H4 714 Me2NCH2CH2NHCH2 4-Me2NC6H4 715 Me2NCH2CH2NHCH2 3-Me2NC6H4 716 Me2NCH2CH2NHCH2 2-Me2NC6H4 717 Me2NCH2CH2NHCH2 4-pyridyl 718 Me2NCH2CH2NHCH2 3-pyridyl 719 Me2NCH2CH2NHCH2 2-pyridyl 720 Me2NCH2CH2NHCH2 2-thiazolyl 721 Me2NCH2CH2NHCH2 2-pyrazolyl 722 Me2NCH2CH2NHCH2 5-isoquinolyl 723 Me2NCH2CH2NHCH2 BA- methylenedioxyC6H3 724 Me2NCH2CH2NHCH2 3,4- ethylenedioxyC6H3 725 Me2NCH2CH2NHCH2 2-imidazolyl 726 Me2NCH2CH2NHCH2 2-oxazolyl 727 Me2NCH2CH2NHCH2 4-isoxazolyl 728 Me2NCH2CH2NHCH2 4-H0C6H4 729 Me2NCH2CH2NHCH2 3-HOC6H4 730 Me2NCH2CH2NHCH2 3 ,4-diHOC6H4 731 Me2NCH2CH2NHCH2 4-NH2CH2C6H4 732 Me2NCH2CH2NHCH2 3-NH2CH2C6H4 733 1-morpholinylmethyl 3-MeOC6H4 734 1-morpholinylmethyl 4-NH-C6H4 735 1-morphoinlylmethyl 3-NH2C6H4 736 1-morpholinylmethyl 2-NH2C6H4 737 1-morpholinylmethyl 4-Me2NC6H4 738 1-morpholinylmethyl 3-Me2NC6H4 739 1-morpholinylmethyl 2-Me2NC6H4 740 1-morpholinylmethyl 4-pyridyl 741 1-morpholinylmethyl 3-pyridyl 742 1-morpholinylmethyl 2-pyridyl 743 1-morpholinylmethyl 2-thiazolyl 744 1-morpholinylmethyl 2-pyrazolyl 745 1-morpholinylmethyl 5-isoquinolyl 746 1-morpholinylmethyl 3,4- methylenedioxyC6H3 747 1-morpholinylmethyl 3,4- ethylenedioxyC6H3 748 1-morpholinylmethyl 2-imidazolyl 749 1-morpholinylmethyl 2-oxazolyl 750 1-morpholinylmethyl 4-isoxazolyl 751 1-morpholinylmethyl 4-HOC6H4 752 1-morpholinylmethyl 3-HOC6H4 753 1-morpholinylmethyl 3,4-diHOC6H4 754 1-morpholinylmethyl 4-NH2CH2C6H4 755 1-morpholinylmethyl 3-NH2CH2C6H4 756 1-thiomorpholinylmethyl 3-MeOC6H4 757 1-thiomorpholinylmethyl 4-NH2C6H4 758 1-thiomorpholinylmethyl 3-NH2C6H4 759 1-thiomorpholinylmethyl 2-NH2C6H4 760 1-thiomorpholinylmethyl 4-Me-NC6H4 761 1-thiomorpholinylmethyl 3-Me2NC6H4 762 1-thiomorpholinylmethyl 2-Me2NC6H4 763 1-thiomorpholinylmethyl 4-pyridyl 764 1-thiomorpholinylmethyl 3-pyridyl 765 1-thiomorpholinylmethyl 2-pyridyl 766 1-thiomorpho1inylmethyl 2-thiazolyl 767 1-thiomorpholinylmethyl 2-pyrazolyl 768 1-thiomorpholinylmethyl 5-isoquinolyl 769 1-thiomorpholinylmethyl 3,4- methylenedioxyC6H3 770 1-thiomorpholinylmethyl 3,4- ethylenedioxyC6H3 771 l-thiomorpholinylmethyl 2-imidazolyl 772 1-thiomorpholinylmethyl 2-oxazolyl 773 1-thiomorpholinylmethyl 4-isoxazolyl 774 1-thiomorpholinylmethyl 4-HOC6H4 775 1-thiomorpholinylmethyl 3-HOC6H- 776 1-thiomorpholinylmethyl 3,4-diHOC6H4 777 1-thiomorpholinylmethyl 4-Me2CH2C6H4 778 1-thiomorpholinylmethyl 3-NH2CH2C6H4 779 1-piperazinylmethyl 3-Me2C6H4 780 1-piperazinylmethyl 4-NH2C6H4 781 1-piperazinylmethyl 3-NH2C6H4 782 1-piperazinylmethyl 2-NH2C6H4 783 1-piperazinylmethyl 4-Me-NC-H- 784 1-piperazinylmethyl 3-Me2NC6H4 785 1-piperazinylmethyl 2-Me2NC6H4 786 1-piperazinylmethyl 4-pyridyl 787 1-piperazinylmethyl 3-pyridyl 788 1-piperazinylmethyl 2-pyridyl 789 1-piperazinylmethyl 2-thiazolyl 790 1-piperazinylmethyl 2-pyrazolyl 791 1-piperazinylmethyl 5-isoquinolyl 792 1-piperazinylmethyl 3,4- methylenedioxyC6H3 793 1-piperazinylmethyl 3,4- ethylenedioxyC6H3 794 1-piperazinylmethyl 2-imidazolyl 795 1-piperazinylmethyl 2-oxazolyl 796 1-piperazinylmethyl 4-isoxazolyl 797 1-piperazinylmethyl 4-HOC6H4 798 1-piperazinylmethyl 3-HOC6H4 799 1-piperazinylmethyl 3,4-diHOC6H4 800 1-piperazinylmethyl 4-NH2CH2C6H4 801 1-piperazinylmethyl 3-NH2CH2C6H4

[0358] 3 TABLE 3 27 Example Number R1 R2 802 2-pyridylmethyl 4-MeOC6H4 803 2-pyridylmethyl 3-MeOC6H4 804 2-pyridylmethyl 4-NH2C6H4 805 2-pyridylmethyl 3-NH2C6H4 806 2-pyridylmethyl 2-NH2C6H4 807 2-pyridylmethyl 4-Me2NC6H4 808 2-pyridylmethyl 3-Me2NC6H4 809 2-pyridylmethyl 2-Me2NC6H4 810 2-pyridylmethyl 4-pyridyl 811 2-pyridylmethyl 3-pyridyl 812 2-pyridylmethyl 2-pyridyl 813 2-pyridylmethyl 2-thiazolyl 814 2-pyridylmethyl 2-pyrazolyl 815 2-pyridylmethyl 5-isoquinolyl 816 2-pyridylmethyl 3,4- methylenedioxyC6H3 817 2-pyridylmethyl 3,4- ethylenedioxyC6H3 818 2-pyridylmethyl 2-imidazolyl 819 2-pyridylmethyl 2-oxazolyl 820 2-pyridylmethyl 4-isoxazolyl 821 2-pyridylmethyl 4-HOC6H4 822 2-pyridylmethyl 3-HOC6H4 823 2-pyridylmethyl 3,4-diHOC6H4 824 2-pyriclymethyl 4-NH2CH2C6H4 825 2-pyridyirmthyl 3-NH2CH2C6H4 826 3-pyridyirmthyl 4-MeOC6H4 827 3-pyridylmethyl 3-MeOC6H4 828 3-pyridylmethyl 4-NH2C6H4 829 3-pyridylmethyl 3-NH2C6H4 830 3-pyridylmethyl 2-NH2C6H4 831 3-pyridylmethyl 4-Me2NC6H4 832 3-pyridylmethyl 3-Me2NC6H4 833 3-pyridylmethyl 2-Me2NC6H4 834 3-pyridylmethyl 4-pyridyl 835 3-pyridyilmethyl 3-pyridyl 836 3-pyridylmethyl 2-pyridyl 837 3-pyridylmethyl 2-thiazolyl 838 3-pyridylmethyl 2-pyrazolyl 839 3-pyridylmethyl 5-isoquinolyl 840 3-pyridylmethyl 3,4- methylenedioxyC6H3 841 3-pyridylmethyl 3,4- ethylenedioxyC6H3 842 3-pyridylmethyl 2-imidazolyl 843 3-pyridylmethyl 2-oxazolyl 844 3-pyridylmethyl 4-isoxazolyl 845 3-pyridylmethyl 4-HOC6H4 846 3-pyridylmethyl 3-HOC6H4 847 3-pyridylmethyl 3,4-diHOC6H4 848 3-pyridylmethyl 4-NH2CH2C6H4 849 3-pyridylmethyl 3-NH2CH2C6H4 850 4-pyridylmethyl 4-MeOC6H4 851 4-pyridylmethyl 3-MeOC6H4 852 4-pyridylmethyl 4-NH2C6H4 853 4-pyridylmethyl 3-NH2C6H4 854 4-pyridylmethyl 2-NH2C6H4 855 4-pyridylmethyl 4-Me2NC6H4 856 4-pyridylmethyl 3-Me2NC6H4 857 4-pyridylmethyl 2-Me2NC6H4 858 4-pyridylmethyl 4-pyridyl 859 4-pyridylmethyl 3-pyridyl 860 4-pyridylmethyl 2-pyridyl 861 4-pyridylmethyl 2-thiazolyl 862 4-pyridylmethyl 2-pyrazolyl 863 4-pyridylmethyl 5-isoquinolyl 864 4-pyridylmethyl 3,4- methylenedioxyC6H3 865 4-pyridylmethyl 3,4- ethyl enedioxyC6H3 866 4-pyridylmethyl 2-imidazolyl 867 4-pyridylmethyl 2-oxazolyl 868 4-pyridylmethyl 4-isoxazolyl 869 4-pyridylmethyl 4-HOC6H4 870 4-pyridylmethyl 3-HOC6H4 871 4-pyridylmethyl 3,4-diHOC6H4 872 4-pyridylmethyl 4-NH2CH2C6H4 873 4-pyridylmethyl 3-NH2CH2C6H4 874 2-NH2C6H4 4-MeOC6H4 875 2-NH2C6H4 3-MeOC6H4 876 2-NH2C6H4 4-NH2C6H4 877 2-NH2C6H4 3-NH2C6H4 878 2-NH2C6H4 2-NH2C6H4 879 2-NH2C6H4 4-Me2NC6H4 880 2-NH2C6H4 3-Me2NC6H4 881 2-NH2C6H4 2-Me2NC6H4 882 2-NH2C6H4 4-pyridyl 883 2-NH2C6H4 3-pyridyl 884 2-NH2C6H4 2-pyridyl 885 2-NH2C6H4 2-thiazolyl 886 2-NH2C6H4 2-pyrazolyl 887 2-NH2C6H4 5-isoquinolyl 888 2-NH2C6H4 3,4- methylenedioxyC6H3 889 2-NH2C6H4 3,4- ethylenedioxyC6H3 890 2-NH2C6H4 2-imidazolyl 891 2-NH2C6H4 2-oxazolyl 892 2-NH2C6H4 4-isoxazolyl 893 2-NH2C6H4 4-HOC6H4 894 2-NH2C6H4 3-HOC6H4 895 2-NH2C6H4 3,4-diHOC6H4 896 2-NH2C6H4 4-NH2CH2C6H4 897 2-NH2C6H4 3-NH2CH2C6H4 898 3-NH2C6H4 4-MeOC6H4 899 3-NH2C6H4 3-MeOC6H4 900 3-NH2C6H4 4-NH2C6H4 901 3-NH2C6H4 3-NH2C6H4 902 3-NH2C6H4 2-NH2C6H4 903 3-NH2C6H4 4-Me2NC6H4 904 3-NH2C6H4 3-Me2NC6H4 905 3-NH2C6H4 2-Me2NC6H4 906 3-NH2C6H4 4-pyridyl 907 3-NH2C6H4 3-pyridyl 908 3-NH2C6H4 2-pyridyl 909 3-NH2C6H4 2-thiazolyl 910 3-NH2C6H4 2-pyrazolyl 911 3-NH2C6H4 5-isoquinolyl 912 3-NH2C6H4 3,4- methylenedioxyC6H3 913 3-NH2C6H4 3,4- ethylenedioxyC6H3 914 3-NH2C6H4 2-imidazolyl 915 3-NH2C6H4 2-oxazolyl 916 3-NH2C6H4 4-isoxazolyl 917 3-NH2C6H4 4-HOC6H4 918 3-NH2C6H4 3-HOC6H4 919 3-NH2C6H4 3,4-diHOC6H4 920 3-NH2C6H4 4-NH2CH2C6H4 921 3-NH2C6H4 3-NH2CH2C6H4 922 4-NH2C6H4 4-NH2CH2C6H4 923 4-NH2C6H4 3-MeOC6H4 924 4-NH2C6H4 4-NH2C6H4 925 4-NH2C6H4 3-NH2C6H4 926 4-NH2C6H4 2-NH2C6H4 927 4-NH2C6H4 4-Me2NC6H4 928 4-NH2C6H4 3-Me2NC6H4 930 4-NH2C6H4 2-Me2NC6H4 931 4-NH2C6H4 4-pyridyl 932 4-NH2C6H4 3-pyridyl 933 4-NH2C6H4 2-pyridyl 934 4-NH2C6H4 2-thiazolyl 935 4-NH2C6H4 2-pyrazolyl 936 4-NH2C6H4 5-isoquinolyl 937 4-NH2C6H4 3,4- methylenedioxyC6H3 938 4-NH2C6H4 3,4- ethylenedioxyC6H3 939 4-NH2C6H4 3,4- ethylenedioxyC6H3 940 4-NH2C6H4 2-oxazolyl 941 4-NH2C6H4 4-isoxazolyl 942 4-NH2C6H4 4-HOC6H4 943 4-NH2C6H4 3-HOC6H4 944 4-NH2C6H4 3,4-diHOC6H4 945 4-NH2C6H4 4-NH2CH2C6H4 946 4-NH2C6H4 3-NH2CH2C6H4 947 2-MeOC6H4 4-MeOC6H4 948 2-MeOC6H4 3-MeOC6H4 949 2-MeOC6H4 4-NH2C6H4 950 2-MeOC6H4 3-NH2C6H4 951 2-MeOC6H4 2-NH2C6H4 952 2-MeOC6H4 4-Me2NC6H4 953 2-MeOC6H4 3-Me2NC6H4 954 2-MeOC6H4 2-Me2NC6H4 955 2-MeOC6H4 4-pyridyl 956 2-MeOC6H4 3-pyridyl 957 2-MeOC6H4 2-pyridyl 958 2-MeOC6H4 2-thiazolyl 959 2-MeOC6H4 2-pyrazolyl 960 2-MeOC6H4 5-isoquinolyl 961 2-MeOC6H4 3,4- methylenedioxy6H3 962 2-MeOC6H4 3,4- ethylenedioxy6H3 963 2-MeOC6H4 2-imidazolyl 964 2-MeOC6H4 2-oxazolyl 965 2-MeOC6H4 4-isoxazolyl 966 2-MeOC6H4 4-HOC6H4 967 2-MeOC6H4 3-HOC6H4 968 2-MeOC6H4 3,4-diHOC6H4 969 2-MeOC6H4 4-NH2CH2C6H4 970 2-MeOC6H4 3-NH2CH2C6H4 971 3-MeOC6H4 4-MeOC6H4 972 3-MeOC6H4 3-MeOC6H4 973 3-MeOC6H4 4-NH2C6H4 974 3-MeOC6H4 3-NH2C6H4 975 3-MeOC6H4 2-NH2C6H4 976 3-MeOC6H4 4-Me2NC6H4 977 3-MeOC6H4 3-Me2NC6H4 978 3-MeOC6H4 2-Me2NC6H4 979 3-MeOC6H4 4-pyridyl 980 3-MeOC6H4 3-pyridyl 981 3-MeOC6H4 2-pyridyl 982 3-MeOC6H4 2-thiazolyl 983 3-MeOC6H4 2-pyrazolyl 984 3-MeOC6H4 5-isoquinolyl 985 3-MeOC6H4 3,4- methylenedioxyC6H3 986 3-MeOC6H4 3,4- ethylenedioxyC6H3 987 3-MeOC6H4 2-imidazolyl 988 3-MeOC6H4 2-oxazolyl 989 3-MeOC6H4 4-isoxazolyl 990 3-MeOC6H4 4-HOC6H4 991 3-MeOC6H4 3-HOC6H4 992 3-MeOC6H4 3,4-diHOC6H4 993 3-MeOC6H4 4-NH2CH2C6H4 994 3-MeOC6H4 3-NH2CH2C6H4 995 4-MeOC6H4 4-MeOC6H4 996 4-MeOC6H4 3-MeOC6H4 997 4-MeOC6H4 4-NH2C6H4 998 4-MeOC6H4 3-NH2C6H4 999 4-MeOC6H4 2-NH2C6H4 1000 4-MeOC6H4 4-Me2NC6H4 1001 4-MeOC6H4 3-Me2NC6H4 1002 4-MeOC6H4 2-Me2NC6H4 1003 4-MeOC6H4 4-pyridyl 1004 4-MeOC6H4 3-pyridyl 1005 4-MeOC6H4 2-pyridyl 1006 4-MeOC6H4 2-thiazolyl 1007 4-MeOC6H4 2-pyrazolyl 1008 4-MeOC6H4 5-isoquinolyl 1009 4-MeOC6H4 3,4- methylenedioxy6H3 1010 4-MeOC6H4 3,4- ethylenedioxyC6H3 1011 4-MeOC6H4 2-imidazolyl 1012 4-MeOC6H4 2-oxazolyl 1013 4-MeOC6H4 4-isoxazolyl 1014 4-MeOC6H4 4-HOC6H4 1015 4-MeOC6H4 3-HOC6H4 1016 4-MeOC6H4 3,4-diHOC6H4 1017 4-MeOC6H4 4-NH2CH2C6H4 1018 4-MeOC6H4 3-NH2CH2C6H4 1019 2-HOC6H4 4-MeOC6H4 1020 2-HOC6H4 3-MeOC6H4 1021 2-HOC6H4 4-NH2C6H4 1022 2-HOC6H4 3-NH2C6H4 1023 2-HOC6H4 2-NH2C6H4 1024 2-HOC6H4 4-Me2NC6H4 1025 2-HOC6H4 3-Me2NC6H4 1026 2-HOC6H4 2-Me2NC6H4 1027 2-HOC6H4 4-pyridyl 1028 2-HOC6H4 3-pyridyl 1029 2-HOC6H4 2-pyridyl 1030 2-HOC6H4 2-thiazolyl 1031 2-HOC6H4 2-pyrazolyl 1032 2-HOC6H4 5-isoquinolyl 1033 2-HOC6H4 3,4- methylenedioXyC6H3 1034 2-HOC6H4 3,4- ethylenedioxyC6H3 1035 2-HOC6H4 2-imidazolyl 1036 2-HOC6H4 2-oxazolyl 1037 2-HOC6H4 4-isoxazolyl 1038 2-HOC6H4 4-HOC6H4 1039 2-HOC6H4 3-HOC6H4 1040 2-HOC6H4 3,4-diHOC6H4 1041 2-HOC6H4 4-NH2CH2C6H4 1042 2-HOC6H4 3-NH2CH2C6H4 1043 3-HOC6H4 4-MeOC6H4 1044 3-HOC6H4 3-MeOC6H4 1045 3-HOC6H4 4-NH2C6H4 1046 3-HOC6H4 3-NH2C6H4 1047 3-HOC6H4 2-NH2C6H4 1048 3-HOC6H4 4-Me2NC6H4 1049 3-HOC6H4 3-Me2NC6H4 1050 3-HOC6H4 2-Me2NC6H4 1051 3-HOC6H4 4-pyridyl 1052 3-HOC6H4 3-pyridyl 1053 3-HOC6H4 2-pyridyl 1054 3-HOC6H4 2-thiazolyl 1055 3-HOC6H4 2-pyrazolyl 1056 3-HOC6H4 5-isoquinolyl 1057 3-HOC6H4 3,4- methylenedioxyC6H3 1058 3-HOC6H4 3,4- ethylenedioxyC6H3 1059 3-HOC6H4 2-imidazolyl 1060 3-HOC6H4 2-oxazolyl 1061 3-HOC6H4 4-isoxazolyl 1062 3-HOC6H4 4-HOC6H4 1063 3-HOC6H4 3-HOC6H4 1064 3-HOC6H4 3,4-diHOC6H4 1065 3-HOC6H4 4-NH2CH2C6H4 1066 3-HOC6H4 3-NH2CH2C6H4 1067 4-HOC6H4 4-MeOC6H4 1068 4-HOC6H4 3-MeOC6H4 1069 4-HOC6H4 4-NH2C6H4 1070 4-HOC6H4 3-NH2C6H4 1071 4-HOC6H4 2-NH2C6H4 1072 4-HOC6H4 4-Me2NC6H4 1073 4-HOC6H4 3-Me2NC6H4 1074 4-HOC6H4 2-Me2NC6H4 1075 4-HOC6H4 4-pyridyl 1076 4-HOC6H4 3-pyridyl 1077 4-HOC6H4 2-pyridyl 1078 4-HOC6H4 2-thiazolyl 1079 4-HOC6H4 2-pyrazolyl 1080 4-HOC6H4 5-isoquinolyl 1081 4-HOC6H4 3,4- methylenedioxyC6H3 1082 4-HOC6H4 3,4- ethylenedioxyC6H3 1083 4-HOC6H4 2-imidazolyl 1084 4-HOC6H4 2-oxazolyl 1085 4-HOC6H4 4-isoxazolyl 1086 4-HOC6H4 4-HOC6H4 1087 4-HOC6H4 3-HOC6H4 1088 4-HOC6H4 3,4-diHOC6H4 1089 4-HOC6H4 4-NH2CH2C6H4 1090 4-HOC6H4 3-NH2CH2C6H4 1091 4-C1C6H4 4-MeOC6H4 1092 4-ClC6H4 3-MeOC6H4 1093 4-ClC6H4 4-NH2C6H4 1094 4-ClC6H4 3-NH2C6H4 1095 4-ClC6H4 2-NH2C6H4 1096 4-ClC6H4 4-Me2NC6H4 1097 4-ClC6H4 3-Me2NC6H4 1098 4-ClC6H4 2-Me2NC6H4 1099 4-ClC6H4 4-pyridyl 1100 4-ClC6H4 3-pyridyl 1101 4-ClC6H4 2-pyridyl 1102 4-ClC6H4 2-thiazolyl 1103 4-ClC6H4 2-pyrazolyl 1104 4-ClC6H4 5-isoquinolyl 1105 4-ClC6H4 3,4- methylenedioxyC6H3 1106 4-ClC6H4 3,4- ethylenedioxyC6H3 1107 4-ClC6H4 2-imidazolyl 1108 4-ClC6H4 2-oxazolyl 1109 4-ClC6H4 4-isoxazolyl 1110 4-ClC6H4 4-HOC6H4 1111 4-ClC6H4 3-HOC6H4 1112 4-ClC6H4 3,4-diHOC6H4 1113 4-ClC6H4 4-NH2CH2C6H4 1114 4-ClC6H4 3-NH2CH2C6H4 1115 2-NH2CH2C6H4 4-MeOC6H4 1116 2-NH2CH2C6H4 3-MeOC6H4 1117 2-NH2CH2C6H4 4-NH2C6H4 1118 2-NH2CH2C6H4 3-NH2C6H4 1119 2-NH2CH2C6H4 2-NH2C6H4 1120 2-NH2CH2C6H4 4-Me2NC6H4 1121 2-NH2CH2C6H4 3-Me2NC6H4 1122 2-NH2CH2C6H4 2-Me2NC6H4 1123 2-NH2CH2C6H4 4-pyridyl 1124 2-NH2CH2C6H4 3-pyridyl 1125 2-NH2CH2C6H4 2-pyridyl 1126 2-NH2CH2C6H4 2-thiazolyl 1127 2-NH2CH2C6H4 2-pyrazolyl 1128 2-NH2CH2C6H4 5-isoquinolyl 1129 2-NH2CH2C6H4 3,4- methylenedioxyC6H3 1130 2-NH2CH2C6H4 3,4- ethylenedioxyC6H3 1131 2-NH2CH2C6H4 2-imidazolyl 1132 2-NH2CH2C6H4 2-oxazolyl 1133 2-NH2CH2C6H4 4-isoxazolyl 1134 2-NH2CH2C6H4 4-HOC6H4 1135 2-NH2CH2C6H4 3-HOC6H4 1136 2-NH2CH2C6H4 3,4-diHOC6H4 1137 2-NH2CH2C6H4 4-NH2CH2C6H4 1138 2-NH2CH2C6H4 3-NH2CH2C6H4 1139 3-NH2CH2C6H4 4-MeOC6H4 1140 3-NH2CH2C6H4 3-MCOC6H4 1141 3-NH2CH2C6H4 4-NH2C6H4 1142 3-NH2CH2C6H4 3-NH2C6H4 1143 3-NH2CH2C6H4 2-NH2C6H4 1144 3-NH2CH2C6H4 4-Me2NC6H4 1145 3-NH2CH2C6H4 3-Me2NC6H4 1146 3-NH2CH2C6H4 2-Me2NC6H4 1147 3-NH2CH2C6H4 4-pyridyl 1148 3-NH2CH2C6H4 3-pyridyl 1149 3-NH2CH2C6H4 2-pyridyl 1150 3-NH2CH2C6H4 2-thiazolyl 1151 3-NH2CH2C6H4 2-pyrazolyl 1152 3-NH2CH2C6H4 5-isoquinolyl 1153 3-NH2CH2C6H4 3,4- methylenedioxyC6H3 1154 3-NH2CH2C6H4 3,4- ethylenedioxyC6H3 1155 3-NH2CH2C6H4 2-imidazolyl 1156 3-NH2CH2C6H4 2-oxazolyl 1157 3-NH2CH2C6H4 4-isoxazolyl 1158 3-NH2CH2C6H4 4-HOC6H4 1159 3-NH2CH2C6H4 3-HOC6H4 1160 3-NH2CH2C6H4 3,4-diHOC6H4 1161 3-NH2CH2C6H4 4-NH2CH2C6H4 1162 3-NH2CH2C6H4 3-NH2CH2C6H4 1163 4-NH2CH2C6H4 4-MeOC6H4 1164 4-NH2CH2C6H4 3-MeOC6H4 1165 4-NH2CH2C6H4 4-NH2C6H4 1166 4-NH2CH2C6H4 3-NH2C6H4 1167 4-NH2CH2C6H4 2-NH2C6H4 1168 4-NH2CH2C6H4 4-Me2NC6H4 1169 4-NH2CH2C6H4 3-Me2NC6H4 1170 4-NH2CH2C6H4 2-Me2NC6H4 1171 4-NH2CH2C6H4 4-pyridyl 1172 4-NH2CH2C6H4 3-pyridyl 1173 4-NH2CH2C6H4 2-pyridyl 1174 4-NH2CH2C6H4 2-thiazolyl 1175 4-NH2CH2C6H4 2-pyrazolyl 1176 4-NH2CH2C6H4 5-isoquinolyl 1177 4-NH2CH2C6H4 3,4- methylenedioxy6H3 1178 4-NH2CH2C6H4 3,4- ethylenedioxy6H3 1179 4-NH2CH2C6H4 2-imidazolyl 1180 4-NH2CH2C6H4 2-oxazolyl 1181 4-NH2CH2C6H4 4-isoxazolyl 1182 4-NH2CH2C6H4 4-HOC6H4 1183 4-NH2CH2C6H4 3-HOC6H4 1184 4-NH2CH2C6H4 3,4-diHOC6H4 1185 4-NH2CH2C6H4 4-NH2CH2C6H4 1186 4-NH2CH2C6H4 3-NH2CH2C6H4 1187 2-Me2NCH2C6H4 4-MeOC6H4 1188 2-Me2NCH2C6H4 3-MeOC6H4 1189 2-Me2NCH2C6H4 4-NH2C6H4 1190 2-Me2NCH2C6H4 3-NH2C6H4 1191 2-Me2NCH2C6H4 2-NH2C6H4 1192 2-Me2NCH2C6H4 4-Me2NC6H4 1193 2-Me2NCH2C6H4 3-Me2NC6H4 1194 2-Me2NCH2C6H4 2-Me2NC6H4 1195 2-Me2NCH2C6H4 4-pyridyl 1196 2-Me2NCH2C6H4 3-pyridyl 1197 2-Me2NCH2C6H4 2-pyridyl 1198 2-Me2NCH2C6H4 2-thiazolyl 1199 2-Me2NCH2C6H4 2-pyrazolyl 1200 2-Me2NCH2C6H4 5-isoquinolyl 1201 2-Me2NCH2C6H4 3,4- methylenedioxyC6H3 1202 2-Me2NCH2C6H4 3,4- ethylenedioxyC6H3 1203 2-Me2NCH2C6H4 2-imidazolyl 1204 2-Me2NCH2C6H4 2-oxazolyl 1205 2-Me2NCH2C6H4 4-isoxazolyl 1206 2-Me2NCH2C6H4 4-HOC6H4 1207 2-Me2NCH2C6H4 3-HOC6H4 1208 2-Me2NCH2C6H4 3,4-diHOC6H4 1209 2-Me2NCH2C6H4 4-NH2CH2C6H4 1210 2-Me2NCH2C6H4 3-NH2CH2C6H4 1211 3-Me2NCH2C6H4 4-MeOC6H4 1212 3-Me2NCH2C6H4 3-MeOC6H4 1213 3-Me2NCH2C6H4 4-NH2C6H4 1214 3-Me2NCH2C6H4 3-NH2C6H4 1215 3-Me2NCH2C6H4 2-NH2C6H4 1216 3-Me2NCH2C6H4 4-Me2NC6H4 1217 3-Me2NCH2C6H4 3-Me2NC6H4 1218 3-Me2NCH2C6H4 2-Me2NC6H4 1219 3-Me2NCH2C6H4 4-pyridyl 1220 3-Me2NCH2C6H4 3-pyridyl 1221 3-Me2NCH2C6H4 2-pyridyl 1222 3-Me2NCH2C6H4 2-thiazolyl 1223 3-Me2NCH2C6H4 2-pyrazolyl 1224 3-Me2NCH2C6H4 5-isoquinolyl 1225 3-Me2NCH2C6H4 3,4- methylenedioxyC6H3 1226 3-Me2NCH2C6H4 3,4- ethylenedioxyC6H3 1227 3-Me2NCH2C6H4 2-imidazolyl 1228 3-Me2NCH2C6H4 2-oxazolyl 1229 3-Me2NCH2C6H4 4-isoxazolyl 1230 3-Me2NCH2C6H4 4-HOC6H4 1231 3-Me2NCH2C6H4 3-HOC6H4 1232 3-Me2NCH2C6H4 3,4-diHOC6H4 1233 3-Me2NCH2C6H4 4-NH2CH2C6H4 1234 3-Me2NCH2C6H4 3-NH2CH2C6H4 1235 4-Me2NCH2C6H4 4-MeOC6H4 1236 4-Me2NCH2C6H4 3-MeOC6H4 1237 4-Me2NCH2C6H4 4-NH2C6H4 1238 4-Me2NCH2C6H4 3-NH2C6H4 1239 4-Me2NCH2C6H4 2-NH2C6H4 1240 4-Me2NCH2C6H4 4-Me2NC6H4 1241 4-Me2NCH2C6H4 3-Me2NC6H4 1242 4-Me2NCH2C6H4 2-Me2NC6H4 1243 4-Me2NCH2C6H4 4-pyridyl 1244 4-Me2NCH2C6H4 3-pyridyl 1245 4-Me2NCH2C6H4 2-pyridyl 1246 4-Me2NCH2C6H4 2-thiazolyl 1247 4-Me2NCH2C6H4 2-pyrazolyl 1248 4-Me2NCH2C6H4 5-isoquinolyl 1249 4-Me2NCH2C6H4 3,4- methylenedioxyC6H3 1250 4-Me2NCH2C6H4 3,4- ethylenedioxyC6H3 1251 4-Me2NCH2C6H4 2-imidazolyl 1252 4-Me2NCH2C6H4 2-oxazolyl 1253 4-Me2NCH2C6H4 4-isoxazolyl 1254 4-Me2NCH2C6H4 4-HOC6H4 1255 4-Me2NCH2C6H4 3-HOC6H4 1256 4-Me2NCH2C6H4 3,4-diHOC6H4 1257 4-Me2NCH2C6H4 4-NH2CH2C6H4 1258 4-Me2NCH2C6H4 3-NH2CH2C6H4 1259 H 4-MeOC6H4 1260 H 3-MeOC6H4 1261 H 4-NH2C6H4 1262 H 3-NH2C6H4 1263 H 2-NH2C6H4 1264 H 4-Me2NC6H4 1265 H 3-Me2NC6H4 1266 H 2-Me2NC6H4 1267 H 4-pyridyl 1268 H 3-pyridyl 1269 H 2-pyridyl 1270 H 2-thiazolyl 1271 H 2-pyrazolyl 1272 H 5-isoquinolyl 1273 H 3,4- methylenedioxyC6H3 1274 H 3,4- methylenedioxyC6H3 1275 H 2-imidazolyl 1276 H 2-oxazolyl 1277 H 4-isoxazolyl 1278 H 4-HOC6H4 1279 H 3-HOC6H4 1280 H 3,4-diHOC6H4 1281 H 4-NH2CH2C6H4 1282 H 3-NH2CH2C6H4 1283 Me 4-MeOC6H4 1284 Me 3-MeOC6H4 1285 Me 4-NH-hd 2C6H4 1286 Me 3-NH2C6H4 1287 Me 2-NH2C6H4 1288 Me 4-Me2NC6H4 1289 Me 3-Me2NC6H4 1290 Me 2-Me2NC6H4 1291 Me 4-pyridyl 1292 Me 3-pyridyl 1293 Me 2-pyridyl 1294 Me 2-thiazolyl 1295 Me 2-pyrazolyl 1296 Me 5-isoquinolyl 1297 Me 3,4- methylenedioxyC6H3 1298 Me 3,4- ethylenedioxy6H3 1299 Me 2-imidazolyl 1300 Me 2-oxazolyl 1301 Me 4-isoxazolyl 1302 Me 4-HOC6H4 1303 Me 3-HOC6H4 1304 Me 3,4-diHOC6H4 1305 Me 4-NH2CH2C6H4 1306 Me 3-NH2CH2C6H4 1307 Et 4-MeOC6H4 1308 Et 3-MeOC6H4 1309 Et 4-NH2C6H4 1310 Et 3-NH2C6H4 1311 Et 2-NH2C6H4 1312 Et 4-Me2NC6H4 1313 Et 3-Me2NC6H4 1314 Et 2-Me2NC6H4 1315 Et 4-pyridyl 1316 Et 3-pyridyl 1317 Et 2-pyridyl 1318 Et 2-thiazolyl 1319 Et 2-pyrazolyl 1320 Et 5-isoquinolyl 1321 Et 3,4- methylenedioxyC6H3 1322 Et 3,4- ethylenedioxyC6H3 1323 Et 2-imidazolyl 1324 Et 2-oxazolyl 1325 Et 4-isoxazolyl 1326 Et 4-HOC6H4 1327 Et 3-HOC6H4 1328 Et 3,4-diHOC6H4 1329 Et 4-NH2CH2C6H4 1330 Et 3-NH2CH2C6H4 1331 2-NH2C6H4CH2 4-MeOC6H4 1332 2-NH2C6H4CH2 3-MeOC6H4 1333 2-NH2C6H4CH2 4-NH2C6H4 1334 2-NH2C6H4CH2 3-NH2C6H4 1335 2-NH2C6H4CH2 2-NH2C6H4 1336 2-NH2C6H4CH2 4-Me2NC6H4 1337 2-NH2C6H4CH2 3-Me2NC6H4 1338 2-NH2C6H4CH2 2-Me2NC6H4 1339 2-NH2C6H4CH2 4-pyridyl 1340 2-NH2C6H4CH2 3-pyridyl 1341 2-NH2C6H4CH2 2-pyridyl 1342 2-NH2C6H4CH2 2-thiazolyl 1343 2-NH2C6H4CH2 2-pyrazolyl 1344 2-NH2C6H4CH2 5-isoquinolyl 1345 2-NH2C6H4CH2 3,4- methylenedioxy6H3 1346 2-NH2C6H4CH2 3,4- ethylenedioxyC6H3 1347 2-NH2C6H4CH2 2-imidazolyl 1348 2-NH2C6H4CH2 2-oxazolyl 1349 2-NH2C6H4CH2 4-isoxazolyl 1350 2-NH2C6H4CH2 4-HOC6H4 1351 2-NH2C6H4CH2 3-HOC6H4 1352 2-NH2C6H4CH2 3,4-diHOC6H4 1353 2-NH2C6H4CH2 4-NH2CH2C6H4 1354 2-NH2C6H4CH2 3-NH2CH2C6H4 1355 3-NH2C6H4CH2 4-MeOC6H4 1356 3-NH2C6H4CH2 3-MeOC6H4 1357 3-NH2C6H4CH2 4-NH2C6H4 1358 3-NH2C6H4CH2 3-NH2C6H4 1359 3-NH2C6H4CH2 2-NH2C6H4 1360 3-NH2C6H4CH2 4-Me2NC6H4 1361 3-NH2C6H4CH2 3-Me2NC6H4 1362 3-NH2C6H4CH2 2-Me2NC6H4 1363 3-NH2C6H4CH2 4-pyridyl 1364 3-NH2C6H4CH2 3-pyridyl 1365 3-NH2C6H4CH2 2-pyridyl 1366 3-NH2C6H4CH2 2-thiazolyl 1367 3-NH2C6H4CH2 2-pyrazolyl 1367 3-NH2C6H4CH2 5-isoquinolyl 1369 3-NH2C6H4CH2 3,4 methylenedioxyC6H3 1370 3-NH2C6H4CH2 3,4- ethylenedioxyC6H3 1371 3-NH2C6H4CH2 2-imidazolyl 1372 3-NH2C6H4CH2 2-oxazolyl 1373 3-NH2C6H4CH2 4-isoxazolyl 1374 3-NH2C6H4CH2 4-HOC6H4 1375 3-NH2C6H4CH2 3-HOC6H4 1376 3-NH2C6H4CH2 3,4-diHOC6H4 1377 3-NH2C6H4CH2 4-NH2CH2C6H4 1378 3-NH2C6H4CH2 3-NH2CH2C6H4 1379 4-NH2C6H4CH2 4-MeOC6H4 1380 4-NH2C6H4CH2 3-MeOC6H4 1381 4-NH2C6H4CH2 4-NH2C6H4 1382 4-NH2C6H4CH2 3-NH2C6H4 1383 4-NH2C6H4CH2 2-NH2C6H4 1384 4-NH2C6H4CH2 4-Me2NC6H4 1385 4-NH2C6H4CH2 3-Me2NC6H4 1386 4-NH2C6H4CH2 2-Me2NC6H4 1387 4-NH2C6H4CH2 4-pyridyl 1388 4-NH2C6H4CH2 3-pyridyl 1389 4-NH2C6H4CH2 2-pyridyl 1390 4-NH2C6H4CH2 2-thiazolyl 1391 4-NH2C6H4CH2 2-pyrazolyl 1392 4-NH2C6H4CH2 5-isoquinolyl 1393 4-NH2C6H4CH2 3,4 methylenedioxyC6H3 1394 4-NH2C6H4CH2 3,4 ethylenedioxyC6H3 1395 4-NH2C6H4CH2 2-imidazolyl 1396 4-NH2C6H4CH2 2-oxazolyl 1397 4-NH2C6H4CH2 4-isoxazolyl 1398 4-NH2C6H4CH2 4-HOC6H4 1399 4-NH2C6H4CH2 3-HOC6H4 1400 4-NH2C6H4CH2 3,4-diHOC6H4 1401 4-NH2C6H4CH2 4-NH2CH2C6H4 1402 4-NH2C6H4CH2 3-NH2CH2C6H4 1403 2-MeOC6H4CH2 4-MeOC6H4 1404 2-MeOC6H4CH2 3-MeOC6H4 1405 2-MeOC6H4CH2 4-NH2C6H4 1406 2-MeOC6H4CH2 3-NH2CH4 1407 2-MeOC6H4CH2 2-NH2C6H4 1408 2-MeOC6H4CH2 4-Me2NC6H4 1409 2-MeOC6H4CH2 3-Me2NC6H4 1410 2-MeOC6H4CH2 2-Me2NC6H4 1411 2-MeOC6H4CH2 4-pyridyl 1412 2-MeOC6H4CH2 3-pyridyl 1413 2-MeOC6H4CH2 2-pyridyl 1414 2-MeOC6H4CH2 2-thiazolyl 1415 2-MeOC6H4CH2 2-pyrazolyl 1416 2-MeOC6H4CH2 5-isoquinolyl 1417 2-MeOC6H4CH2 3,4- methylenedioxyC6H3 1418 2-MeOC6H4CH2 3,4- ethylenedioxyC6H3 1419 2-MeOC6H4CH2 2-imidazolyl 1420 2-MeOC6H4CH2 2-oxazolyl 1421 2-MeOC6H4CH2 4-isoxazolyl 1422 2-MeOC6H4CH2 4-HOC6H4 1423 2-MeOC6H4CH2 3-HOC6H4 1424 2-MeOC6H4CH2 3,4-diHOC6H4 1425 2-MeOC6H4CH2 4-NH2CH2C6H4 1426 2-MeOC6H4CH2 3-NH2CH2C6H4 1427 3-MeOC6H4CH2 4-MeOC6H4 1428 3-MeOC6H4CH2 3-MeOC6H4 1429 3-MeOC6H4CH2 4-NH2C6H4 1430 3-MeOC6H4CH2 3-NH2C6H4 1431 3-MeOC6H4CH2 2-NH2C6H4 1432 3-MeOC6H4CH2 4-Me2NC6H4 1433 3-MeOC6H4CH2 3-Me2NC6H4 1434 3-MeOC6H4CH2 2-Me2NC6H4 1435 3-MeOC6H4CH2 4-pyridyl 1436 3-MeOC6H4CH2 3-pyridyl 1437 3-MeOC6H4CH2 2-pyridyl 1438 3-MeOC6H4CH2 2-thiazolyl 1439 3-MeOC6H4CH2 2-pyrazolyl 1440 3-MeOC6H4CH2 5-isoquinolyl 1441 3-MeOC6H4CH2 3,4 methylenedioxyC6H3 1442 3-MeOC6H4CH2 3,4- ethylenedioxyC6H3 1443 3-MeOC6H4CH2 2-imidazolyl 1444 3-MeOC6H4CH2 2-oxazolyl 1445 3-MeOC6H4CH2 4-isoxazolyl 1446 3-MeOC6H4CH2 4-HOC6H4 1447 3-MeOC6H4CH2 3-HOC6H4 1448 3-MeOC6H4CH2 3,4-diHOC6H4 1449 3-MeOC6H4CH2 4-NH2CH2C6H4 1450 3-MeOC6H4CH2 3-NH2CH2C6H4 1451 4-MeOC6H4CH2 4-MeOC6H4 1452 4-MeOC6H4CH2 3-MeOC6H4 1453 4-MeOC6H4CH2 4-NH2C6H4 1454 4-MeOC6H4CH2 3-NH2C6H4 1455 4-MeOC6H4CH2 2-NH2C6H4 1456 4-MeOC6H4CH2 4-Me2NC6H4 1457 4-MeOC6H4CH2 3-Me2NC6H4 1458 4-MeOC6H4CH2 2-Me2NC6H4 1459 4-MeOC6H4CH2 4-pyridyl 1460 4-MeOC6H4CH2 3-pyridyl 1461 4-MeOC6H4CH2 2-pyridyl 1462 4-MeOC6H4CH2 2-thiazolyl 1463 4-MeOC6H4CH2 2-pyrazolyl 1464 4-MeOC6H4CH2 5-isoquinolyl 1465 4-MeOC6H4CH2 3,4- methylenedioxyC6H3 1466 4-MeOC6H4CH2 3,4- ethylenedioxyC6H3 1467 4-MeOC6H4CH2 2-imidazolyl 1468 4-MeOC6H4CH2 2-oxazolyl 1469 4-MeOC6H4CH2 4-isoxazolyl 1470 4-MeOC6H4CH2 4-HOC6H4 1471 4-MeOC6H4CH2 3-HOC6H4 1472 4-MeOC6H4CH2 3,4-diHOC6H4 1473 4-MeOC6H4CH2 4-NH2CH2C6H4 1474 4-MeOC6H4CH2 3-NH2CH2C6H4 1475 2-HOC6H4CH2 4-MeOC6H4 1476 2-HOC6H4CH2 3-MeOC6H4 1477 2-HOC6H4CH2 4-NH2C6H4 1478 2-HOC6H4CH2 3-NH2C6H4 1479 2-HOC6H4CH2 2-NH2C6H4 1480 2-HOC6H4CH2 4-Me2NC6H4 1481 2-HOC6H4CH2 3-Me2NC6H4 1482 2-HOC6H4CH2 2-Me2NC6H4 1483 2-HOC6H4CH2 4-pyridyl 1484 2-HOC6H4CH2 3-pyridyl 1485 2-HOC6H4CH2 2-pyridyl 1486 2-HOC6H4CH2 2-thiazolyl 1487 2-HOC6H4CH2 2-pyrazolyl 1488 2-HOC6H4CH2 5-isoquinolyl 1489 2-HOC6H4CH2 3,4- methylenedioxy6H3 1490 2-HOC6H4CH2 3,4- ethylenedioxy6H3 1491 2-HOC6H4CH2 2-imidazolyl 1492 2-HOC6H4CH2 2-oxazolyl 1493 2-HOC6H4CH2 4-isoxazolyl 1494 2-HOC6H4CH2 4-HOC6H4 1495 2-HOC6H4CH2 3-HOC6H4 1496 2-HOC6H4CH2 3,4-diHOC6H4 1497 2-HOC6H4CH2 4-NH2CH2C6H4 1498 2-HOC6H4CH2 3-NH2CH2C6H4 1499 3-HOC6H4CH2 4-MeOC6H4 1500 3-HOC6H4CH2 3-MeOC6H4 1501 3-HOC6H4CH2 4-NH2C6H4 1502 3-HOC6H4CH2 3-NH2C6H4 1503 3-HOC6H4CH2 2-NH2C6H4 1504 3-HOC6H4CH2 4-Me2NC6H4 1505 3-HOC6H4CH2 3-Me2NC6H4 1506 3-HOC6H4CH2 2-Me2NC6H4 1507 3-HOC6H4CH2 4-pyridyl 1508 3-HOC6H4CH2 3-pyridyl 1509 3-HOC6H4CH2 2-pyridyl 1510 3-HOC6H4CH2 2-thiazolyl 1511 3-HOC6H4CH2 2-pyrazolyl 1512 3-HOC6H4CH2 5-isoquinolyl 1513 3-HOC6H4CH2 3,4- methylenedioxyC6H3 1514 3-HOC6H4CH2 3,4- ethylenedioxyC6H3 1514 3-HOC6H4CH2 2-imidazolyl 1516 3-HOC6H4CH2 2-oxazolyl 1517 3-HOC6H4CH2 4-isoxazolyl 1518 3-HOC6H4CH2 4-HOC6H4 1519 3-HOC6H4CH2 3-HOC6H4 1520 3-HOC6H4CH2 3,4-diHOC6H4 1521 3-HOC6H4CH2 4-NH2CH2C6H4 1522 3-HOC6H4CH2 3-NH2CH2C6H4 1523 4-HOC6H4CH2 4-MeOC6H4 1524 4-HOC6H4CH2 3-MeOC6H4 1525 4-HOC6H4CH2 4-NH2C6H4 1526 4-HOC6H4CH2 3-NH2C6H4 1527 4-HOC6H4CH2 2-NH2C6H4 1528 4-HOC6H4CH2 4-Me2NC6H4 1529 4-HOC6H4CH2 3-Me2NC6H4 1530 4-HOC6H4CH2 2-Me2NC6H4 1531 4-HOC6H4CH2 4-pyridyl 1532 4-HOC6H4CH2 3-pyridyl 1533 4-HOC6H4CH2 2-pyridyl 1534 4-HOC6H4CH2 2-thiazolyl 1535 4-HOC6H4CH2 2-pyrazolyl 1536 4-HOC6H4CH2 5-isoquinolyl 1537 4-HOC6H4CH2 3,4- methylenedioxyC6H3 1538 4-HOC6H4CH2 3,4 ethylenedioxyC6H3 1539 4-HOC6H4CH2 2-imidazolyl 1540 4-HOC6H4CH2 2-oxazolyl 1541 4-HOC6H4CH2 4-isoxazolyl 1542 4-HOC6H4CH2 4-HOC6H4 1543 4-HOC6H4CH2 3-HOC6H4 1544 4-HOC6H4CH2 3,4-diHOC6H4 1545 4-HOC6H4CH2 4-NH2CH2C6H4 1546 4-HOC6H4CH2 3-NH2CH2C6H4 1547 4-ClC6H4CH2 4-MeOC6H4 1548 4-ClC6H4CH2 3-MeOC6H4 1549 4-ClC6H4CH2 4-NH2C6H4 1550 4-ClC6H4CH2 3-NH2C6H4 1551 4-ClC6H4CH2 2-NH2C6H4 1552 4-ClC6H4CH2 4-Me2NC6H4 1553 4-ClC6H4CH2 3-Me2NC6H4 1554 4-ClC6H4CH2 2-Me2NC6H4 1555 4-ClC6H4CH2 4-pyridyl 1556 4-ClC6H4CH2 3-pyridyl 1557 4-ClC6H4CH2 2-pyridyl 1558 4-ClC6H4CH2 2-thiazolyl 1559 4-ClC6H4CH2 2-pyrazolyl 1560 4-ClC6H4CH2 5-isoquinolyl 1561 4-ClC6H4CH2 3,4 methylenedioxyC6H3 1562 4-ClC6H4CH2 3,4 ethylenedioxyC6H3 1563 4-ClC6H4CH2 2-imidazolyl 1564 4-ClC6H4CH2 2-oxazolyl 1565 4-ClC6H4CH2 4-isoxazolyl 1566 4-ClC6H4CH2 4-HOC6H4 1567 4-ClC6H4CH2 3-HOC6H4 1568 4-ClC6H4CH2 3,4-diHOC6H4 1569 4-ClC6H4CH2 4-NH2CH2C6H4 1570 4-ClC6H4CH2 3-NH2CH2C6H4 1571 2-NH2CH2C6H4CH2 4-MeOC6H4 1572 2-NH2CH2C6H4CH2 3-MeOC6H4 1573 2-NH2CH2C6H4CH2 4-NH2C6H4 1574 2-NH2CH2C6H4CH2 3-NH2C6H4 1575 2-NH2CH2C6H4CH2 2-NH2C6H4 1576 2-NH2CH2C6H4CH2 4-Me2NC6H4 1577 2-NH2CH2C6H4CH2 3-Me2NC6H4 1578 2-NH2CH2C6H4CH2 2-Me2NC6H4 1579 2-NH2CH2C6H4CH2 4-pyridyl 1580 2-NH2CH2C6H4CH2 3-pyridyl 1581 2-NH2CH2C6H4CH2 2-pyridyl 1582 2-NH2CH2C6H4CH2 2-thiazolyl 1583 2-NH2CH2C6H4CH2 2-pyrazolyl 1584 2-NH2CH2C6H4CH2 5-isoquinolyl 1585 2-NH2CH2C6H4CH2 3,4- methylenedioxyC6H3 1586 2-NH2CH2C6H4CH2 3,4- ethylenedioxyC6H3 1587 2-NH2CH2C6H4CH2 2-imidazolyl 1588 2-NH2CH2C6H4CH2 2-oxazolyl 1589 2-NH2CH2C6H4CH2 4-isoxazolyl 1590 2-NH2CH2C6H4CH2 4-HOC6H4 1591 2-NH2CH2C6H4CH2 3-HOC6H4 1592 2-NH2CH2C6H4CH2 3,4-diHOC6H4 1593 2-NH2CH2C6H4CH2 4-NH-I2CH2C6H4 1594 2-NH2CH2C6H4CH2 3-NH2CH2C6H4 1595 3-NH2CH2C6H4CH2 4-MeOC6H4 1596 3-NH2CH2C6H4CH2 3-MeOC6H4 1597 3-NH2CH2C6H4CH2 4-NH2C6H4 1598 3-NH2CH2C6H4CH2 3-NH2C6H4 1599 3-NH2CH2C6H4CH2 2-NH2C6H4 1600 3-NH2CH2C6H4CH2 4-Me2NC6H4 1601 3-NH2CH2C6H4CH2 3-Me2NC6H4 1602 3-NH2CH2C6H4CH2 2-Me2NC6H4 1603 3-NH2CH2C6H4CH2 4-pyridyl 1604 3-NH2CH2C6H4CH2 3-pyridyl 1605 3-NH2CH2C6H4CH2 2-pyridyl 1606 3-NH2CH2C6H4CH2 2-thiazolyl 1607 3-NH2CH2C6H4CH2 2-pyrazolyl 1608 3-NH2CH2C6H4CH2 5-isoquinolyl 1609 3-NH2CH2C6H4CH2 3,4- methylenedioxyC6H3 1610 3-NH2CH2C6H4CH2 3,4- ethylenedioxyC6H3 1611 3-NH2CH2C6H4CH2 2-imidazolyl 1612 3-NH2CH2C6H4CH2 2-oxazolyl 1613 3-NH2CH2C6H4CH2 4-isoxazolyl 1614 3-NH2CH2C6H4CH2 4-HOC6H4 1615 3-NH2CH2C6H4CH2 3-HOC6H4 1616 3-NH2CH2C6H4CH2 3,4-diHOC6H4 1617 3-NH2CH2C6H4CH2 4-NH2CH2C6H4 1618 3-NH2CH2C6H4CH2 3-NH2CH2C6H4 1619 4-NH2CH2C6H4CH2 4-MeOC6H4 1620 4-NH2CH2C6H4CH2 3-MeOC6H4 1621 4-NH2CH2C6H4CH2 4-NH2C6H4 1622 4-NH2CH2C6H4CH2 3-NH2C6H4 1623 4-NH2CH2C6H4CH2 2-NH2C6H4 1624 4-NH2CH2C6H4CH2 4-Me2NC6H4 1625 4-NH2CH2C6H4CH2 3-Me2NC6H4 1626 4-NH2CH2C6H4CH2 2-Me2NC6H4 1627 4-NH2CH2C6H4CH2 4-pyridyl 1628 4-NH2CH2C6H4CH2 3-pyridyl 1629 4-NH2CH2C6H4CH2 2-pyridyl 1630 4-NH2CH2C6H4CH2 2-thiazolyl 1631 4-NH2CH2C6H4CH2 2-pyrazolyl 1632 4-NH2CH2C6H4CH2 5-isoquinolyl 1633 4-NH2CH2C6H4CH2 3,4 methylenedioxyC6H3 1634 4-NH2CH2C6H4CH2 3,4 ethylenedioxyC6H3 1635 4-NH2CH2C6H4CH2 2-imidazolyl 1636 4-NH2CH2C6H4CH2 2-oxazolyl 1637 4-NH2CH2C6H4CH2 4-isoxazolyl 1638 4-NH2CH2C6H4CH2 4-HOC6H4 1639 4-NH2CH2C6H4CH2 3-HOC6H4 1640 4-NH2CH2C6H4CH2 3,4-diHOC6H4 1641 4-NH2CH2C6H4CH2 4-NH2CH2C6H4 1642 4-NH2CH2C6H4CH2 3-NH2CH2C6H4 1643 2-Me2NCH2C6H4CH2 4-MeOC6H4 1644 2-Me2NCH2C6H4CH2 3-MeOC6H4 1645 2-Me2NCH2C6H4CH2 4-NH2C6H4 1646 2-Me2NCH2C6H4CH2 3-NH2C6H4 1647 2-Me2NCH2C6H4CH2 2-NH2C6H4 1648 2-Me2NCH2C6H4CH2 4-Me2NC6H4 1649 2-Me2NCH2C6H4CH2 3-Me2NC6H4 1650 2-Me2NCH2C6H4CH2 2-Me2NC6H4 1651 2-Me2NCH2C6H4CH2 4-pyridyl 1652 2-Me2NCH2C6H4CH2 3-pyridyl 1653 2-Me2NCH2C6H4CH2 2-pyridyl 1654 2-Me2NCH2C6H4CH2 2-thiazolyl 1655 2-Me2NCH2C6H4CH2 2-pyrazolyl 1656 2-Me2NCH2C6H4CH2 5-isoquinolyl 1657 2-Me2NCH2C6H4CH2 3,4 methylenedioxyC6H3 1658 2-Me2NCH2C6H4CH2 3,4 ethylenedioxyC6H3 1659 2-Me2NCH2C6H4CH2 2-imidazolyl 1660 2-Me2NCH2C6H4CH2 2-oxazolyl 1661 2-Me2NCH2C6H4CH2 4-isoxazolyl 1662 2-Me2NCH2C6H4CH2 4-HOC6H4 1663 2-Me2NCH2C6H4CH2 3-HOC6H4 1664 2-Me2NCH2C6H4CH2 3,4-diHOC6H4 1665 2-Me2NCH2C6H4CH2 4-NH2CH2C6H4 1666 2-Me2NCH2C6H4CH2 3-NH2CH2C6H4 1667 3-Me2NCH2C6H4CH2 4-MeOC6H4 1668 3-Me2NCH2C6H4CH2 3-MeOC6H4 1669 3-Me2NCH2C6H4CH2 4-NH2C6H4 1670 3-Me2NCH2C6H4CH2 3-NH2C6H4 1671 3-Me2NCH2C6H4CH2 2-NH2C6H4 1672 3-Me2NCH2C6H4CH2 4-Me2HC6H4 1673 3-Me2NCH2C6H4CH2 3-Me2NC6H4 1674 3-Me2NCH2C6H4CH2 2-Me2NC6H4 1675 3-Me2NCH2C6H4CH2 4-pyridyl 1676 3-Me2NCH2C6H4CH2 3-pyridyl 1677 3-Me2NCH2C6H4CH2 2-pyridyl 1678 3-Me2NCH2C6H4CH2 2-thiazolyl 1679 3-Me2NCH2C6H4CH2 2-pyrazolyl 1680 3-Me2NCH2C6H4CH2 5-isoquinolyl 1681 3-Me2NCH2C6H4CH2 3,4- methylenedioxyC6H3 1682 3-Me2NCH2C6H4CH2 3,4 ethylenedioxyC6H3 1683 3-Me2NCH2C6H4CH2 2-imidazolyl 1684 3-Me2NCH2C6H4CH2 2-oxazolyl 1685 3-Me2NCH2C6H4CH2 4-isoxazolyl 1686 3-Me2NCH2C6H4CH2 4-HOC6H4 1687 3-Me2NCH2C6H4CH2 3-HOC6H4 1688 3-Me2NCH2C6H4CH2 3,4-diHOC6H4 1689 3-Me2NCH2C6H4CH2 4-NH2CH2C6H4 1690 3-Me2NCH2C6H4CH2 3-NH2CH2C6H4 1691 4-Me2NCH2C6H4CH2 4-MeOC6H4 1692 4-Me2NCH2C6H4CH2 3-MeOC6H4 1693 4-Me2NCH2C6H4CH2 4-NH2C6H4 1694 4-Me2NCH2C6H4CH2 3-NH2C6H4 1695 4-Me2NCH2C6H4CH2 2-NH2C6H4 1696 4-Me2NCH2C6H4CH2 4-Me2NC6H4 1697 4-Me2NCH2C6H4CH2 3-Me2NC6H4 1698 4-Me2NCH2C6H4CH2 2-Me2NC6H4 1699 4-Me2NCH2C6H4CH2 4-pyridyl 1700 4-Me2NCH2C6H4CH2 3-pyridyl 1701 4-Me2NCH2C6H4CH2 2-pyridyl 1702 4-Me2NCH2C6H4CH2 2-thiazolyl 1703 4-Me2NCH2C6H4CH2 2-pyrazolyl 1704 4-Me2NCH2C6H4CH2 5-isoquinolyl 1705 4-Me2NCH2C6H4CH2 3,4- methylenedioxyC6H3 1706 4-Me2NCH2C6H4CH2 3,4- ethylenedioxyC6H3 1707 4-Me2NCH2C6H4CH2 2-imidazolyl 1708 4-Me2NCH2C6H4CH2 2-oxazolyl 1709 4-Me2NCH2C6H4CH2 4-isoxazolyl 1710 4-Me2NCH2C6H4CH2 4-HOC6H4 1711 4-Me2NCH2C6H4CH2 3-HOC6H4 1712 4-Me2NCH2C6H4CH2 3,4-diHOC6H4 1713 4-Me2NCH2C6H4CH2 4-NH2CH2C6H4 1714 4-Me2NCH2C6H4CH2 3-NH2CH2C6H4

[0359] 4 TABLE 4 28 Example Number R1 R2 1715 Methyl 4-MeOC6H4 1716 ClCH2 4-MeOC6H4 1717 cyclopropyl 4-MeOC6H4 1718 isopropyl 4-MeOC6H4 1719 ethyl 4-MeOC6H4 1720 cyclopentyl 4-MeOC6H4 1721 cyclobutyl 4-MeOC6H4 1722 benzyl 4-MeOC6H4 1723 n-propyl 4-MeOC6H4 1724 4-ClC6H4CH2 4-MeOC6H4 1725 3-MeOC6H4CH2 4-MeOC6H4 1726 4-MeOC6H4CH2 4-MeOC6H4 1727 3,4-diMeOC6H4CH2 4-MeOC6H4 1728 2,5-diMeOC6H4CH2 4-MeOC6H4 1729 Methyl 2-MeOC6H4 1730 Methyl 3,4-diMeOC6H4 1731 3,4-(OCH2O)C6H4CH2 4-MeOC6H4 1732 3-thiophenylCH2 4-MeOC6H4 1733 2-MeOC6H4CH2 4-MeOC6H4 1734 3,4-diClOC6H4CH2 4-MeOC6H4 1735 2,4-diClOC6H4CH2 4-MeOC6H4 1736 2-ClC6H4CH2 4-MeOC6H4 1737 H2NCH2 4-MeOC6H4 1738 HOCH2NHCH2CH2 4-MeOC6H4 1739 Me2NCH2 4-MeOC6H4 1740 piperazinylCH2 4-MeOC6H4 1741 4-Me-piperazinylCH2 4-MeOC6H4 1742 4-HOCH2CH2— 4-MeOC6H4 piperazinylCH2 1743 piperidinylCH2 4-MeOC6H4 1744 4-NH2CH2— 4-MeOC6H4 piperidinylCH2 1745 CH3CH2NHCH2 4-MeOC6H4 1746 thiomorpholinylCH2 4-MeOC6H4 1747 morpholinylCH2 4-MeOC6H4 1748 pyyrolidinylCH2 4-MeOC6H4 1749 4-pyridylCH2NHCH2 4-MeOC6H4 1750 4-CH3CONHC6H4CH2 4-MeOC6H4 1751 4-CH3OCONHC6H4CH2 4-MeOC6H4 1752 4-NH2CH2CONHC6H4CH2 4-MeOC6H4 1753 4-Me2NCH2CONHC6H4CH2 4-MeOC6H4 1754 4-N3C6H4CH2 4-MeOC6H4 1755 4-NH2C6H4CH2 4-MeOC6H4 1756 C6H5NH 4-MeOC6H4 1757 CH3CH2CH2NH 4-MeOC6H4 1758 4-NH2C6H4CH2NH 4-MeOC6H4 1759 4-pyridyCH2NH 4-MeOC6H4 1760 Methyl 4-HOC6H4 1761 H 4-MeOC6H4 1762 Methyl 3-pyridyl 1763 Methyl 4-pyridyl 1764 H 4 -pyridyl 1765 Methyl C6H5 1766 Methyl 4-MeSC6H4 1767 Methyl 4-MeSO2C6H4 1768 Methyl 4-Me2NC6H4 1769 MorpholinylCH2 4-Me2NC6H4 1770 Me2NCH2 4-Me2NC6H4 1771 Me2NCH2 4-(piperdinyl)C6H4 1772 Me2NCH2 4-(morpholinyl)- C6H4 1773 Me2NCH2 4-CH3CH2OC6H4 1774 Me2NCH2 4-CH3CH2CH2CH2C6H4 1775 Me2NCH2 4-CH3CH2C6H4 1776 Me2NCH2 4-CH3CH2CH2C6H4

Claims

1. A compound according to formula (I):

29

3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

X is selected from the group: O, S, and NR;

R is selected from the group: H, C1-4 alkyl, and NR5R5a;

R1 is selected from the group: H, C1-10 alkyl substituted with 0-3 Rc, C2-10 alkenyl substituted with 0-3 Rc, C2-10 alkynyl substituted with 0-3 Rc, —NHR4, C3-10 carbocycle substituted with 0-5 Ra, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

R2 is selected from the group: H, C1-10 alkyl substituted with 0-3 Rc, C2-10 alkenyl substituted with 0-3 Rc, C2-10 alkynyl substituted with 0-3 Rc, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 Ra, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

R3 is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR R5a, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

provided that if R3 is phenyl, it is substituted with 1-5 Ra;

R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

Ra is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3a, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

Rb is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, and SO2R3b;

Rc is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR5NR5R5a, NR3C(O)OR3, NR3C(O)R3, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 4-8 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3b, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R5 is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

R5b is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

m is selected from 0, 1, 2, and 3.

2. A compound according to claim 1, wherein:

X is selected from the group: O, S, and NR;

R is selected from the group: H, C1-4 alkyl, and NR5R5a;

R1 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-5 alkenyl substituted with 0-3 Rc, C2-5 alkynyl substituted with 0-3 Rc, —NHR4, C3-6 carbocycle substituted with 0-5 Ra, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

R2 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-5 alkenyl substituted with 0-3 Rc, C2-5 alkynyl substituted with 0-3 Rc, —(CF2)mCF3, C3-6 carbocycle substituted with 0-5 Ra, and 3-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

R3 is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR R5a, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, CS-1O alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

provided that if R3 is phenyl, it is substituted with 1-5 Ra;

R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

Ra is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

Rb is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, and SO2R3b;

Rc is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, NR5NR5R5a, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 4-8 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3b, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3b, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R5 is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

R5b is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

m is selected from 0, 1, 2, and 3.

3. A compound according to claim 2, wherein:

X is selected from the group: O and S;

R1 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-5 alkenyl substituted with 0-3 Rc, —NHR4, C3-6 carbocycle substituted with 0-5 Ra, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

R2 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, C2-5 alkenyl substituted with 0-3 Rc, —(CF2)mCF3, C3-6 carbocycle substituted with 0-5 Ra, and 3-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

R3 is selected from the group: H, halo, —CN, NO2, Cl-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

provided that if R3 is phenyl, it is substituted with 1-5 Ra;

R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

Ra is independently at each occurrence selected from the group: halo, —CN, N3, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)R3C(O)R3, OR3, COR3, CO2R3,

CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

Rb is independently at each occurrence selected from the group: halo, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, and SO2R3b;

Rc is independently at each occurrence selected from the group: halo, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR5NR5R5a, NR3C(O)OR3, NR3C(O)R3, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 5-6 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3b, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3b, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R5 is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

R5b is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

m is selected from 0, 1, 2, and 3.

4. A compound according to claim 3, wherein:

X is selected from the group: O and S;

R1 is selected from the group: H, C1-5 alkyl substituted with 0-2 Rc, —NHR4, C3-6 carbocycle substituted with 0-5 Ra, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-5 Rb;

R2 is selected from the group: H, C1-5 alkyl substituted with 0-3 Rc, —(CF2)mCF3, C3-6 carbocycle substituted with 0-5 Ra, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S and substituted with 0-3 Rb;

R3 is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR5R5a, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

provided that if R3 is phenyl, it is substituted with 1-5 Ra;

R4 is independently at each occurrence selected from the group: H, —CN, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

provided that at least one R3 is present and that this R3 is selected from the group: C1-4 alkyl substituted with 1-3 R6, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6;

Ra is independently at each occurrence selected from the group: halo, —CN, N3, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

alternatively, when two Ra's are present on adjacent carbon atoms they combine to form —OCH2O— or —OCH2CH2O—;

Rb is independently at each occurrence selected from the group: halo, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, and SO2R3b;

Rc is independently at each occurrence selected from the group: halo, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR5NR5R5a, NR3C(O)OR3, NR3C(O)R3, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, form a heterocycle having 5-6 atoms in the ring containing an additional 0-1 N, S, or O atom and substituted with 0-3 R3c;

R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R3c is independently at each occurrence selected from the group: halo, —CN, N3, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3b, ═O, OR3, COR3, CO2R3, CONR3R3b, NHC(O)NR3R3b, NHC(S)NR3R3b, NR3C(O)OR3, NR3C(O)R3, SO2NR3R3b, SO2R3b, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S;

R5 is independently selected from the group: H and C1-4 alkyl;

R5a is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

R5b is independently selected from the group: H and C1-4 alkyl;

R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5R5a, NHC(S)NR5R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5; and

m is selected from 0, 1, 2, and 3.

5. A compound according to claim 1, wherein the compound is selected from:

(a) 3-(4-methoxyphenyl)-5(2-benzoylhydrazinecarboxamido)indeno [1,2-c]pyrazol-4-one;

(b) 3-(4-methoxyphenyl)-5-(2-isonicotinoylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(c) 3-(4-methoxyphenyl)-5-(2-nictinoylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(d) 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(e) 3-(4-methoxyphenyl)-5-(2-(4-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(f) 3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(g) 3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(h) 3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(i) 3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylaminobenzoyl) hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

(j) 3-(4-methoxyphenyl)-5-(2-phenethylacetylhydrazine carboxamido)indeno[1,2-c]pyrazol-4-one;

(k) 3-(4-methoxyphenyl)-5-(2-(2-hydroxybenzoyl)hydrazine carboxamido)indeno[1,2-c]pyrazol-4-one; and

(l) 3-(4-methoxyphenyl)-5-(2-methoxycarbonyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

or pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

7. A method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

9. A method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

10. A compound according to formula (II)

30

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

X is selected from the group: O and NR;

R is selected from the group: H, C1-4 alkyl, NR3R3a, and C1-4 alkyl substituted with 1-3 Rc;

R3 is selected from the group: H, halo, —CN, NO2, C1-4 haloalkyl, NR5R5a, NR5NR5R5a, NR5C(O)OR5, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR5Ra, NHC(S) NR5R5a, SO2NR5R5a, SO2R5b, C1-4 alkyl, phenyl, benzyl, C1-4 alkyl substituted with 1-3 Rc, C5-10 alkyl substituted with C2-10 alkenyl optionally substituted with 0-3 R6, C2-10 alkynyl substituted with 0-3 R6, —(CF2)mCF3, C3-10 carbocycle substituted with 0-5 R6, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R6; and

provided that if R3 is phenyl, it is substituted with 1-5 Ra;

R3a is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R3b is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R5 is independently selected from the group: H, C1-4 alkyl, phenyl and benzyl;

R5a is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R5b is independently selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

R6 is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR5R5, NR5NR5R5a, NR5C(O)OR, NR5C(O)R5, ═O, OR5, COR5, CO2R5, CONR5R5a, NHC(O)NR 5R5a, NHC(S)NR R5a, SO2NR5R5a, SO2R5b, C3-10 carbocycle substituted with 0-5 R5, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R5;

Ra is independently at each occurrence selected from the group: H, halo, C1-4 alkyl, NR3R3a, and R3;

Rc is independently at each occurrence selected from the group: halo, —CN, NO2, C1-4 alkyl, C1-4 haloalkyl, NR3R3a, NR5NR5R5a, NR3C(O)OR3, NR3C(O)R3, ═O, OR3, COR3, CO2R3, CONR3R3a, NHC(O)NR3R3a, NHC(S)NR3R3a, SO2NR3R3a, SO2R3b, C3-10 carbocycle substituted with 0-5 Ra, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, substituted with 0-3 R3;

Rd is independently at each occurrence selected from the group: OR3, COR3, and NR3R3a; and

m is selected from 0, 1, 2, and 3.

11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 8.

12. A method of treating cancer and proliferative diseases comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of claim 8, or a pharmaceutically acceptable salt or prodrug form thereof.